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Abstract 
 
This thesis is divided into five main chapters which all lay their focus on 
controlling neuronal cell differentiation using the tools of chemical biology. The 
individual projects have benefited strongly from cross-pollination of ideas and are all 
linked in several ways. We hope that our findings could assist the development of 
therapies for people suffering from neurodegenerative diseases or spinal cord injuries.  
 
Chapter 1 starts with a brief description on the growing impact the diseases 
we address have on society and introduces different concepts that aim to increase the 
efficiency of total synthesis and drug discovery. 
 
In Chapter 2, the first total synthesis of the neuritotrophic natural product 
gelsemiol and its biological evaluation is described and discussed. 
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 After the successful total synthesis of the natural product farinosone C by our 
group, we aimed to reduce its structural complexity while retaining its unique 
biological activity. In the present study, farinosone C served as a lead structure and 
inspired the preparation of small molecules with reduced complexity of which several 
could induce neurite outgrowth. This in turn allowed the elaboration of a detailed 
structure-activity relationship and also distinguished the essential from non-essential 
structural motives, which is discussed in Chapter 3. 
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To date, many natural products and their structural analogs with neuritogenic 
or neuritotrophic properties have been reported. Nevertheless, the underlying 
biological pathways involved in neuronal cell differentiation, which are influenced by 
such compounds, are only partially understood. In Chapter 4, we attempted to 
address this issue and present our findings on the mode of action studies.    
 
Chapter 5 describes a facile and modular natural product (NP) analog-based 
approach to assemble neuritogenic surfaces. The coating procedure involved 
incubation of glass slides in a solution containing a neurotrophin-like small molecule 
and an extracellular matrix followed by intense washing and sterilization only. This 
system has been proven to be very robust and may offer new directions in spinal cord 
injury treatments.  
 
Coated with neuritogenic
 NP analogs
Uncoated
 
 
Keywords: • Natural Products • Total Synthesis • Gelsemiol • Neurite Outgrowth • 
Mode of Action • Spinal Cord Injuries • Neuritogenic Surfaces • Structure Activity 
Relationship 
 
vii  
 
Kurzbeschreibung  
 
 Diese Doktorarbeit gliedert sich in fünf Hauptkapitel, die sich alle damit 
befassen, wie man die Differenzierung von Nervenzellen kontrollieren kann. Die 
verschiedenen Projekte haben sich gegenseitig beeinflusst und stark voneinander 
profitiert. Wir hoffen, mit unseren Ergebnissen die Entwicklung von Therapien für 
Menschen mit neurodegenerativen Erkrankungen oder Verletzungen des 
Rückenmarks unterstützen zu können. 
 
Kapitel 1 weist auf die zunehmende Bedeutung von neuronalen Erkrankungen 
wie Alzheimer in einer immer älter werdenden Gesellschaft hin. Auch werden hier 
Richtlinien vorgestellt, deren Beachtung die Effizienz einer Synthese oder 
Wirkstoffentwicklung erhöhen. 
 
In Kapitel 2 wird die erstmalige enantioselektive Totalsynthese des 
Naturstoffs Gelsemiol diskutiert. Wir haben eine kurze und effiziente Synthese 
entwickelt und die Bioaktivität des erhaltenen Naturstoffs evaluiert.  
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 Nachdem der Naturstoff Farinosone C von unserer Gruppe erstmalig in einem 
Labor hergestellt wurde, haben wir versucht, dessen strukturelle Komplexität, bei 
gleichbleibender biologischer Aktivität, zu reduzieren. In der im Kapitel 3 
präsentierten Studie diente Farinosone C als Leitstruktur und inspirierte die 
Herstellung von Molekülen mit reduzierter Komplexität von denen mehrere 
Neuritenwachstum induzierten. Die Resultate dieser Struktur-Aktivitäts-Beziehung 
erlaubten uns die wesentlichen, strukturellen Motive von Farinosone C zu 
identifizieren.  
 viii 
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 Es sind viele Naturstoffe und deren Derivate bekannt, welche das 
Neuritenwachstum von verschiedenen Zellen modulieren können. Dennoch sind die 
zugrunde liegenden biologischen Mechanismen, welche durch solche Verbindungen 
beeinflusst werden, nur unzureichend begriffen. Kapitel 4 befasst sich genau mit 
dieser Frage und präsentiert die Ergebnisse, welche die Untersuchung der 
Wirkungsweise ergab. 
 
 Kapitel 5 beschreibt die Herstellung von neuritogenen Oberflächen unter 
Verwendung von Naturstoff-Derivaten. Bei diesem Beschichtungverfahren werden 
Glasplättchen mit Neurotrophin-artigen kleinen Molekülen und einer extrazellulären 
Matrix inkubiert, gefolgt von intensivem Waschen und Sterilisieren. Diese Methode 
könnte unserer Meinung nach helfen, neue Wege zur Behandlung von 
Rückenmarksverletzungen zu beschreiten.  
 
Coated with neuritogenic
 NP analogs
Uncoated
 
 
Schlüsselwörter: • Naturprodukte • Totalsynthese • Gelsemiol • Neuritenwachstum • 
Wirkungsweise • Rückenmarksverletzungen • Neuritogene Oberflächen • Struktur-
Aktivitäts-Beziehungen.
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 CHAPTER 1 – INTRODUCTION                                                                                                             1 
1.1 General Justification  
 
The methods with which physicians treat ill persons have improved 
tremendously over time and allowed us to live a longer life. The deep-rooted 
philosophical concept that states that “There cannot be good without bad” 1 also 
comes into play for this matter since in an ageing society, diseases such as 
neurodegenerative dementias (ND) become increasingly prevalent. Among these 
sufferings, Alzheimer’s disease (AD) is the most prominent one accounting for 
approximately 60 to 80 % of the diagnosed cases. Other types of ND include 
Parkinson’s or Creutzfeldt-Jakob disease, which gained much public attention in the 
mid 90’s after it was linked to the consumption of beef infected with bovine 
spongiform encephalopathy (BSE) also known as ”mad cow disease“. One out of 
three seniors dies suffering from ND in its different types and stages. AD is currently 
the 6th leading cause of death and still rising. The very diverse set of symptoms 
besides memory loss are e.g. reduced ability to speak, confusion with time and space, 
social withdrawal or severe changes in mood and personality. Those in the terminal 
stages often become bed-bound and cannot precede living without around-the-clock 
assistance. These symptoms result in tremendous sufferings for patients and their 
associates. Approved medication only stops, slows down or is reducing the 
symptoms. To date, there is no therapy available that restores brain function. It is 
therefore of eminent importance to dedicate recourses and to find ways to overcome 
this 21st century plague.2  
While we aim to understand and regulate the formation and restoration of 
neuronal networks to treat ND we may also find ways to rebuild nerve tracts damaged 
by spinal cord injuries. Despite of recently made substantial progress in therapy, such 
as approaches based on electrochemical stimulations3 or stem cells transplantation,4 
we still are far away from successfully treating chronic paralysis.  
                                                
1 St. Augustine, T. S. Hibbs, Enchiridion on Faith, Hope and Love, Regnery Pub., 
Washington, D.C, 1996. 
2 J. Gaugler, B. James, T. Johnson, K. Scholz, W. J, Alzheimer's & Dementia 2013, 9, 
208–245. 
3 R. van den Brand, J. Heutschi, Q. Barraud, J. DiGiovanna, K. Bartholdi, M. 
Huerlimann, L. Friedli, I. Vollenweider, E. M. Moraud, S. Duis, et al., Science 2012, 
336, 1182–1185. 
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1.2 Efficiency of Natural Products Synthesis   
 
In traditional medicine, plant extracts were applied to cure the most diverse 
illnesses.5 The bioactivity of these extracts is typically owed to the present natural 
products (NP).6 Since nature was given the appropriate time to optimize these NP in 
an evolutionary fashion, they can exhibit enormous potencies and still represent a 
major source of inspiration for modern drug discovery. In fact, approximately half of 
the available drugs currently on the market contain NP motifs.7 A fair amount of 
characterized NP, which can induce desirable biological responses, possess a 
challenging molecular architecture. Figure 1.1 shows four well-known and very 
complex NP, which have been synthesized.8  
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Fig. 1.1. Natural products obtained in synthetic form.  
 
                                                
5 D. S. Fabricant, D. S. Farnsworth, Environmental Health Perspectives 2001, 109, 
69–75. 
6 J. W. Blunt, B. R. Copp, M. Munro, P. T. Northcote, Nat. Prod. Rep. 2011, 196–
268. 
7 a) I. Paterson, Science 2005, 310, 451–453. b) S. Danishefsky, Nat. Prod. Rep. 2010, 
27, 1114-1116. c) D. J. Newman, G. M. Cragg, K. M. Snader, J. Nat. Prod. 2003, 66, 
1022–1037. 
8 K. C. Nicolaou, C. R. H. Hale, C. Nilewski, Chem. Record. 2012, 12, 407–441. 
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As one can image, obtaining these NP was neither trivial, quick nor could 
large amounts of the final natural product be produced. 9  Nevertheless, these 
remarkable accomplishments illustrate how far organic chemistry has evolved over 
the last couple of decades. When such total synthesis programs are staged, it is crucial 
to design a synthetic route that is as efficient as possible. Hendrickson defined the 
ideal or most efficient synthesis as “The ideal synthesis creates a complex skeleton 
[...] in a sequence only of successive construction reactions involving no intermediary 
refunctionalizations, and leading directly to the structure of the target, not only its 
skeleton but also its correctly placed functionality.”10 In order to make this general 
concept more applicable and more specific, guidelines needed to be defined. Trost 
introduced the concept of atom economy, which states that reactions used in a 
synthesis have to be selective and economical in atom count, meaning that the number 
of atoms of reactants appearing in the product has to be maximised.11 The two Nobel 
Prize laureates Otto Diels and Kurt Alder introduced the model type reaction that 
meets these requirements. Diels-Alder reactions are selective and all atoms from the 
starting material are also present in the product.12 For the large-scale chemical 
production atom economy is similar to the E factor (waste per kg product) and of 
extreme importance to fulfil environmental criteria and be profitable. It also seems 
obvious that a good synthetic route always should involve as less synthetic 
transformations as possible. This so-called step economy can be increased by the 
development of new synthetic strategies and methodology that allows for shorter 
routes to a target structure.13   
Baran and Hoffmann introduced in 2009 their concept of redox economy. The 
idea of this concept is to minimise non-strategic redox manipulations in order to 
achieve an isohypsic synthesis, which consequently leads to a step economic synthesis 
(Fig. 1.2).14  
                                                
9 K. C. Nicolaou, C. R. H. Hale, C. Nilewski, Chem. Record. 2012, 12, 407–441. 
10 J. B. Hendrickson, J. Am. Chem. Soc. 1975, 97, 5784–5800. 
11 a) B. M. Trost, Angew. Chem. Int. Ed. 1995, 34, 259–281. b) B. M. Trost, Science 
1991, 254, 1471–1477. 
12 O. Diels, K. Alder, Justus Liebigs Ann. Chem. 1928, 460, 98-122. 
13 a) T. Newhouse, P. S. Baran, R. W. Hoffmann, Chem. Soc. Rev. 2009, 38, 3010–
3021 b) P. A. Wender, V. A. Verma, T. J. Paxton, T. H. Pillow, Acc. Chem. Res. 
2008, 41, 40–49. 
14 N. Z. Burns, P. S. Baran, R. W. Hoffmann, Angew. Chem. Int. Ed. 2009, 48, 2854–
2867. 
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Figure 1.2. Schematic Redox Economy. Reprinted with permission from  
 Ref.: 14, Copyright (2009) Wiley. 
 
These atom-, step- and redox efficiency concepts or guidelines can help 
chemists to better judge the quality of their synthetic scheme. However, in cases 
where there is not a precisely defined molecule as the target, but rather a desired 
biological function, an additional concept can come into play developed by Wender: 
function orientated synthesis (FOS). The concept is based on the reduction of 
molecular complexity by retained function (bioactivity) resulting in increased step 
economy (Fig 1.3).15 
 
 
Figure 1.3. Function Orientated Synthesis. Reprinted with permission from  
 Ref.: 15 Copyright (2008) ACS. 
 
FOS concept has been applied to several therapeutically important natural 
product leads and is gaining importance.16 Often simplified structures can mimic or 
even exceed the function of those from which they are inspired but can be supplied 
                                                
15 a) P. A. Wender, V. A. Verma, T. J. Paxton, T. H. Pillow, Acc. Chem. Res. 2008, 
41, 40–49. 
16 S. L. Schreiber, Science 2000, 287, 1964–1969. 
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easier.17 For instance, the sesquiterpen artemisin (1.1) a widely used antimalarial, 
FOS allowed medicinal chemists to generate its NP analog 1.2 with improved activity 
and step economy as shown in scheme 1.1.18 Dynemicin (1.3) can act as an antitumor 
agent by generating a diradical species through a Bergman cyclization19 that can 
cleave DNA. The simplified derivative 1.4 is an effective functional mimic of the NP 
1.3 and kills tumour cells through the identical mode of action.20 Another anti-tumour 
agent that gained strong interest is bryostatin 1 (1.5). This NP 1.5 represents an 
enormous synthetic challenge and requires over 70 synthetic steps to obtain. Wender 
and co-workers were able to dramatically reduce the step count by FOS approach. Not 
only did they reduce the number of steps by more than half, the resulting bryostatin 1 
analog 1.6 was also more potent than the parental NP 1.5.21 
 
                                                
17 P. A. Wender, V. A. Verma, T. J. Paxton, T. H. Pillow, Acc. Chem. Res. 2008, 41, 
40–49. 
18 a) C. Zhu, S. P. Cook, J. Am. Chem. Soc. 2012, 134, 13577-13579. b) G. H. Posner, 
P. M. O'Neill, Acc. Chem. Res. 2004, 6, 397-404. c) G. H. Posner, J. N. Cumming, S.-
H. Woo, P. Ploypradith, S. Xie, T. A. Shapiro, J. Med. Chem. 1998, 41, 940–951. 
19 R. R. Jones, R. G. Bergman, J. Am. Chem. Soc. 1972, 6, 660-661. 
20 a) M. D. Shair, T. Y. Yoon, K. K. Mosny, T. C. Chou, S. J. Danishefsky, J. Am. 
Chem. Soc. 1996, 118, 9509–9525. b) P. A. Wender, C. K. Zercher, J. Am. Chem. 
Soc. 1991, 131, 2311-2313. 
21 a) P. A. Wender, V. A. Verma, T. J. Paxton, T. H. Pillow, Acc. Chem. Res. 2008, 
41, 40–49. b) I. Paterson, Science 2005, 310, 451–453. 
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Scheme 1.1. Natural products simplified applying FOS  
 
Another approach is to truncate certain parts of the target molecule.22 A 
prominent example of this approach is the removal of the polycyclic side chain of 
halichondrin B (1.7) by Kishi and co-workers, where the shortened analog E 7389 
                                                
22 a) F. Schmid, H. J. Jessen, P. Burch, K. Gademann, MedChemComm 2013, 4, 135–
139. b) J.-Y. Wach, K. Gademann, Synlett 2011, 2012, 163–170. 
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(1.8) has successfully reached the market to treat metastatic breast cancer (Scheme 
1.2).23 
O
O
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HO
HO
HO
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Me
O
Me
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O
O
H
HH
H Me O
O O
O
O
H
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O
Me
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H
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O O
O
O
H
H
O
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O
O
H
O
MeO
H2N OH
Truncate
Halichondrin B (1.7)
E7389 or Erbulin  (1.8)
 
Scheme 1.2. Truncation of halichondrin B (1.7). 
 
 
 
 
 
 
 
 
                                                
23 a) D. P. Stamos, S. S. Chen, Y. Kishi, J. Org. Chem. 1997, 7552–7553. b) M. J. 
Towle, K. A. Salvato, J. Budrow, B. F. Wels, G. Kuznetsov, K. K. Aalfs, S. Welsh, 
W. Zheng, B. M. Seletsky, M. H. Palme, et al., Cancer Res. 2001, 61, 1013–102. c) T. 
D. Aicher, K. R. Buszek, F. G. Fang, C. J. Forsyth, S. H. Jung, Y. Kishi, M. C. 
Matelich, P. M. Scola, D. M. Spero, S. K. Yoon, J. Am. Chem. Soc. 1992, 114, 3162–
3164. 
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Parts of this chapter are published similarly or identically.24  
2.1 Introduction  
2.1.1 Isolation and Neuritotrophic Activity  
 
Gelsemiol (2.1) was first isolated from Gelsemium semprevirens (Gentianales) 
and characterized in 1987 by Jensen and co-workers.25 Seven years later 2.1 was also 
found in the leaves of Gelsemium elegans (Gentianales).26 A subsequent publication 
by Ohizumi and co-workers reported the isolation of 2.1 from Verbena littoralis 
(Lamiales) and demonstrated its neuritotrophic properties in the PC12D cell-line in 
the presence of nerve growth factor (NGF).27 Moreover, these plants which produce 
2.1 can be found on different continents and their use in traditional medicine to treat 
e.g. diarrhea, typhoid fever or migraine is reported.28 These findings made gelsemiol 
(2.1) an ideal candidate for our program on the synthesis and biological evaluation of 
neuritogenic natural products, which is described in this chapter.  
 
2.1.2 Iridoids  
 
A large number of plant families and some insects rely on iridoids as 
secondary metabolites, of which to date over 1000 have been isolated and 
characterized.29 The first isolation dates back to 1835 and is credited to Geiger.30 The 
name however originates from Cavill and co-workers who characterized the 1,3-
dialdehyde iridodial (2.2, Scheme 2.1) and named it after the Australian ants 
                                                
24 a) P. Burch, M. Binaghi, M. Scherer, C. Wentzel, D. Bossert, L. Eberhardt, M. 
Neuburger, P. Scheiffele, K. Gademann, Chem. Eur. J. 2013, 19, 2589–2591. b) M. 
Scherer, Master Thesis, 2012. c) D. Bossert, Master Thesis, 2012. 
25 S. R. Jensen, O. Kirk, B. J. Nielsen, R. Norrestam, Phytochem. 1987, 6, 1725–1731. 
26 H. Takayama, Y. Morohoshi, M. Kitajima, N. Aimi, S. Wongseripipatana, D. 
Ponglux, S.-I. Sakai, Nat. Prod. Lett. 1994, 5, 15–20. 
27 a) Y. S. Li, K. Matsunaga, R. Kato, Y. Ohizumi, J.  Pharmacy.  Pharmacol. 2001, 
53, 915–919. b) Y. S. Li, M. Ishibashi, M. Satake, Y. Oshima, Y. Ohizumi, Chem. 
Pharm. Bull. 2003, 51, 1103–1105 b) Y. Li, Y. Ohizumi, Yakugaku Zasshi 2004, 124, 
417–424. 
28 a) Y.-S. Li, K. Matsunaga, M. Ishibashi, Y. Ohizumi, J. Org. Chem. 2001, 66, 
2165–2167 b) F. Sun, Q. Y. Xing, X. T. Liang, J. Nat. Prod. 1989, 52, 1180–1182. 
29 A. Oudin, M. Courtois, M. Rideau, M. Clastre, Phytochem. Rev. 2007, 6, 259–276. 
30 P. L. Geiger, Ann. 1835, 14, 206. 
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(Iridomyrmex detectus) from which it was isolated.31 The hemiacetal form of iridodial 
(2.2) characterized by a methylcyclopentan[c]pyran backbone which is formed out of 
ten carbon atoms represents the common structural motif for the vast majority of 
iridoids.32 These compound possess a wide range of interesting pharmacological 
properties such as anti-inflammatory, anti-fungal, anti-bacterial or 
immunomodulatory activities.33 
 
1
34O
56 9
HH
11
O
OH
H
CH3
OH
Gelsemiol (2.1)
1
3O
4
56 9
OHCH3
H3C
11
Iridodial (2.2)
H
H
1
3
56 9
OCH3
H3C
11
H
H O
4
(–)-Brasoside (2.3)
4
O
56H
11
O
CH3
O
H O
OHO
OH
OH
OH
19
3
 
Scheme 2.1. Gelsemiol (2.1), iridodial (2.2) and (–)-brasoside (2.3). 
 
Gelsemiol (2.1) also belongs to the iridoid family, as one might see on the 
second glance. If iridodial (2.2, Scheme 2.1) is oxidized at the C(6) and C(11) 
position followed by lactonization and both aldehydes are reduced, gelsemiol (2.1) 
could be obtained.34 In all plant extracts where 2.1 has been isolated to date, the 
iridolactone (–)-brasoside (2.3) was also found.35 We therefore speculated that these 
compounds originate from an overlapping biosynthetic pathway. The iridoid 
biosynthesis is well investigated.36 Starting from pyruvate and glyceraldehyde-3-
phosphate, 7-deoxyloganic acid (2.4) is formed in over a dozen enzymatic steps. 
                                                
31 G. Cavill, D. L. Ford, H. D. Locksley, Aust. J. Chem. 1956, 9, 288–293. 
32 PhD Thesis of I. K. Mangion, Development of Organocatalytic Direct Aldol 
Transformations, Total Syntheses of Brasoside and Littoralisone, and Progress 
Toward the Total Synthesis of Diazonamide A, Cal. Tech., 2006. 
33 B. Dinda, S. Debnath, R. Banik, Chem. Pharm. Bull. 2011, 59, 803–833. 
34 a) H. Takayama, Y. Morohoshi, M. Kitajima, N. Aimi, S. Wongseripipatana, D. 
Ponglux, S.-I. Sakai, Nat. Prod. Lett. 1994, 5, 15–20 b) P. Burch, M. Binaghi, M. 
Scherer, C. Wentzel, D. Bossert, L. Eberhardt, M. Neuburger, P. Scheiffele, K. 
Gademann, Chem. Eur. J. 2013, 19, 2589–2591. 
35 a) S. R. Jensen, O. Kirk, B. J. Nielsen, R. Norrestam, Phytochem. 1987, 6, 1725–
1731. b) H. Takahashi, Y. Haga, T. Shibata, K. Nonoshita, T. Sakamoto, M. Moriya, 
T. Ohe, M. Chiba, Y. Mitobe, H. Kitazawa, et al. Bioorg. Med. Chem. Lett. 2009, 19, 
5436–5439 c)Y. S. Li, M. Ishibashi, M. Satake, Y. Oshima, Y. Ohizumi, Chem. 
Pharm. Bull. 2003, 51, 1103–1105. 
36 a) R. van der Heijden, A. Lefeber, R. Verpoorte, FEBS Lett. 1998, 343, 313-316. b) 
A. Oudin, M. Courtois, M. Rideau, M. Clastre, Phytochem. Rev. 2007, 6, 259–276. 
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Intermediate 2.4 could then undergo selective oxidation at the C(6) position yielding 
the alcohol 2.5, which is also present in Gelsemium semprevirens.37 Such oxidations 
are known for similar substrates.38 Intermolecular lactonization would then lead to the 
tricyclic (–)-brasoside 2.3. Following the previously mentioned keto-hemiactetal 
tautomerism, the dialdehyde 2.7 could be formed after deglycosylation of 2.3. The 
final step would involve the reduction of both aldehydes to obtain gelsemiol (2.1).  
 
O
HH
O
OH
H
CH3
OH
O
H3C OGlc
H
H
COOH
O
H3C OGlc
H
H
COOHHO
O
H3C OR
H
H
O
O
R = Glc 2.3
R = H 2.6
O
HH
O
O
H
CH3
O
2.1
2.4 2.5
2.7
oxidation lactonisation
reduction
keto-hemiacetal
tautomerism
 
Scheme 2.2. Proposed biosynthetic pathway of gelsemiol (2.1) 
 
 
 
 
 
 
 
 
                                                
37 a) Y.-S. Li, K. Matsunaga, M. Ishibashi, Y. Ohizumi, J. Org. Chem. 2001, 66, 
2165–2167. b) F. Sun, Q. Y. Xing, X. T. Liang, J. Nat. Prod. 1989, 52, 1180–1182. 
38 a) A. Oudin, M. Courtois, M. Rideau, M. Clastre, Phytochem. Rev. 2007, 6, 259–
276. b) N. Rønsted, E. Göbel, H. Franzyk, S. R. Jensen, C. E. Olsen, Phytochem. 
2000, 55, 337–348. 
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2.1.3 Gelsemiol as an Advanced Intermediate 
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Scheme 2.3. Natural products that could be derived from gelsemiol 2.1 
 
Out of these six natural products (NP) shown in scheme 2.3, three of them 
have been synthesized to date. An elegant biomimetic route to access (–)-littoralisone 
(2.8) and (–)-brasoside (2.3) has been established by MacMillan and Mangion.39 
Zanoni et al., synthesized semperoside A (2.9), which has also been isolated from 
Gelsemium semprevirens.40 The glycosylated congeners of gelsemiol 2.10, 2.11 and 
2.12 have not yet been synthetically produced and none of these six NP has been 
investigated regarding their neuritogenic properties. We envisioned that gelsemiol 
(2.1) could be an excellent advanced intermediate to access such interesting 
compounds. For 2.10, 2.11 and 2.12 an elaborate protecting group strategy should 
allow their production. If one could oxidize 2.1 to the dialdehyde 2.7, hemiacetal 
formation could lead to tricycle 2.13a. The acetylated derivative 2.13b was used by 
MacMillan to synthesize (–)-littoralisone (2.8) and (–)-brasoside (2.3) in two 
                                                
39 a) P. L. Geiger, Ann. 1835, 14, 206. b) I. K. Mangion, D. MacMillan, J. Am. Chem. 
Soc. 2005, 127, 3696–3697. 
40 a) G. Cavill, D. L. Ford, H. D. Locksley, Aust. J. Chem. 1956, 9, 288–293. b) P. 
Piccinini, G. Vidari, G. Zanoni, J. Am. Chem. Soc. 2004, 126, 5088–5089 c) S. R. 
Jensen, O. Kirk, B. J. Nielsen, R. Norrestam, Phytochem. 1987, 6, 1725–1731. 
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additional steps each (Scheme 2.4).44 With the dialdehyde 2.7 in hand, a selective 
reduction at the C(1) position would allow the formation of the hemiacetal starting 
form the opposite side than in the case of 2.13. After glycosylation, semperoside A 
(2.9) should be available for biological evaluation.   
 
O
O O
O
HH
CH3
H
O
H
O
O
H
CH3
OR
H
(–)-Brasoside 2.3
(–)-Littoralisone 2.81
MacMillan
i)   selective reduction at C(1)
ii)  hemiacetal formation
iii) glycosylation
Semperoside A (2.9)
2.7 R = H :  2.13a
R = Ac :  2.13b
 
Scheme 2.4 Synthetic strategy towards semperoside A (2.9), (–)-brasoside 
 (2.3) and (–)-littoralisone (2.8) starting form dialdehyde 2.7. 
 
2.1.4 Previous Synthetic Contributions 
 
In 1981 Grieco reported the total synthesis of (+)-iridomyrmecin (1.14) 
starting from the bicyclo[2.2.1]heptane derivative 2.15, which can be accessed in 
seven steps. The key step involved a Baeyer-Villiger oxidation using H2O2 and 
subsequent treatment of the resulting carbonyl acid with BF3 to yield bicyclic 
compound 2.16. The lactone 2.16 was then methylated twice. First, via enolate 
formation using LDA followed by a cuprate mediated anti-SN2’ alkylation. 
Deprotection with Raney-Nickel then initiated the lactonization and furnished (+)-
iridomyrmecin (2.14, Scheme 2.5).41 Later in 1997, Gibbs also reported the total 
synthesis of (+)-iridomyrmecin (2.14) using a partly different approach. The key 
intermediate 2.17 was synthesized in five steps. Iodolactonization followed by HI 
                                                
41 a) PhD Thesis of I. K. Mangion, Development of Organocatalytic Direct Aldol 
Transformations, Total Syntheses of Brasoside and Littoralisone, and Progress 
Toward the Total Synthesis of Diazonamide A, Cal. Tech., 2006. b) P. A. Grieco, C. 
V. Srinivasan, J. Org. Chem. 1981, 46, 2591–2593. 
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elimination using DBU yielded compound 2.16 in 86% over two steps. Three 
additional steps similar to Grieco’s approach then led to (+)-iridomyrmecin (2.14).42 
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2.14
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Scheme 2.5. Total synthesis of  (+)-iridomyrmecin (2.14) by Grieco and Gibbs. 
 
As previously mentioned, Zanoni reported the total synthesis of semperoside 
A (2.9) in 2004. In his strategy he employed synthetic knowledge, which he and his 
group had acquired earlier.43 A Baeyer-Villiger oxidation turned the Weiss diketone 
2.18 into the lactone 2.19, which upon a reduction-elimination sequence yielded the 
regioisomers 2.20a/b as an equimolar mixture. The Zanoni group found two different 
ways to convert this mixture into lactone 2.21. Both approaches started with the 
saponification of the 2.20a/b mixture, which was then either followed by lipase 
                                                
42 a) D. M. Hodgson, A. R. Gibbs, Synlett 1997, 6, 657–658. b) D. M. Hodgson, A. R. 
Gibbs, M. G. B. Drew, J. Chem. Soc., Perkin Trans. 1 1999, 3579–3590. 
43 a) P. Piccinini, G. Vidari, G. Zanoni, J. Am. Chem. Soc. 2004, 126, 5088–5089. b) 
G. Zanoni, A. Porta, A. Meriggi, M. Franzini, G. Vidari, J. Org. Chem. 2002, 67, 
6064–6069. 
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catalysed kinetic resolution in vinyl acetate/Et3N (5:1) as solvent system44 or by a 
sequence that is more suitable for scale up. For this approach a catalytic combination 
of Pd(II)- and Cu(II)(OAc)2 was applied. With this new type of Pd(II)-mediated 
lactonization 2.21 was obtained on gram scale. After acetylation, the Curran reaction 
was used for diastereoselective methylation and yielded the six-membered lactone 
2.22. Saponification followed by KI3 promoted iodolactonization gave the lactone 
2.23 in excellent yield. Raney-Nickel mediated hydrodeiodination followed by 
protection of the hydroxyl group and formylation yielded the SEM ether 2.24. Seven 
additional steps, including a mercury mediated 6-endo-trig cyclisation then led to 
semperoside A (2.9, Scheme 2.6).45 
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7 steps
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2.21
2.222.232.24  
Scheme 2.6 Total synthesis of semperoside A (1.9) by Zanoni. 
                                                
44 G. Zanoni, F. Agnelli, A. Meriggi, G. Vidari, Tetrahedron Asym. 2001, 1779-1784. 
45 P. Piccinini, G. Vidari, G. Zanoni, J. Am. Chem. Soc. 2004, 126, 5088–5089. 
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In 2004, Robertson described their attempt towards the total synthesis of (–)-
brasioside (2.3). 46 Even though their approach to cyclised compound 2.25 was 
unsuccessful, they discovered an efficient route for the synthesis of the bicyclic 
carbon backbone of gelsemiol-like iridoids in only three steps. First, cyclopent-2-
enone (2.26) was subjected to Luche reduction followed by esterification to furnish 
compound 2.27. Now the stage was set for a one pot radical reaction/olefination 
sequence initiated by dilauroyl peroxide (DLP, CH3-(CH2)10-COO)2) to give rise to 
2.28. After ozonolysis and ketal-protection, the α-position of the carbonyl group 
could then be modified.46  
O
O
O
I O
HH
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O
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O
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i) NaBH4, 
CeCl3*7H2O, MeOH
ii) ICH2CO2H, PPh3
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then EPVS, (t-BuO)2
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H
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i) O3, CH2Cl2, DMS
quant.
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OH
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O
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Scheme 2.7. Efforts towards the synthesis of (–)-brasioside (2.3) by Robertson. 
 
Our attention was also caught by the work of Markó and co-workers. An 
enantioselective copper-mediated inverse electron demanding Diels-Alder reaction 
(IEDDA) sets the stage for a radical cascade/skeletal rearrangement leading to the 
oxabicyclo[3.3.0]octanone skeleton (Scheme 2.8). Depending on the ligand and metal 
of choice, both isomers could be obtained in high yields, practical selectivity and only 
two steps.47 
                                                
46 J. Robertson, M. Menard, R. Ford, Synlett 2004, 15, 2788–2790. 
47 a) I. E. Markó, S. L. Warriner, B. Augustyns, Org. Lett. 2000, 2, 3123–3125. b) B. 
Augustyns, N. Maulide, I. E. Markó, Tetrahedron Lett. 2005, 46, 3895–3899. 
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 Efforts towards the structurally similar Corey endo-lactone (Scheme 2.8) used 
in the synthesis of prostaglandins are not discussed as the stereochemistry at C(9) 
position is inverted.48 
O
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O
OH OH
Corey endo-lactone 2.30
Cu(OTf)2, CH2Cl2,
90%, 56% ee
2.40
9
 
Scheme 2.8. Selective IEDDA and the Corey endo-lactone (2.30). 
 
Recently, Waldmann reported an interesting conceptional approach that led to 
the discovery of two novel NP-inspired neuritogenic compound classes. Different 
sesquiterpenoids and iridoids, including gelsemiol (2.1) and (–)-littoralisone (2.2) 
were analysed and the pentaleone 2.31 and iridoid-inspired scaffold 2.32 were defined 
as lead structures. 2.31 can be derived form a [3+2]-cycloaddition employing a chiral 
phosphine catalyst. These pentalenones 2.31 could then be further converted into the 
cyclopental[c]pyranone scaffold 2.32 by regioselective Baeyer-Villiger oxidation. 
With this methodology, they were able to build up a library with over 35 compounds 
and found several neurite outgrowth-promoting small molecules (2.33-2.37). These 
results proved their rational design approach to be valid and therefore presenting an 
antetype example how NP synthesis and function oriented drug discovery are able to 
                                                                                                                                       
c) J.-H. Liao, N. Maulide, B. Augustyns, I. E. Markó, Org. Biomol. Chem. 2006, 4, 
1464–1467 d) I. E. Markó, I. Chellé-Regnaut, B. Leroy, S. L. Warriner, Tetrahedron 
Lett. 1997, 97, 4269-4271. 
48 a) G. Zanoni, A. Porta, A. Meriggi, M. Franzini, G. Vidari, J. Org. Chem. 2002, 67, 
6064–6069. b) E. J. Corey, N. M. Weinshenker, T. K. Schaaf, W. Huber, J. Am. 
Chem. Soc. 1969, 91, 5675–5677. 
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interlock frictionless.49  
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Scheme 2.9. NP inspired neuritogenic compounds reported by Waldmann  
 and co-workers. 
 
From the different approaches discussed in this section, several parts are 
interesting for our synthetic endeavour. By applying Zanoni’s strategy, the formation 
of gelsemiol (2.1) might be possible if the lactone 2.21 or 2.23 can be reduced 
selectively at the C(4)-position in around 14 steps (Scheme 2.6). Walking on the 
synthetic pathways of either Grieco or Gibbs towards the lactone 2.16 in seven to nine 
steps might also be a promising route (Scheme 2.5). Lactone 2.16 then would be 
selectively formylated at the C(4) and alkylated at the C(8) position. If the radical 
reaction developed by Robertson and co-workers would also proceed smoothly with a 
methyl group present at the C(8) position, one might use his approach to obtain 
gelsemiol (2.1). However, since Markó provided the chemistry community with the 
shortest route to the oxabicyclo[3.3.0]octanone skeleton, we based our retrosynthetic 
analysis upon his approach.  
                                                
49 P.-Y. Dakas, J. A. Parga, S. Höing, H. R. Schöler, J. Sterneckert, K. Kumar, H. 
Waldmann, Angew. Chem. Int. Ed. 2013, 52, 9576–9581. 
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2.2 Results and Discussion                  
2.2.1 Retrosynthetic Analysis 
 
Gelsemiol (2.1) bears five stereocenters in a ten carbon atom skeleton, 
therefore its total synthesis in a selective, scalable and economic fashion remains 
challenging. From a retrosynthetic point of view, we envisioned that the best way to 
start might be with the cleavage of the C(6)-O bond, followed by the C(3) alcohol 
oxidation to obtain the desymmetrized diacid 2.38. Next, the removal of the methyl 
group was considered in a retro anti-SN2’ fashion. Intermediate 2.39 shows strong 
structural similarities with 2.40 (Scheme 2.8) arising form the previously introduced 
and by definition atom economic IEDDA reaction followed by the radical 
reaction/skeleton rearrangement.50 
If this reaction sequence tolerates a C(9) functionalization, 2.39 should be 
accessible from the selenium containing dienophil 2.41 and the diene 2.42. We also 
envisioned that the protection of the alcohol 2.41 might be beneficial to improve the 
selectivity of the IEDDA and the methylation process. A benzyl protection group 
seemed the most appropriate since it can be removed simultaneously during the 
deiodination step at the end of the synthesis using reductive hydrogenation conditions. 
    
                                                
50 a) I. E. Markó, S. L. Warriner, B. Augustyns, Org. Lett. 2000, 2, 3123–3125. b) B. 
I. Augustyns, N. Maulide, I. E. Markó, Tetrahedron Lett. 2005, 46, 3895–3899 c) J.-
H. Liao, N. Maulide, B. Augustyns, I. E. Markó, Org. Biomol. Chem. 2006, 4, 1464–
1467 d) I. E. Markó, I. Chellé-Regnaut, B. Leroy, S. L. Warriner, Tetrahedron Lett. 
1997, 97, 4269-4271. 
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Scheme 2.10. Retrosynthetic analysis of gelsemiol (2.1). 
2.2.2 Total Synthesis 
The synthesis began with the benzyl protection of propargyl alcohol (2.43) 
following a known literature procedure53 51 pursued by its trans-selective 
hydrozirconation using Schwartz’s reagent with PhSeBr to afford the stable 
vinylselenide 2.44 in 72% yield.52 Separate preparation of the Schwartz’s reagent 
resulted in higher yields and absolute stereocontrol compared to in situ procedures. 
Synthesis of intermediate 2.44 proved to be more challenging than anticipated. We 
initially attempted the IEDDA reaction at ambient pressure and in the presence of a 
catalytic amount of the in situ formed Cu(II)-complex chelated by the tert-BuBox 
ligand, which was prepared following a procedure from Evans,53 but mostly the [2+2] 
product was obtained. Interestingly, conducting the IEEDA reaction under reduced 
                                                
51 B. L. Ashfeld, S. F. Martin, Tetrahedron 2006, 62, 10497–10506. 
52 a) Z. Z. Huang, X. Huang, L. S. Zhu, Tetrahedron 1996, 29, 9819–9822. b) S. L. 
Buchwald, S. J. LaMaire, R. B. Nielsen, B. T. Watson, S. M. King, Org. Synth 1998, 
9, 162. b) J. Schwartz, J. A. Labinger, Angew. Chem. Int. Ed. 1976, 15, 333–340. c) 
D. W. Hart, J. Schwartz, J. Am. Chem. Soc. 1974, 26, 8115–8116. 
53 D. A. Evans, G. S. Peterson, J. S. Johnson, D. M. Barnes,  K. R. Campos, K. A. 
Woerpel, J. Org. Chem. 1998, 63, 4541–4544. 
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pressure in neat conditions led to the bicyclic compound 2.44 in high yields and with 
a reasonable enantiomeric excess of 83% (Scheme 2.11).  
OO
O
OCH3
OBnPhSe
Cp2ZrHCl 
PhSeBr, THF
72%
OBn
2.43 2.41 Cu(OTf)2, t-BuBox,DCM, 
then overnight under 
vacuum, 91%, 83% ee
O
O
Se
OBn
OMe
O
2.44
Sn(Bu)3H, AIBN 
PhH, reflux
then Silica, 60 h
88%, 2:1 d.r.
O
HH
OO
OBn
OCH3
2.44
2.42
2.39
Scheme 2.11. Synthesis of bicycle 2.39. 
In principle, four different transition states are possible for the IEDDA 
reaction. However, only one seems sterically favoured. By protecting the propargyl 
alcohol, we assume that this effect contributes to the enhanced selectivity in 
comparison to the reported 56% ee by Markó as speculated earlier (Fig. 2.1).54  
                                                
54 I. E. Markó, S. L. Warriner, B. Augustyns, Org. Lett. 2000, 2, 3123–3125. 
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Figure 2.1. Visualization of the possible transition states during the IEDDA 
 reaction. 
 
With 2.44 in hand, we were then able to obtain the rearranged bicyclic lactone 
2.39 in high yield via the radical reaction/skeleton rearrangement developed by 
Markó. The mechanism for this cascade reaction was proposed by the authors and is 
shown in scheme 2.12.55 With the help of AIBN, the radical 2.45 is generated, which 
then attacks the proximal sp2-carbon leading to cyclopropylmethyl intermediate 2.46. 
This 3-membered ring is then opened in the opposite direction to its closure, forming 
the stable tertiary radical 2.47. This intermediate 2.47 is then intercepted by the 
Sn(Ph)3H to yield the primary adduct 2.48. A [1,3]-shift of the carboxyl function 
results in the formation of lactone 2.39. Markó reported a diastereomeric ratio of 15:1, 
but we only obtained 2:1 in favour of the R-configured diastereoisomer of 2.39. 
Nevertheless, in our strategy, this stereocenter is irrelevant. In this step, the exclusion 
of oxygen was important, also requiring degasing of the silica gel.56 
    
                                                
55 a) B. I. Augustyns, N. Maulide, I. E. Markó, Tetrahedron Lett. 2005, 46, 3895–
3899. b) J.-H. Liao, N. Maulide, B. Augustyns, I. E. Markó, Org. Biomol. Chem. 
2006, 4, 1464–1467 b) I. E. Markó, S. L. Warriner, B. Augustyns, Org. Lett. 2000, 2, 
3123–3125. 
56 a) I. E. Markó, S. L. Warriner, B. Augustyns, Org. Lett. 2000, 2, 3123–3125. b) J.-
H. Liao, N. Maulide, B. Augustyns, I. E. Markó, Org. Biomol. Chem. 2006, 4, 1464–
1467 c) I. E. Markó, I. Chellé-Regnaut, B. Leroy, S. L. Warriner, Tetrahedron Lett. 
1997. 97, 4269-4271. 
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Scheme 2.12. Radical rearrangement and [1,3]-shift of the carboxyl function. 
 
Preparation of compound 2.49 was realized from olefin 2.39 without 
purification or isolation of the different intermediates. The bicyclic lactone 2.39 was 
treated with methyl cuprate, prepared in situ, in the presence of trimethylchlorosilane 
to undergo alkylation followed by opening of the lactone 2.39 in a anti-SN2’ type 
reaction.57 Saponification of the mono-ester malonate moiety in water, mild pH-
acidification of the mixture with solid CO2 to prevent decarboxylation, followed by 
iodolactonisation58 gave the carboxylic acid 2.49 in 45% yield over three steps. X-ray 
crystallographic analysis of 2.49 unambiguously confirmed the absolute configuration 
of all six stereogenic centres (Scheme 2.13). 
                                                
57 a) D. P. Curran, M.-H. Chen, Tetrahedron Lett. 1985, 26, 4991–4994. b) D. P. 
Curran, M. H. Chen, D. Leszczweski, J. Org. Chem. 1986, 51, 1612–1614. c) H. 
Weinmann, E. Winterfeldt, Synthesis 1995, 9, 1097–1101. 
58 P. Piccinini, G. Vidari, G. Zanoni, J. Am. Chem. Soc. 2004, 126, 5088–5089. 
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Scheme 2.13. The synthesis of bicyclic lactone 2.49 via selective methyl- 
 ation and iodolactonization.   
 
Finding an acceptable way to reduce the acid 2.49 became the most 
challenging part of the synthesis. After screening multiple conditions including: 
NaBH4 in combination with the Vilsmeier salt or ethyl chloroformate in combination 
with NaBH4, BH3-DMS and DIBAL-H, or NaBH(OAc)3 without activator using 
different solvents and temperatures. The best yields were obtained by making a detour 
via the lactol 2.50. Initially, the acid 2.49 was successfully reduced with an excess of 
BH3-DMS. After a solvent exchange from THF to EtOH, Raney-Nickel was added 
and a hydrogen atmosphere applied to trigger the benzyl group deprotection59 and the 
deiodination,60 which led to the desired NP 2.1 and the lactol 2.50 in a 2:3 mixture. To 
our delight, Raney-Nickel was able to oxidize lactol 2.50 to gelsemiol (2.1) at a slow 
rate but quantitatively. Since compound 2.1 and 2.50 could be separated, we were 
able to show that only lactol 2.50 could undergo oxidation to yield gelsemiol (2.1) 
using Raney-Nickel in EtOH without hydrogen at room temperature (Scheme 2.14).  
                                                
59 K. Horita, T. Yoshioka, T. Tanaka, Y. Oikawa, O. Yonemitsu, Tetrahedron 1986, 
42, 3021–3028. 
60 a) P. Piccinini, G. Vidari, G. Zanoni, J. Am. Chem. Soc. 2004, 126, 5088–5089. b) 
R. Di Florio, M. A. Rizzacasa, J. Org. Chem. 2002, 4392–4398. 
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Scheme 2.14. Endgame of the total synthesis of gelsemiol (2.1).   
 
Even though oxidations of secondary alcohols to ketones using refluxing 
Raney-Nickel conditions are known61 this example represents the first Raney-Nickel- 
mediated lactol oxidation at room temperature to our knowledge. We wondered about 
the generality of this reaction and performed a very limited screen of similar 
commercially available compounds. However, no successful oxidations were 
observed (Scheme 2.15).  
Another finding made during this project was that NaBH(OAc)3 was able to 
fully decarboxylate the acid 2.49 in quantitative yields, even at catalytic amounts. In 
literature, many examples for decarboxylations are known, including the use of 
simple alkali metals salts as NaCl or LiCl,62 but to the best of our knowledge, 
examples with catalytic amounts of NaBH(OAc)3 have never been reported.    
                                                
61 a) M. E. Krafft, W. J. Crooks, B. Zorc, S. E. Milczanowski, J. Org. Chem. 1988, 53, 
3158–3163. b) M. E. Krafft, B. Zorc, J. Org. Chem. 1986, 51, 5482–5484. 
62 A. P. Krapcho, J. F. Weimaster, J. M. Eldridge, J. Org. Chem. 1978. 1, 138-147. 
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Scheme 2.15. Limited scope explorations of lactol oxidations using Raney- 
 Nickel and decarboxylation using NaBH(OAc)3. 
 
Iridoid 2.1 was also synthesized without the formation of the lactol 2.50 via 
the activation of the acid 2.49 using the Vilsmeier salt, followed by NaBH4 
reduction63 giving rise to alcohol 2.51. This alcohol is then treated under similar 
conditions for the last step (Scheme 2.14). This route however, resulted in a much 
lower yield (35% over two steps). 
The 1H and 13C NMR spectra were then compared with the literature data.64 
They were in excellent agreement besides a small misassignment in the original 
isolation paper we could manage to clarify. In the isolation paper it is claimed that the 
C(4) carbon signal is displayed at 51.1 ppm and the C(9) at 44.7 ppm, but according 
to 2D-NMR experiments, the assignment is interchanged.  
For analytical proposes, Jensen and co-workers acetylated gelsemiol (2.1) on 
both alcohols and compared the analytical data with the data from natural 
glycosylated gelsemiol congeners. We decided to acetylate 2.1 as well and synthesize 
the diacetylated gelsemiol analog 2.52, which had the same chemical shifts as the 
reported ones.66 To dispel eventual last doubts, single crystals of 2.1 were grown in 
                                                
63 T. Fujisawa, T. Mori, T. Sato, Chem. Lett. 1983, 6, 835–838. 
64 S. R. Jensen, O. Kirk, B. J. Nielsen, R. Norrestam, Phytochem. 1987, 6, 1725–1731. 
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pentane/CH2Cl2 mixture and were then subjected to X-ray diffraction analysis 
(Scheme 2.14).  
2.2.3 Synthesis of Natural Congeners of Gelsemiol 
 
After having established a versatile route to gelsemiol (2.1), we intended to 
synthesize some of the previous mentioned natural congeners of gelsemiol (Scheme 
2.3). First, we focused on the oxidation of 2.1 to the dialdehyde 2.7 as briefly 
discussed in scheme 2.1 to find a pathway towards the (–)-brasoside (2.3), (–)-
littoralisole (2.8) or semperoside A (2.9) core structure. Unfortunately, all attempts to 
oxidize both lactones were unsuccessful as shown in table 2.1 below. Since 
MacMillan and Zanoni already have reported elegant ways to obtain these three cyclic 
iridolactones 2.3, 2.8, 2.9 we decided not to spend further recourses on these targets.  
 
Entry 
Oxidation 
Method 
Activation 
Agent 
Solvent Temp. Observation 
1 TPAP NMO MeCN r.t. Mono-oxidation 
2 MnO2 - DCM r.t. No reaction 
3 PCC - DCM r.t. Mono-oxidation 
4 PCC MeCO2Na DCM r.t. Mono-oxidation 
5 DMP - DCM 0 °C Mono-oxidation 
6 Swern - THF –78 °C No reaction 
7 Swern - DCM –78 °C Decomposition 
8 Moffatt DCC DMSO r.t. Decomposition 
9 Moffatt EDC DMSO r.t. Decomposition 
           
Table 2.1. Conditions attempted towards the synthesis of dialdehyde 2.7 
 (Scheme 2.2 and 2.4)  
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2.2.4 Biological Evaluation 
 
Gelsemiol 2.1 is known to induce neurite outgrowth in combination with nerve 
growth factor (NGF) in the PC12 cell line (rat adrenal pheochromocytoma) as 
mentioned previously.65 First, we successfully reproduced these reported results as 
shown (Fig. 2.2), then we attempted to find a similar morphological response using 
primary cells.  
 
            
  
          
 
 
 
 
 
                                                
65 a) Y. S. Li, K. Matsunaga, R. Kato, Y. Ohizumi, J.  Pharmacy.  Pharmacol. 2001, 
53, 915–919. b) Y. Li, Y. Ohizumi, Yakugaku Zasshi 2004, 124, 417–424. 
  A  B 
 
C 
  
 D  
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We therefore sacrificed mice pups to extract their primary cerebellar granule 
cells following a known procedure66 in collaboration with the group of Prof. Dr. Peter 
Scheiffele (Biozentum, Basel). For this type of primary neurons we had to establish a 
different way to analyse the neurite outgrowth than in the PC12 cell model. The 
difference is that all of these cells bear long axons and dendrites and are forming an 
unmanageable network. Therefore, we focused on the amount of branching-points, 
meaning how much processes (axon and dendrites) of a single neuron cross the eight 
concentric cycles being focused on the soma, to see if gelsemiol (2.1) initiates any 
morphological changes. To be able to do so, the cells were transfected with green 
fluorescent protein (GFP). In only a small percentage of the primary cells the 
transfection was successful and the few fluorescent neurons were distinguishable from 
the rest. Since we knew that 2.1 was only active in combination with NGF, we 
speculated that brain-derived neurite growth factor (BDGF) might be an appropriate 
substitution for this model. However, we could only find a significant difference in 
branching-points when samples with and without BDGF where compared. The 
addition of gelsemiol (2.1) made no difference.     
 
                                                
66 C. Dean, F. G. Scholl, J. Choih, S. DeMaria, J. Berger, E. Isacoff, P. Scheiffele, 
Nat. Neurosci. 2003, 6, 708–716. 
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Figure 2.2. A: Blank (DMSO 0.1 %), B: Blank (NGF 7S 10 ng mL-1 + 
DMSO 0.1 %), C: gelsemiol (2.1) (50 µM) D: gelsemiol (2.1) (50 µM 
+ NGF 7S  ng  mL-1), E: plotted activity, Incubation period: 2 days. 
Values are reported as mean ± SEM. (unpaired tow-tailed t-test 
significance: *** = P < 0.0001) 
 
   30             CHAPTER 2 - TOTAL SYNTHESIS AND BIOLOGICAL EVALUATION OF GELSEMIOL 
 
 
 Figure 2.3. Representative inverted image of a GFP expressing primary gran- 
 ule cell and the eight concentric cycles. 
 
In order to restore brain function, it is not only sufficient to induce neurite 
outgrowth, but is also mandatory to form new synapses. A synapse consists of a pre- 
and postsynapse (also see Fig. 4.10). Only if these are overlapping, a port for neuronal 
signal transaction can be formed. The formation of synapses is called synaptogenesis 
and can be investigated using an elaborate antibody staining methodology. Therefore 
the primary cerebellar granule cells were again seeded in a 24-well plate, transfected 
with GFP as before and incubated for 2 days with 50 µM of gelsemiol (2.1). Then the 
cells were fixed and stained using pre- and postsynaptic specific and their respective 
fluorescent secondary antibodies. When these blue (postsynapes) and red (presynapse) 
dots overlap, they represent a functionable synapse. If this overlap is located on the 
green neuron of interest, a yellow dot can be observed as shown (Fig. 2.4). The 
amount of these spots is then analysed using a confocal microscope and compared to 
the control experiments. Our findings suggest that synaptogenesis cannot be attributed 
to gelsemiol (2.1).  
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Figure 2.4. Representative image of a GFP expressing primary granule  
 cell stained with post- and presynaptic antibody markers.  
2.3 Conclusion 
 
The first enantioselective total synthesis of gelsemiol (2.1) was accomplished 
in nine steps and an overall yield of 14 %. The key features of the synthesis involved 
a stereoselective IEDDA as well as the following radical rearrangement, and the 
highly efficient and stereoselective iodolactonisation. Selective reduction of 
carboxylic acid 2.39 kept the lactone moiety intact and retained the absolute 
configuration of the six stereogenic centers. Additionally, the final three 
transformation can be performed in one pot. This versatile synthetic approach, which 
also follows some of the in chapter 1.2 introduced criteria for an efficient total 
synthesis, is expected to be widely utilized for the syntheses of iridoids and 
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iridoalkaloids. The biological evaluation reproduced the neuritogenic activity in the 
PC12 cell line but could not be transferred onto primary cell models.67  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
67 P. Burch, M. Binaghi, M. Scherer, C. Wentzel, D. Bossert, L. Eberhardt, M. 
Neuburger, P. Scheiffele, K. Gademann, Chem. Eur. J. 2013, 19, 2589–2591. 
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3.1 Introduction 
3.1.1 General Outline 
 
Our group accomplished the total synthesis of several neuritogenic alkaloids 
originating from entomopathogenic fungi such as pretenellin (3.1), farinosone A (3.2), 
militarinone D (3.3) or farinosone C (3.4) and assigned their absolute configurations 
(Fig. 3.1).68 The biosynthesis of these compounds is likely to be related, as recent 
contributions suggested.69 From a very limited structure-activity relationship (SAR) 
study of farinosone C (3.4), we found that the simplified L-tyrosinol-propionamide 
analog 3.5 was able to induce neuronal differentiation, albeit at higher concentration 
than the parent NP 3.4. We therefore aimed to synthesize structurally optimized 
derivatives of farinosone C (3.4), which retain or even display more potent neurite 
outgrowth-inducing capability. At the same time, this endeavour would also result in a 
more defined description of the pharmacophore. In this chapter, we report the results 
of this SAR study on farinosone C analogs. 
 
 
                                                
68 a) H. J. Jessen, A. Schumacher, T. Shaw, A. Pfaltz, K. Gademann, Angew. Chem. 
Int. Ed. 2011, 4222–4226 b) Y. Li, Y. Ohizumi, Yakugaku Zasshi 2004, 124, 417–424 
c) H. J. Jessen, D. Barbaras, M. Hamburger, K. Gademann, Org. Lett. 2009, 11, 
3446–3449 d) Y. Cheng, B. Schneider, U. Riese, B. Schubert, Z. Li, M. Hamburger, 
J. Nat. Prod. 2004, 67, 1854–1858. 
69 a) J. Xu, L. Trzoss, W. K. Chang, E. A. Theodorakis, Angew. Chem. 2011, 123, 
3756–3760 b) S. Bergmann, J. Schümann, K. Scherlach, C. Lange, A. A. Brakhage, 
C. Hertweck, Nat. Chem. Biol. 2007, 3, 213–217 c) L. Trzoss, J. Xu, M. H. Lacoske, 
W. C. Mobley, E. A. Theodorakis, Chem. Eur. J. 2013, 19, 6398–6408 d) L. M. Halo, 
J. W. Marshall, A. A. Yakasai, Z. Song, C. P. Butts, M. P. Crump, M. Heneghan, A. 
M. Bailey, T. J. Simpson, C. M. Lazarus, et al., Chembiochem 2008, 9, 585–594. 
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Figure 3.1. Neuritogenic natural products and lead analog 3.5. 
 
3.1.2 Parasite Host Control    
 
Understanding the ways in which parasites are able to manipulate the 
behaviour of their hosts has become a popular research field.70 An interesting example 
is the effects Toxoplasma gondii has on rats and mice. These rodents are in a classic 
predator/prey system with cats and it was essential for their survival to develop 
efficient defence strategies. The native fear of the odour of cat urine is one of these 
strategies rodents have developed to avoid contact with their predators. But when 
mice are infected by Toxoplasma gondii, this fear turns into a fatal attraction. This 
parasite must find its way to a cat’s intestines for sexual reproduction. After 
successful copulation, the formed oocytes are excreted in the cat’s feces and rodents 
are then employed to serve as transport vesicles to the next cat host. The way 
Toxoplasma gondii is affecting the rodents behaviour is not fully, but quite well 
understood: This parasite is one of the few pathogens that is able to cross the blood-
brain-barrier of the host. Once in the brain, it increases the dopamine (4.12) levels up 
to 15%. When in contrary the dopamine receptors of infected mice are blocked, the 
natural fear of cat’s urine could be restored. This strongly suggests a link between the 
behavioural changes of the host and the neurotransmitter that is known to be key for 
reward and decision-making. The effects Toxoplasma gondii has on humans have 
been investigated intensively, but not considered a major health risk. Hence 20-40% 
                                                
70 a) R. Poulin, Adv. Stud. Behav. 2010, 41, 151–186. b) F. Libersat, A. Delago, R. 
Gal, Annu. Rev. Entomol. 2009, 54, 189–207. 
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of the world’s population is infected by Toxoplasma gondii, this is important.71    
In addition, entomopathogenic fungi that infect and kill insects can physically 
control their hosts using a variety of complex interactions, of which some are believed 
to be mediated by small molecules.72 These organisms receive growing interest from 
the scientific community, not only because their host-parasite interactions could 
potentially led to new insecticides, but also because these fungi have been widely 
used in traditional Chinese medicine over centuries and understanding their effects on 
humans in detail is important.73  
In 2004, Hamburger and co-workers (Pharmazentrum Basel) reported on the 
isolation and partial characterization of farinosone A (3.2), B, and C (3.4) originating 
from the entomopathogenic fungi Paecilomyces farinosus,74 also known as Isaria 
farinose.75 If these compounds are involved in the observed behavioural changes is 
unclear. Nevertheless, these compounds are known to significantly induce neurite 
outgrowth in PC12 cells and, therefore lie exactly in the overlap of two of our main 
research focuses: natural product synthesis and restoration of brain function.76 
   
                                                
71 a) P. K. House, A. Vyas, R. Sapolsky, PLOS ONE 2011, 6, e23277. b) A. Vyas, S.-
K. Kim, N. Giacomini, J. C. Boothroyd, R. M. Sapolsky, Proc. Natl. Acad. Sci. 2007, 
15, 6442-6447. c) G. Schatz, Jenseits Der Gene, Wiley-VCH Verlag GmbH & Co. 
KGaA, Weinheim, 2012. 
72 a) A. E. Hajek, R. S. Leger, Annu. Rev. Entomol. 1994, 39, 293–322. b) H. E. Roy, 
D. C. Steinkraus, J. Eilenberg, A. E. Hajek, J. K. Pell, Annu. Rev. Entomol. 2006, 51, 
331–357. c) M. Rohlfs, A. C. L. Churchill, Fungal Genetics and Biology 2011, 48, 
23–34. d) H. J. Jessen, A. Schumacher, F. Schmid, A. Pfaltz, Org. Lett. 2011. 16, 
4368-4370. 
73 R. Paterson, Phytochem. 2008, 69, 1469–1495. 
74 Y. Cheng, B. Schneider, U. Riese, B. Schubert, Z. Li, M. Hamburger, J. Nat. Prod. 
2004, 67, 1854–1858. 
75 G. Zimmermann, Biocontrol. Sci. Tech. 2008, 18, 865–901. 
76 Y. Cheng, B. Schneider, U. Riese, B. Schubert, Z. Li, M. Hamburger, J. Nat. Prod. 
2004, 67, 1854–1858. 
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Figure 3.2. Entomopathogenic fungus Paecilomyces farinosus growing out  
 of an insect corpse.77 
  
3.1.3 Total Synthesis of Farinosone C by Jessen et al.   
 
With the absolute stereochemistry of the natural products not clearly assigned, 
all four possible farinosone C isomers had to be synthesized to elaborate the absolute 
stereochemistry by comparing the analytical data of the synthesized compounds with 
the isolated natural product. The synthesis began by TIPS protection of iodoethanol 
that was then coupled with either (+)- or (–)-pseudoephedrine-propionamide, 
following an optimized procedure from Myers.78 Direct reductive cleavage of the 
obtained amide 3.6 employing LAH resulted in the formation of the respective 
aldehydes 3.7 in high to excellent enantiomeric excess. The trans-selective double 
bond was introduced by a Wittig reaction using the ylid 3.8. The resulting ester was 
reduced with DIBAL-H before it was re-oxidized with activated manganese dioxide 
to obtain the aldehyde 3.9 (Scheme 3.1a). The second double-bond was introduced via 
a Horner-Wadsworth-Emmons reaction giving rise to the (E,E) configured ester 3.10 
in both enantiomers in quantitative yields. These compounds proved to be unstable 
and partial racemization was observed. Separation of the isomers could be performed 
                                                
77 Photograph reprinted with permission of Renée Lebeuf, 2011   
78 A. G. Myers, B. H. Yang, H. Chen, L. McKinstry, D. J. Kopecky, J. L. Gleason, J. 
Am. Chem. Soc. 1997, 119, 6496–6511. 
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satisfyingly at a later stage of the synthesis, and this issue could be resolved. After 
TIPS removal, a mild two step oxidation sequence of a Swern oxidation, followed by 
sodium chlorite oxidation yielded compound 3.11 in high yields. Tert-butylation of 
acid 3.12 and selective LiOH saponification, then set the stage for the peptide 
coupling with either L- or D-tyrosinol. The total synthesis was completed by 
deprotection of the acid terminus with TFA. The analytical data of the 1’S,3R 
configurated isomer was in full agreement with the reported values for farinosone C 
(3.4). This first, enantioselective total synthesis of 3.4 required 14 steps and achieved 
an overall yield of 23% (Scheme 3.1b).79  
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Scheme 3.1a. Total Synthesis of farinosone C (3.4) by Jessen et al. part A.  
                                                
79 H. J. Jessen, D. Barbaras, M. Hamburger, K. Gademann, Org. Lett. 2009, 11, 3446–
3449. 
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Scheme 3.1b. Total Synthesis of farinosone C (3.4) by Jessen et al. part B.  
 
3.1.4 Function Oriented Synthetic Approaches from Gademann and Co-Workers    
 
The Gademann laboratory has a long-standing tradition in exploring the 
biological and synthetic scope of natural products and their analogs after successful 
completion of their total synthesis. As outlined in section 1.2, simplification of a NP 
while retaining the bioactivity will facilitate its supply. Bonazzi et al. for example 
showed that the potent CRM1 nuclear export inhibitors anguinomycin C (3.13) and D 
(3.14) can be strongly simplified by truncation of the polyketide chain, hence the 
resulting analog 3.15 retained most of the biological activity (Fig. 3.2).80 Another 
satisfying endeavour was the truncation of polypeptide chain from farinosone A (3.2) 
and militarinone D (3.16). In this investigation, not only was the side chain 
subtracted, but also the pharmacophore was optimized during the SAR study. The 
most potent analog SF33 (3.17) origination from this project conducted by Schmid et 
                                                
80 S. Bonazzi, O. Eidam, S. Guettinger, J.-Y. Wach, I. Zemp, U. Kutay, K. Gademann, 
J. Am. Chem. Soc. 2010, 132, 1432–1442. 
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al. was able to induce neuronal differentiation in the PC12 assay at a 20-fold lower 
concentration than the parent NP 3.2 and 3.16.81 Other SAR investigations focused on 
the A ring of the neuritogenic NP withanolide A (3.18) conducted by Liffert and 
Hoecker et al.82 or the antibacterial alkaloid nostocarboline (3.18) and its dimeric 
analogs synthesized by Barbaras and Bonazzi et al.83 These two latter approaches did 
not lead to significantly simplified analogs, but did provide valuable insight in to the 
structural requirements for bioactivity. Moreover, in the case of nostocarboline (3.19), 
several derivatives showed strongly improved selectivity and bioactivity.  
                                                
81 F. Schmid, H. J. Jessen, P. Burch, K. Gademann, MedChemComm 2013, 4, 135–
139. 
82 a) R. Liffert, J. Hoecker, C. K. Jana, T. M. Woods, P. Burch, H. J. Jessen, M. 
Neuburger, K. Gademann, Chem. Sci. 2013, 4, 2851–2857. b) C. K. Jana, J. Hoecker, 
T. M. Woods, H. J. Jessen, M. Neuburger, K. Gademann, Angew. Chem. 2011, 123, 
8557–8561. c) C. K. Jana, J. Hoecker, T. M. Woods, H. J. Jessen, M. Neuburger, K. 
Gademann, Angew. Chem. Int. Ed. 2011, 50, 8407–8411. 
83 a) J. F. Blom, T. Brütsch, D. Barbaras, Y. Bethuel, H. H. Locher, C. Hubschwerlen, 
K. Gademann, Org. Lett. 2006, 8, 737–740. b) D. Barbaras, M. Kaiser, R. Brun, K. 
Gademann, Bioorg. Med. Chem. Lett. 2008, 18, 4413–4415. c) H. H. Locher, D. Ritz, 
P. Pfaff, M. Gaertner, A. Knezevic, D. Sabato, S. Schroeder, D. Barbaras, K. 
Gademann, Chemotherapy 2010, 56, 318–324. d) S. Bonazzi, D. Barbaras, L. Patiny, 
R. Scopelliti, P. Schneider, S. T. Cole, M. Kaiser, R. Brun, K. Gademann, Bioorg. 
Med. Chem. 2010, 18, 1464–1476. 
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Figure 3.2. FOS approaches by Gademann and co-workers. 
3.1.5 The Rat Pheochromocytoma PC12 Cell Assay as a Brain Model  
In 1976, Greene and Tischler set the foundation for the rat pheochromocytoma 
PC12 assay. This immortal cell line was harvested from a solid tumour located in the 
adrenal glands from a New England Deaconess Hospital strain white rat; washed, 
cultivated and made accessible for the scientific community. In their publication they 
stated that: “The PC12 line appears to be a useful model system for the study of 
numerous problems in neurobiology and neurochemistry”84  which is evident by 
hundreds of scientific contributions, including at least four originating form our 
laboratory.85  
                                                
84 L. A. Greene, A. S. Tischler, Proc. Natl. Acad. Sci. 1980, 77, 1701–1705. 
85 a) P. Burch, M. Binaghi, M. Scherer, C. Wentzel, D. Bossert, L. Eberhardt, M. 
Neuburger, P. Scheiffele, K. Gademann, Chem. Eur. J. 2013, 19, 2589–2591.            
b) F. Schmid, H. J. Jessen, P. Burch, K. Gademann, MedChemComm 2013, 4, 135–
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These cells also respond to the nerve growth factor (NGF). This neurotrophin 
initiates the formation and elongation of dendrites and axons.86 Certain NP such as 
gelsemiol (2.1) promote the effects of NGF and lead to a more pronounced 
differentiation, but show no effect when NGF is not present.87 Other compounds such 
as the ones discussed in this chapter induce neurite outgrowth without the need to 
supply NGF. Nevertheless, the screening is facilitated by overnight priming of the 
PC12 cells using 20-120 ng/mL concentration of NGF, increasing the cell sensitivity 
towards potential neuritogenic compounds. 88  NGF also represents our standard 
positive control and, thus allows for quality judgment of each single run. Even though 
research on neuritogenic compounds is shifting more and more towards primary cell 
models,89 this relatively stable and robust in vitro assay does allow a chemical 
laboratory to efficiently screen their promising molecules in house.  
  The large protein NGF lacks metabolic stability and is incapable to cross the 
Blood-Brain-Barrier. Therefore, a NGF-based treatment of neuronal diseases would 
rely on direct injection of NGF in the patient’s brain. Despite the fact that this 
approach showed acceptable results in animal studies, adaption of this procedure to 
humans is unpractical.90  More promising in this regard are gene therapy-based 
strategies. In these approaches the NGF-expressing gene is delivered into neuronal 
cells using a virus vector. After successful implementation of the gene, the neurons 
are able to increase the NGF concentrations permanently.91 However, one could 
                                                                                                                                       
139. c) H. J. Jessen, A. Schumacher, T. Shaw, A. Pfaltz, K. Gademann, Angew. 
Chem. Int. Ed. 2011, 4222–4226. d) H. J. Jessen, D. Barbaras, M. Hamburger, K. 
Gademann, Org. Lett. 2009, 11, 3446–3449. 
86 a) L. A. Greene, A. S. Tischler, Proc. Natl. Acad. Sci. 1976. 7, 2424-2428. b) I. 
Dikic, J. Schlessinger, I. Lax, Curr. Biol. 1994, 4, 702–708. 
87 a) Y. S. Li, K. Matsunaga, R. Kato, Y. Ohizumi, J.  Pharmacy  Pharmacol. 2001, 
53, 915–919. b) P. Burch, M. Binaghi, M. Scherer, C. Wentzel, D. Bossert, L. 
Eberhardt, M. Neuburger, P. Scheiffele, K. Gademann, Chem. Eur. J. 2013, 19, 2589–
2591. c) Y. S. Li, M. Ishibashi, M. Satake, Y. Oshima, Y. Ohizumi, Chem. Pharm. 
Bull. 2003, 51, 1103–1105. 
88 L. Trzoss, J. Xu, M. H. Lacoske, W. C. Mobley, E. A. Theodorakis, Org. Lett. 
2011, 13, 4554–4557. 
89 P.-Y. Dakas, J. A. Parga, S. Höing, H. R. Schöler, J. Sterneckert, K. Kumar, H. 
Waldmann, Angew. Chem. Int. Ed. 2013, 52, 9576–9581. 
90 U. Bickel, T. Yoshikawa, W. M. Pardridge, Adv. Drug Deliv. Rev. 2001, 46, 247–
279. 
91 a) R. J. Mandel, Curr. Opin. Mol. Ther. 2010, 12, 240–247. b) M. H. Tuszynski, L. 
Thal, M. Pay, D. P. Salmon, H. S. U, R. Bakay, P. Patel, A. Blesch, H. L. Vahlsing, 
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consider a small molecule-driven approach that would ultimately lead to an oral 
treatment more efficient.92   
3.2 Results and Discussion  
3.2.1 Synthesis of Farinosone C Analogs 
 
Initially, compound 3.5 was intended to be obtained by combining L-tyrosinol 
hydrochloride with propionic acid using EDC and HOBt as coupling reagents, but the 
yields were unsatisfying. Replacing HOBt/EDC with PyBoB also gave in impractical 
results and the combination the DMF/THF as solvent mixture in both cases was 
inconvenient regarding its removal. We then tried the Schotten-Baumann method, 
which employs a biphasic solvent mixture of H2O and THF (or MeCN in some cases) 
in combination with the respective acid chloride and potassium carbonate.93 With this 
method, the amide 3.5 could be obtained in high yields. This method was then used to 
perform most of the corresponding amide formations. We noted that if the acid 
chloride is added approximately 0.5 h later, the reactions proceeded with higher yields 
and less reaction times. This might be due to the fact that if the amine is deprotonated 
beforehand, it will react faster with the acid chloride, thereby reducing the ability of 
the acid chloride to decompose. Using this method, all target compounds expect 
3.20s,p,l could be successfully prepared in yields ranging form 9 to 99% (Fig. 3.2 and 
Table 3.1).  
 
R2
NH3 O
R3ClR
1
R2
H
N
R1
O
R3K2CO3, H2O/THF, 
r.t., 3 h - o.n.,
9 - 99%  
 Scheme 3.2. General procedure for the tyrosinol amide synthesis. 
           
 
 
 
                                                                                                                                       
G. Ho, et al., Nat Med 2005, 11, 551–555. a) E. D. Roberson, L. Mucke, Science 
2006, 314, 781–784. 
92 F. M. Longo, S. M. Massa, Nat. Rev. Drug Discovery 2013, 12, 507–525. 
93 L. Kürti, B. Czako, Strategic Applications of Named Reactions in Organic 
Synthesis: Background and Detailed Mechanisms, Elsevier, Amsterdam, 2005. 
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Table 3.1. Complete farinosone C analog (3.5, 3.20a-t) collection. 
 
Cpd R1 R2 R3 
3.5 OH CH2OH CH2CH3 
3.20a H CH2OH CH2CH3 
3.20b OCH3 CH2OH CH2CH3 
3.20c OCOCH2CH3 CH2OH CH2CH3 
3.20d OH CH2OCH3 CH2CH3 
3.20f OCH3 CH2OCH3 CH2CH3 
3.20g OH COOH CH2CH3 
3.20h OH COOCH3 CH2CH3 
3.20j OH H CH2CH3 
3.20m OH CH2OH Ph 
3.20n OH CH2OH CH(CH3)2 
3.20o OH CH2OH C(CH3)3 
  3.20r OH CH2OH  (CH2)7CH3 
3.20s OH CH2OH  (CH2)7COOH 
3.20t OH CH2OH  (CH2)7OH 
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O N N
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During the production of compound 3.5 the two isomeric diester side products 
3.20c and 3.20r were also formed and therefore added to the analog collection. 1H 
NMR analysis of the OH signals of each isomer allowed differentiation of their 
structures. The phenolic proton signal of 3.20e is more downfield shifted than the 
primary alcohol of 3.20c as shown in the spectra below (Fig. 3.3). 
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Figure 3.3. 1H NMR in deuterated DMSO of the diesters 3.20c (upper) and  
3.20e (lower).   
 
Selective methylation of the hydroxyl groups was accomplished using caesium 
carbonate as base in combination with methyl iodide.94 Mostly methylation of the 
phenolic hydroxyl group 3.20b and a minor amount the dimethylated product 3.20e 
were observed (Scheme 3.3).  
O
H
N
OHO
Cs2CO3, MeI, 
MeCN, r.t.
+
O
H
N
OO
 53%, 3.20b 9%, 3.20f
3.5
 
Scheme 3.3. Selective phenolic hydroxyl group methylation. 
                                                
94 G. Balboni, V. Onnis, C. Congiu, M. Zotti, Y. Sasaki, A. Ambo, S. D. Bryant, Y. 
Jinsmaa, L. H. Lazarus, I. Lazzari, Bioorg. Med. Chem. 2007, 15, 3143–3151. 
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The selective methylation of the less basic, primary alcohol was not as 
straightforward. Therefore, the previously prepared methyl ester 3.20h was protected 
with TBSCl using a catalytic amount of DMAP. Then, the protected methyl ester 3.21 
was reduced employing LiAlH4 to furnish the primary alcohol 3.22. This alcohol was 
then methylated utilizing methyl iodide and sodium hydride, followed by a TBAF 
deprotection yielding ether 3.20d (Scheme 3.4).   
HO
H
N
OO O O
H
N
OO O
TBS
O
H
N
OHO
TBS
HO
H
N
OO
TBSCl, DMAP,
Et3N, CH2Cl2,
r.t. 96%
LiAlH4, DMF, 
0 °C, 86%
i) NaH, MeI, DMF
0 °C to r.t.
ii) TBAF, THF, r.t.,
23% over 2 steps
3.21
3.22
3.20h
3.20d  
              Scheme 3.4. Methylation of the primary alcohol 3.20d.  
 
 Reduction of the carbonyl functionality was more challenging than 
anticipated. First attempts with LiAlH4, even under refluxing conditions, 
demonstrated no reactivity. Activation of the amide function with TMSCl in 
combination with HMDS, followed by reduction with BH3-DMS complex solution 
was unsuccessful as well, even though this approach was applied for the synthesis of 
similar compounds, as it will be discussed in chapter 4. The same was observed for 
the reductive amination with L-tyrosinol (3.23) and propionaldehyde. At this point, 
we turned our synthetic efforts towards a direction we wanted to avoid in the first 
place: 1-bromopropane (1 equiv.) was added to a solution of L-tyrosinol (1 equiv.) 
and potassium carbonate in a mixture of THF/H2O. At room temperature no reactivity 
was observed, but at 70 °C, the expected overalkylation occurred. 1H NMR and 
UPLC analysis (data not shown) indicated that all three possible dialkylation products 
and one monoalkylated product were formed. Neither temperature reduction to 45 °C 
nor change of the base to Et3N or DBU in DMF improved selectivity. We then 
reduced the amount of 1-bromopropane to 0.5 equiv. and tried the aforementioned 
Schotten-Baumann conditions. UPLC analysis revealed mainly the monoalkylated 
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product and semi-preparative HPLC separation yielded the pure amine 3.20l in 39% 
yield.    
HO
NH2
HO
BrCH2CH2CH3 (0.5 equiv.),
K2CO3, THF/H2O, 60 °C. 
                  39%
HO
H
N
HO
3.23 3.20l  
Scheme 3.5. Synthesis of amine 3.20q. 
 
The adamantyl derivative 3.20p was synthesized employing the copper-
catalyzed Huisgen 1,3-dipolar cycloaddition, commonly known as the “click 
reaction”. To improve the process, TBTA 3.24 was added as catalyst (Scheme 3.5). 
Sharpless and Fokin noticed in early mechanistic investigations that the reaction rates 
of some polyvalent substrates were remarkably high and that these “click reactions” 
were autocatalytic. They then prepared and screened a collection of polyvalent 
triazoles and discovered that TBTA 3.24 (Scheme 3.6) was able to accelerate the 
model reaction the most; the [1,2,3]-triazole groups and the tertiary amine were 
postulated to work therefore in concert. The amine nitrogen is expected to provide 
additional electron density to the copper, which results in a higher reactivity. The 
[1,2,3]-triazole rings on the other hand shield the metal centre from potential 
destabilizing interactions but nevertheless are labile enough to allow the copper(I)-
acetylide/ligand complex formation. This complex is then carried through the 
catalytic cycle.95 
                                                
95 T. R. Chan, R. Hilgraf, K. B. Sharpless, V. V. Fokin, Org. Lett. 2004, 6, 2853–
2855. 
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Scheme 3.6. Synthesis of the [1,2,3]-triazole analog 3.20p. 
 
The formation oft the acid 3.20s was accomplished by monoactivation of 
suberic acid (3.25) with pentafluorophenol (PFP) using EDC after direct amide 
coupling approaches with ByPoP failed. The activated PFP-ester was reacted with L-
tyrosinol (3.23) under basic conditions (Scheme 3.6).96 Regular flash chromatography 
proved to be insufficient for purification, but preparative HPLC gave rise to the pure 
acid (3.20s). This amphipilic product crystalized and was investigated by X-ray 
diffraction analysis (chapter 7).     
 
HOHO
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OH
O
5
O
5
HO
1) PFP, EDC,
THF/DMF, r.t. 
2) Et3N, THF/DMF
r.t., 9% over 2 steps3.25 3.20s  
Scheme 3.6. Synthesis of the acid analog 3.20s. 
 
3.2.2 Structure-Activity Relationship Study Results  
 
First, the role of the phenolic OH group was evaluated. Since phenols are 
known to be easily oxidized in an enzymatic environment,97 we envisioned that the 
removal ( 3.20a), methylation (3.20b) or esterification (3.20c) of the hydroxyl 
group might be beneficial for metabolic stability. However, all these modifications led 
                                                
96 K. J. Hamblett, B. B. Kegley, D. K. Hamlin, M.-K. Chyan, D. E. Hyre, O. W. Press, 
D. S. Wilbur, P. S. Stayton, Bioconjugate. Chem. 2002, 13, 588–598. 
97 A. M. Mayer, Phytochem. 2006, 67, 2318–2331. 
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to a complete loss of bioactivity, which suggested that this functional group is 
essential for activity. The role of the primary hydroxyl group was investigated next. 
Again, methylation and esterification were not tolerated, as the corresponding 
compounds 3.20d and 3.20e were found to be inactive, as was the doubly methylated 
compound 3.20f. Interestingly, however, oxidation to the carboxylic acid 3.20g and 
derivatization to its methyl ester analog 3.20h led to biologically active compounds. 
We then investigated the influence of the stereogenic center: Formation of the D-
tyrosinol-propionamide 3.20i or complete removal of the CH2OH side chain in 3.20j 
resulted in inactivity, showing that the presence of the hydroxymethylene moiety in 
the (S)-configuration is mandatory for neuritogenic activity. The close catechol analog 
of 3.20j, the dopaminyl propanoate (3.20k) caused cytotoxicity at our standard 
concentration of 50 µM and was inactive at 5 µM. The amide moiety was also shown 
to be essential, as the secondary amine 3.20l was inactive. Modifications of the amide 
only tolerated a planar aromatic substituent (3.20m), as the more 3D space 
demanding isobutyramide 3.20n and pivalamide analogs 3.20o displayed no 
significant activity. 
 With these results in hand, we turned our attention towards the alkyl chain, 
the part of farinosone C (3.4) that had synthetically been the most demanding. The 
very bulky triazole-adamantyl derivative 3.20p was not active, however the dimer 
3.20q of the L-tyrosinol-propionamide (3.5) showed significant bioactivity. Finally, 
we were interested in the role of the acidic terminus of farinosone C (3.5). It appears 
that a polar terminus is required for the long chain aliphatic compounds, as the apolar 
amide 3.20r showed no activity. Terminal acid 3.20s and the terminal alcohol 3.20t 
showed good activity; the latter compound was even able to induce cell differentiation 
at 10 µM concentration, thus rendering the triol 3.20t an even more potent compound 
than the parent NP (3.4). This interesting result demonstrated that the synthetically 
challenging side chain of farinosone C (3.4) can be replaced by an unbranched and 
fully saturated one. 
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3.3 Conclusion  
 
With our synthesized collection of farinosone C analogs we were able to 
differentiate the essential from the non-essential structural moieties from farinosone C 
(3.4) as summarized in figure 3.4. 
 
H
N
O
OH
CH3 OCH3
HOHO
H
H
H
essential
non-essential
Farinosone C (3.4)  
Figure 3.4. Visual summary of the SAR study results.   
 
It was demonstrated that the branched and unsatured side chain can be 
simplified or truncated. The phenolic hydroxyl group allowed no alteration, but the 
primary one did to a certain extend. This SAR study unearthed six novel active 
molecules 3.20f,g,m,q,s,t, of which the triol 3.20t possessed superior neurotrophin-
like functionality than the parental NP 3.4 itself, but with much reduced molecular 
complexity. Both can be obtained from cheap commercial starting materials in one 
step, hereby fulfilling the economical requirements outlined in chapter 1.  
 
Figure 3.3. Neuritogenic activity of the simplified farinosone C analogs in 
the PC12 assay. All values were determined at 50 µM, except; I: 20 µM, II: 
5 µM, III: 10 µM. Positive control: Nerve growth factor (NGF): 20 ng mL-1. 
Solvent  
control: DMSO (0.1%). Incubation period: 2 days. Values are 
reported as    mean ± SEM. 
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4.1 Introduction 
4.1.1 General Overview and Known Pathways 
 
Reported NP and their analogs with neuritogenic properties are numerous. 
Only in the first half of 2013, at least seven new compounds from four different 
molecule classes have been reported.98 But, the underlying biological pathways 
involved in neuronal cell differentiation are only partially understood. It is e.g. known 
that MEK1/2, also called MAP kinases, which function in a mitogen-activated protein 
kinase cascade, can control cell differentiation and growth. In PC12 cells, this 
pathway can be activated via NGF. It has been shown that if MEK1/2 are inhibited 
using the selective antagonist PD 098059 (4.1, Fig. 4.1), NGF cannot induce cell 
differentiation further.99 We then showed that the neuritogenic activity of the pyridone 
SF33 (3.16), the truncated NP analog introduced in section 3.1.4, can also be 
suppressed by MEK1/2 inhibition using antagonist 4.1. This led to the assumption that 
the mode of action for 3.1 is involving the MAP kinase pathway.100 Nonetheless, from 
this data we cannot define the molecular binding site, hereafter referred to as target, 
which 4.1 preferentially modulates, initiating the signal cascade that results in 
morphological changes. In general, it can be stated that not much is known about the 
targets to which neuritogenic small molecules bind to thereby triggering cell 
differentiation. Therefore we started a program to shed some more light on the mode 
of action and the targets involved in neuronal cell differentiation.  
                                                
98 a) P.-Y. Dakas, J. A. Parga, S. Höing, H. R. Schöler, J. Sterneckert, K. Kumar, H. 
Waldmann, Angew. Chem. Int. Ed. 2013, 52, 9576–9581. b) M. B. Hadimani, M. K. 
Purohit, C. Vanampally, R. Van der Ploeg, V. Arballo, D. Morrow, K. E. Frizzi, N. A. 
Calcutt, P. Fernyhough, L. P. Kotra, J. Med. Chem. 2013, 56, 5071–5078. c) M. 
Kubo, R. Ishii, Y. Ishino, K. Harada, N. Matsui, M. Akagi, E. Kato, S. Hosoda, Y. 
Fukuyama, J. Nat. Prod. 2013, 76, 769–773. 
99 a) D. R. Alessi, A. Cuenda, P. Cohen, D. T. Dudley, A. R. Saltiel, J. Biol. Chem. 
1995, 270, 27489–27494. b) L. Pang, T. Sawada, S. J. Decker, A. R. Saltiel, J. Biol. 
Chem. 1995, 270, 13585–13588. c) C. M. Crews, A. Alessandrini, R. L. Erikson, 
Science 1992, 258, 478–480. 
100 F. Schmid, H. J. Jessen, P. Burch, K. Gademann, MedChemComm, 2013, 4, 135–
139. 
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Fig. 4.1. The selective MEK1/2 antagonist (4.1) and SF33 (3.16). 
  
4.1.2 Neuritogenic Natural Products Bearing Long Alkyl Chains 
 
Several neurotrophin-like NP and close analogs are reported which bear long 
aliphatic chains such as lembehyne A (4.2),101 docosahexaenoic acid (4.3)102 and 
gentiside B (4.4, Fig.4.2).103 An analog of the latter compound will be further 
discussed in in chapter 5.  
O
OH
OH
O
O
OH
OH
Gentiside B (4.4)
Docosahexaenoic acid (4.3)
Lembehyne A (4.2)
 
Fig. 4.2. Neurotrophin-like natural products bearing long alkyl chains. 
 
However, our compounds of interest are the tryptamine-derived alkaloids 
isolated from the seeds of Annona atemoya and initially reported with no associated 
bioactivity.104 Due to the structural similarity with melatonin (4.5, Table 4.1), which 
is known to initiate neuronal differentiation, Figadère and co-workers investigated 
                                                
101 a) S. Aoki, K. Matsui, T. Takata, W. Hong, Biochem. Biophys. Res. Commun. 
2001, 558–563. b) F. Schmidt, P. Champy, B. Seon-Meniel, X. Franck, R. Raisman-
Vozari, B. Figadere, Plos One 2009, 4, e6215. 
102 F. Calderon, H.-Y. Kim, J. Neurochem. 2004, 90, 979–988. 
103 a) Y. Luo, K. Sun, L. Li, L. Gao, G. Wang, Y. Qu, L. Xiang, L. Chen, Y. Hu, J. Qi, 
ChemMedChem 2011, 6, 1986–1989. b) L. Gao, L. Xiang, Y. Luo, G. Wang, J. Li, J. 
Qi, Bioorg. Med. Chem. 2010, 18, 6995–7000. c) J. Qi, Y. Luo, L. Gao, Mini-Rev. 
Med. Chem. 2011, 658–677. 
104 M. Leboeuf, A. Caré, M. E. Tohami, J. Pusset, J. Nat. Prod. 1982, 617–623. 
 CHAPTER 4 - INVESTIGATIONS ON THE MODE OF ACTION AND MOLECULAR                 57                                                                           
TARGETS OF NEURONAL DIFFERENTIATION  
this compound class in more detail. They performed an SAR study using primary 
dopaminergic neurons, which indeed confirmed their hypothesis and identified several 
potent novel neurotrophin-like melatonin derivatives. Table 4.1 shows the 18 NP and 
close analogs, which were synthesized and evaluated. At a 10 nM concentration, all 
compounds showed some bioactivity, but four (4.6c,l,q,r, highlighted in red) showed 
superior neuritogenic properties. They found that the length of the aliphatic chains is 
crucial, with the strongest hits all bearing a 16-atom chain. Another general trend 
observed was that secondary amines were more active than the amides. Unsaturated 
aliphatic chains are also well tolerated, even when the chain length is increased by 
two carbon atoms.105      
 
N
H
H
N
O
O
N
H
X R
n
Melatonin (4.5) Gerneral structure  
 
Cpd X n R Cpd X n R 
4.6a NH2–C=O 9 CH3 4.6j NH2–CH2 9 CH3 
4.6b NH2–C=O 11 CH3 4.6k NH2–CH2 11 CH3 
   4.6c NH2–C=O 12 CH3    4.6l NH2–CH2 12 CH3 
   4.6d NH2–C=O 13 CH3    4.6m NH2–CH2 13 CH3 
   4.6e NH2–C=O 14 CH3    4.6n NH2–CH2 14 CH3 
   4.6f NH2–C=O 16 CH3    4.6o NH2–CH2 16 CH3 
   4.6g NH2–C=O 19 CH3    4.6p NH2–CH2 19 CH3 
   4.6h NH2–C=O 5  ∇    4.6q NH2–CH2 5 ∇ 
   4.6i NH2–C=O 11 OH    4.6r NH2–CH2 11 OH 
 
Table 4.1. NP and close analogs used in the SAR study of Figadère.   
 ∇ = [CH=CH–CH2–CH=CH–(CH2)4–CH3].107 
 
 
                                                
105 F. Schmidt, G. Le Douaron, P. Champy, M. Amar, B. Seon-Meniel, R. Raisman-
Vozari, B. Figadere, Bioorg. Med. Chem. 2010, 18, 5103–5113. 
 58                    CHAPTER 4 - INVESTIGATIONS ON THE MODE OF ACTION AND MOLECULAR                                                                               
TARGETS OF NEURONAL DIFFERENTIATION 
4.1.3 Similarity Ensemble Approach 
 
Information technology has fundamentally changed our daily life but also had 
a big impact on chemistry and drug discovery in particular, as exemplified by the 
2013 Nobel Prize in chemistry. In this field, the techniques can be separated into two 
major principles: the ligand-based or receptor-based approach. Pharmaceutical 
research is applying these two strategies in combination with fragment-based lead 
discovery. Together these two approaches are considered to be complementary to 
high-throughput screening that has become the primary source of innovation for 
several pharmaceutical enterprises, which will be discussed later. As the name already 
suggests, an accurate 3D receptor model is required for a receptor-based approach. 
Virtual screening then allows analysis of enormous compound collections to find 
appropriate chemical keys for the particular lock. In ligand-based or chemocentric 
approaches, the structural features of a given ligand can virtually be screened against 
thousands of ligands of which the molecular target is known. Several methods are 
known for ligand- and receptor based-approaches and a combination of both is 
possible if required.106 Besides making the discovery of lead structures more efficient, 
computational approaches also aim to estimate the safety of potential drugs. Often, 
promising drug candidates fail in late-stage clinical trials due to adverse side effects 
and toxicity issues, which represents a tremendous financial loss. Consequently, 
possible adverse effects of a drug candidate should be predicted and confirmed as 
early as possible in the development process (also see section 4.1.5). With in silico 
assessments, researchers also aim to reduce animal testing, where financial recourses 
are not the only concern that has to be considered.107   
 One ligand-based technique is called Similarity Ensemble Approach (SEA) 
developed by Shoichet and colleagues.108 This program relates receptors to each other 
quantitatively based on the structural similarity of their binding ligands. In this 
seminal study, they applied 246 drug relevant receptor subsets. For each subset, the 
binding affinities of multiple ligands are known, resulting in a total number of over 
                                                
106 a) Y. Tanrikulu, G. Schneider, Nat. Rev. Drug Discovery 2008, 7, 667–677. b) J. 
Hert, P. Willett, D. J. Wilton, P. Acklin, J. Chem. Inf. Modl. 2006. 46, 462-470. 
107 a) A. Vedani, M. Dobler, M. Smieško, Toxicol. Appl. Pharm. 2012, 261, 142-153. 
b)  S. Eid, A. Zalewski, M. Smieško, B. Ernst, A. Vedani, IJMS 2013, 14, 684–700. 
108 a) M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, B. K. 
Shoichet, Nat. Biotech. 2007, 25, 197–206. b) www.sea.bkslab.org/search 
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65’000 ligands. Then, every ligand of each subset was compared to each ligand in 
every other set. If two ligand ensembles (or sets) score high regarding structural 
similarity, the two receptors subsets can quantitatively be related and visually mapped 
in close proximity. With this information, medicinal chemists have an indication 
which other receptor types are likely to interfere if a particular compound is 
developed as a drug candidate. This approach was proven valid since its results are in 
accordance with known polypharmacological interactions. This method also allows 
investigations of molecules not related to a certain protein target by comparing its 
chemical topology to the previously investigated 65’000 ligands.109 
 
4.1.4 The Endocannabinoid System 
 
The hemp plant Cannabis sativa L. has been used by humans for either 
ritualistic or therapeutic purposes, dating back 5’000 years ago, starting in China. 
Over the centuries, traditional medicine used extracts of Cannabis sativa L. to treat 
various medical conditions such as pain or loss of appetite.110 Despite the constant 
medical use of cannabis, it was not before 1964 until Gaoni and Mechoulam isolated 
and characterized the main psychoactive constituent from this plant: ∆9-
tetrahydrocannabinol (THC, 4.7, Fig. 4.3) and reported its first total synthesis one 
year after.111 In 1990 Matsuda112 and, three years later, Abu-Shaar113 identified and 
cloned cannabinoid (CB) receptors 1 and 2, which are the cellular targets of THC 4.7 
and other natural cannabinoids.114 The two receptors display a divergent distribution 
pattern throughout the organisms; CB1 is mainly found in the central nervous system 
and CB2 in the peripheral and immune cells.115  
                                                
109 M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, B. K. 
Shoichet, Nat. Biotech. 2007, 25, 197–206. 
110 D. M. Lambert, C. J. Fowler, J. Med. Chem. 2005, 48, 5059–5087. 
111 a) Y. Gaoni, R. Mechoulam, J. Am. Chem. Soc. 1964, 86, 1646–1647. b) R. 
Mechoulam, Y. Gaoni, J. Am. Chem. Soc. 1965, 87, 3273–3275. 
112 L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, T. I. Bonner, Nature 
1990, 346, 561–564. 
113 S. Munro, K. L. Thomas, M. Abu-Shaar, Nature 1993, 365, 61–65. 
114 Cannabinoids: compounds, which bind to the CB1/2 receptors 
115 D. M. Lambert, C. J. Fowler, J. Med. Chem. 2005, 48, 5059–5087. 
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Fig 4.3. THC 4.7, arachidonic acid (4.9) and the two main endocannabinoids  
 AEA 4.8 and 2-AG 4.10.  
 
Once the cannabinoid receptors were discovered, research focused on the 
identification of the endogenous ligands that would modulate these receptors. Because 
THC 4.7 is rather lipophilic, extraction approaches focused on apolar substances. 
Anandamide (AEA, 4.8) was the first endogenous cannabinoid (endocannabinoid) 
discovered.116 Other endocannabinoids where then reported in high frequency, most 
derived from arachidonic acid (4.9), of which 2-arachidonylglycerol (2-AG, 4.10) is 
the most prominent.117 Other important pillars of the endocannabinoid system (ECS) 
signalling processes include the fatty acid amide hydrolase (FAAH), the 
monoacylglycerol lipase (MAGL) and the α,β-hydrolase-6 and -12 (ABHD-6 and -12) 
which end the bioactivity of AEA 4.8 or 2-AG 4.10, respectively after cellular re-
uptake.120 118 Additionally, the putative bidirectional endocannabinoid membrane 
transporter (EMT) has also become a dynamic research topic establishing an 
                                                
116 W. Devane, L. Hanus, A. Breuer, R. Pertwee, L. Stevenson, G. Griffin, D. Gibson, 
A. Mandelbaum, A. Etinger, R. Mechoulam, Science 1992, 258, 1946–1949. 
117 R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N. E. Kaminski, A. R. 
Schatz, A. Gopher, S. Almog, B. R. Martin, D. R. Compton, et al., Biochem. 
Pharmacol. 1995, 50, 83–90. 
118 a) M. K. McKinney, B. F. Cravatt, Annu. Rev. Biochem. 2005, 1, 411–432. b) A. 
Chicca, J. Marazzi, S. Nicolussi, J. Gertsch, J. Biological Chem. 2012, 287, 34660–
34682. c) T. P. Dinh, T. F. Freund, D. Piomelli, Chem. Phys. Lipids 2002, 149–158. 
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alternative rational to passive membrane diffusion of endocannabinoids in recent 
years.119 
An increasing number of pathophysiological conditions related to the ECS, 
such as fertility, cancer and cardiovascular diseases in addition to the previously 
mentioned (pain, appetite) explains the interest of the pharmaceutical industry and the 
multiple drug candidates which are in clinical trials now. The main entry point to 
modulate the ECS is via FAAH inhibitors.120 Moreover, there is increasing evidence 
that the ECS is involved in the progression and potential healing of neurodegenerative 
disorders. The brain region that controls movement, basal ganglia is strongly 
disturbed by patient suffering from Parkinsons’ and Huntingtons’ disease. Hence 
these sufferings can also be classified as movement disorders, this is consistent. It has 
been shown that 1) CB1 receptors are highly overexpressed in this brain area, 2) 
endocannabinoids are abundant in these area as well, 3) natural or synthetic 
cannabinoids have potent effects on motor activity and 4) people suffering from 
movement disorders express altered CB1 receptors and endocannabinoid levels in that 
region. As a consequence, there is broad agreement that the ECS is heavily involved 
in the evolution of these suffering based on these and other findings.121 The most 
abundant neurodegenerative disorder, Alzheimers’ disease, characterised by the 
formation of β-amyloid (βA) plaques (also see section 4.1.7) seems to be influenced 
by the ECS as well. Milton showed that AEA (4.8) can prevent βA-induced 
toxicity.122 Additionally, the memory deficit induced by βA admission could be 
improved by CB1 receptor inhibition in animal models.123 Others report that the 
                                                
119 a) A. Chicca, J. Marazzi, S. Nicolussi, J. Gertsch, J. Biological Chem. 2012, 287, 
34660–34682. b) N. Battista, M. Di Tommaso, M. Bari, M. Maccarrone, Front. 
Behav. Neurosci. 2012, 9, 1-7.  
120 a) K. Ahn, S. E. Smith, M. B. Liimatta, D. Beidler, N. Sadagopan, D. T. Dudley, T. 
Young, P. Wren, Y. Zhang, S. Swaney, et al., J. Pharm. Exp. Ther. 2011, 338, 114–
124. b) S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, A. Tontini, M. Mor, 
G. Tarzia, G. L. Rana, A. Calignano, et al., Nat. Med. 2002, 9, 76–81. c) V. Di Marzo, 
Nat. Rev. Drug Discovery 2008, 7, 438–455. d) E. L. Scotter, M. E. Abood, M. Glass, 
Br. J. Pharmacol. 2010, 160, 480–498. 
121 a) T. Nagayama, A. D. Sinor, R. P. Simon, J. Chen, S. H. Graham, K. Jin, D. A. 
Greenberg, J. Org. Chem. 1999. b) P. Pacher, S. Bátkai, G. Kunos, Pharmacol. Rev. 
2006. 58, 389-462. 
122 N. Milton, Neurosci. Lett. 2002, 332, 127–130. 
123 C. Mazzola, V. Micale, F. Drago, Euro. J. Pharmaco. 2003, 477, 219-225.  
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overexpression of FAAH and CB2 receptors in brains of patients suffering from 
Alzheimers’ disease.124  
 
4.1.5 The HIP HOP Assay 
 
Despite enormous financial costs and novel technologies, surprisingly low 
numbers of new drugs receive approval each year. In 2006 a study conducted by 
Overington, Al-Lazikani, and Hopkins counted 21’000 licenced drug products. 
However, when duplicates, salt forms, vitamins, supplements, along with others are 
removed, only 1’357 unique drugs remain. Out of these drugs, 1’204 are small 
molecule drugs and 166 are “biological” drugs such as therapeutic antibodies.125 And 
all these drugs act on only 324 molecular targets, of which 266 are located in humans 
and the remaining 58 in pathogens. In 2010, only 21 new drugs had been approved by 
the FDA. This represents the lowest number in at least 15 years (Fig. 4.4). On the 
contrary, the R&D expenditures are constantly increasing and since 2002, have almost 
doubled, reaching over 120 billion USD in 2010. This means that the development of 
one new drug costs, on average, approximately five billion USD and will take around 
13 years. This costs however also include unsuccessful endeavours.126 
 
                                                
124 C. Benito, E. Núñez, R. M. Tolón, E. J. Carrier, A. Rábano, C. J. Hillard, J. 
Romero, J. Neurosci. 2003, 23, 11136–11141. 
125 a) O. H. Brekke, I. Sandlie, Nat. Rev. Drug Discovery 2003, 2, 52–62. b) J. P. 
Overington, B. Al-Lazikani, A. L. Hopkins, Nat. Rev. Drug Discovery 2006, 5, 993–
996. 
126 E, Pisani, The Pharmaceutical Industry and Global Health: Facts and Figures, 
IFPMA, Geneva, 2011. 
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Fig. 4.4. Number of FDA approved drugs per year. (Reprinted from Ref.: 127 with 
  permission from NPG) 
 
While looking at these numbers, the pharmaceutical industry cannot be too 
confident regarding its performance and a higher efficiency should be aimed for 
where possible. One way in achieving this goal, are innovative, high-throughput 
screening platforms.129 To build up, steadily improve and adequately operate these 
platforms has become a very important part of today’s drug discovery. Consequently, 
a multitude of quite diverse methodologies have evolved, and companies consider a 
strong screening facility a market advantage.128 Novartis, a major drug producer, 
operates several high-throughput screening platforms, and is the only company 
running a phenotypic screen using yeast Sacharomyces cerevisiae (the first eukaryotic 
genome decoded in 1995)129 called HIP HOP assay, on this scale.  
 The term HIP HOP originates in this regard from haploinsufficiency profiling 
and homozygous profiling. This screening platform can help to identify potential drug 
targets. While target recognition is not essential for drug development, it does 
                                                
127 M. Allison, Nat. Biotech. 2012, 30, 41–49. 
128 R. Macarron, M. N. Banks, D. Bojanic, D. J. Burns, D. A. Cirovic, T. Garyantes, 
D. V. S. Green, R. P. Hertzberg, W. P. Janzen, J. W. Paslay, et al., Nat. Rev. Drug 
Discovery 2011, 10, 188–195. 
129 S. Hoon, R. S. Onge, G. Giaever, C. Nislow, Trends Pharmacol. Sci. 2008, 10, 
499-504. 
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facilitate the optimization of a compound’s inhibitory activity. For the 
haploinsufficiency profiling (HIP), one functional copy of a specific gene was 
deleted. If one copy cannot overcome growth inhibition, this indicates supersensitive 
pathways that are affected directly and allows direct identification of the molecular 
target. In the homozygous profiling (HOP), both gene copies are deleted and the 
synthetic lethality is examined. Synthetic lethality occurs when a compound is able to 
block pathways which compensate for the deleted one.130 This assay takes advantage 
on the evolutionary certainly beneficial tendency of organisms to preserve buffering 
schemes that grant phenotypic stability, despite genetic variation or environmental 
changes (scheme 4.6).131 While homozygous profiling (HOP) is less approvingly for 
target identification, it can help to confirm haploinsufficiency profiling (HIP) results 
and more importantly, identify off-target effects of drug candidates at an early stage 
(also see section 4.1.4).132 
 Since each strain is labelled using a unique barcode derived from around 20 
base-pairs incorporated in the DNA, microarray analysis allows to pool many 
different strains in the same well.133 Then, these microorganisms are grown in the 
presence and absence of the compounds of interest for several generations on an 
automated system. Strains that are sensitive to the added chemicals are then identified 
by their lower relative abundance, as compared to the reference strains.134 In the HIP 
case genome-wide specific gene deletion is tolerated where in the HOP case only 
deletion of non-essential genes are possible. Limitation of this assay include that only 
genes influencing the growth rate of the yeast can be detected and the fact that the 
investigated compounds need to be able to enter the yeast cells prior to potential gene 
interactions.135 
   
                                                
130 D. L. Richie, K. V. Thompson, C. Studer, V. C. Prindle, T. Aust, R. Riedl, D. 
Estoppey, J. Tao, J. A. Sexton, T. Zabawa, et al., Antimicrob. Agents Chemother. 
2013, 57, 2272–2280. 
131 a) J. L. Hartman, B. Garvik, L. Hartwell, Science 2001, 291, 1001–1004. b) S. 
Hoon, R. S. Onge, G. Giaever, C. Nislow, Trends Pharmacol. Sci. 2008. 10, 499-504.  
132 S. Hoon, R. S. Onge, G. Giaever, C. Nislow, Trends Pharmacol. Sci. 2008, 10, 
499-504 
133 S. E. Pierce, E. L. Fung, D. F. Jaramillo, A. M. Chu, R. W. Davis, C. Nislow, G. 
Giaever, Nat. Meth. 2006, 3, 601–603. 
134 D. L. Richie, K. V. Thompson, C. Studer, V. C. Prindle, T. Aust, R. Riedl, D. 
Estoppey, J. Tao, J. A. Sexton, T. Zabawa, et al., Antimicrob. Agents Chemother. 
2013, 57, 2272–2280. 
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Scheme 4.6. Difference of HIP vs. HOP profiling. 
  
4.1.6 Amphetamine-Type Designer Drugs and Potentially Psychostimulant 
Structural Analogs 
 
Given that substances 3.20a-t originating from our SAR study on farinosone C 
structurally resemble the psychostimulant amphetamine-type designer drugs (ATDD), 
in part of their molecular structure, we investigated the activity of our library at 
amphetamine targets in the brain. The background and dangers of ATDD effects are 
specified in this section. The emergence of new psychoactive designer drugs and the 
willingness of drug abusers to look for new alternatives to traditional ATDD make it 
necessary to consider the psychoactive potential of our library, ideally to demonstrate 
absence of any potential psychoactive effects. Thereby we prevent drug users to 
experiment with substances designed in accordance to our lead structure. 
ATDD have long been abused for their psychostimulant properties. Well-
known and popular psychostimulants are amphetamine (“speed”, 4.10a), 
methamphetamine (“crystal-meth”, 4.10b) and 3,4-methylenedioxymethamphetamine 
(MDMA, “ecstasy”, 4.11a). While amphetamine (4.10a) and methamphetamine 
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(4.10b) are psychostimulants, MDMA’s psychoactive properties are less distinct.135 
MDMA 4.11a triggers the feelings happiness and subjective closeness to other 
people.136 The widespread popularity of these ATDD drugs revealed their dangers in 
the last decades. Amphetamine 4.10a and particularly methamphetamine 4.10b have a 
considerable potential for inducing addiction.137 While MDMA 4.11a is considered as 
less addictive compared to the other two 4.10a and 4.10a,138 its neurotoxic potential is 
a matter of on-going research to finally predict the long-term impact on regular user’s 
mental health.139 Furthermore, ATDD are potentially life-threatening on acute dosing. 
Methamphetamine (4.10b) and MDMA 4.11a both typically are cardiostimulants and 
might lead to hyperthermia. Organ failure due to untreated hyperthermia has caused 
many deaths in young drug users. 140  MDMA 4.11a might also lead to brain 
oedema.141 The health risks and consequences of these drugs are well understood. 
However, a new problem in terms of stimulant drug use emerged in the last decade. 
The evolution of the internet made it possible for dealers to distribute legal substances 
world-wide, thereby offering drug abusers a wide set of alternatives to their 
“traditional” ATDD.142 By modulation of functional groups of amphetamine 4.10a, 
new molecular entities with potentially psychoactive properties come into existence. 
Some of these ATDD 4.10a-f (Fig. 4.7) and 4.11a-g (Fig. 4.8) are shown. The 
motivation to sell or consume some of these drugs besides their psychoactivity, is the 
fact that they are legal, at least as long as authorities banned the single substances. 
This, however, drives the production of different derivatives, causing an unknown 
accumulation of new psychoactive drugs for availability to consumers. The European 
                                                
135 a) H. Kalant, CMAJ 2001, 165, 917–928. b) J. C. Cole, H. R. Sumnall, Pharmacol. 
Therapeutics 2003, 98, 35–58. c) C. C. Cruickshank, K. R. Dyer, Addiction 2009, 
104, 1085–1099. 
136 M. Liechti, Neuropsychopharmacology 2000, 22, 513–521. 
137 A. M. Barr, W. J. Panenka, W. G. MacEwan, A. E. Thornton, D. J. Lang, W. G. 
Honer, T. Lecomte, J. Psychiatry. Neurosci. 2006, 31, 301–314. 
138 Z. Wang, W. L. Woolverton, Psychopharmacology 2006, 189, 483–488. 
139 a) M. H. Baumann, J. S. Partilla, K. R. Lehner, Euro. J. Pharmaco. 2012, 1–5. b) J. 
P. Capela, H. Carmo, F. Remião, M. L. Bastos, A. Meisel, F. Carvalho, Mol 
Neurobiol 2009, 39, 210–271. c) J. H. Halpern, A. R. Sherwood, J. I. Hudson, S. 
Gruber, D. Kozin, H. G. Pope Jr, Addiction 2011, 106, 777–786. 
140 a) H. Kalant, CMAJ 2001, 165, 917–928. b) J. C. Cole, H. R. Sumnall, Pharmacol. 
Therapeutics 2003, 98, 35–58. c) C. C. Cruickshank, K. R. Dyer, Addiction 2009, 
104, 1085–1099. 
141 H. Kalant, CMAJ 2001, 165, 917–928. 
142 S. L. Hill, S. H. L. Thomas, Clin. Toxicol. 2011, 49, 705–719. 
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Monitoring Centre for Drug and Drug Addiction (ECDDA) highlights in their annual 
report 2013 that the threat arising by these novel psychoactive substances.143 Even 
though the parent molecules of these drugs are well investigated, the effects induced 
in humans by similar drugs can dramatically change between analogs. As an example, 
the pharmacology of 3,4-methylenedioxypyrovalerone (MDPV, “bath salt”, 4.11g), is 
unlike the pharmacology of both MDMA 4.11a and methamphetamine (4.10b). 
MDPV 4.11g is an extraordinarily highly potent drug that has caused enormous 
damages to abusers.144 Therewith MDPV 4.11g demonstrates that the concern about 
the unknown risks of new psychoactive substances is a justified one.  
 
R = H, R' = CH3, R'' = H, X = CH2 :  Amphetamine (4.10a)
R = CH3, R' = CH3, R'' = H, X = CH2 : Methamphetamine (4.10b)
R = H, R' = CH3, R'' = H, X = CO : Cathinone (4.10c)
R = CH3, R' = CH3, R'' = H, X = CO : Methcathinone (4.10d)
R = CH3, R' = CH3, R'' = CH3, X = CO : Methedrone (4.10e)
R = CH3, R' = CH3, R'' = F, X = CO : Flephedrone (4.10f)
X
H
N
R
R'
R''
 
Figure 4.7. ATDD derived from amphetamine (4.10a) 
 
R = CH3, R' = CH3, X = CH2 : MDMA (4.11a) 
R = CH3, R' = CH2CH3, X = CH2 : MBDB (4.11b)
R = CH2CH3, R' = CH3, X = CH2 : MDEA (4.11c) 
R = CH3, R' = CH2CH3, X = CO : Methylone (4.11d) 
R = CH2CH3, R' = CH3, X = CO : Butylone (4.11e) 
R = CH3, R' = CH2CH3, X = CO : Ethylone (4.11f)
X
H
N
R
R'
O
O
O
N O
O
MDPV 4.11g  
Figure 4.8. ATDD derived from MDMA (4.11a) 
                                                
143 EMCDDA, 2013, 1–80. 
144 a) L. D. Simmler, T. A. Buser, M. Donzelli, Y. Schramm, L.-H. Dieu, J. Huwyler, 
S. Chaboz, M. C. Hoener, M. E. Liechti, Br. J. Pharmacol. 2012, 168, 458–470. b) M. 
H. Baumann, X. Wang, R. B. Rothman, Psychopharmacology 2006, 189, 407–424. 
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The main site of action for these drugs is at the synapse of monoaminergic 
neurons present in the brain. The effects of ATDD are mainly due to re-uptake 
inhibition of dopamine (DA, 4.12), norepinephrine (NE, 4.13) and serotonin (5-
hydroxytryptamine, 5-HT, 4.14) shown in figure 4.9.  
NH2
H
N
HO
Serotonine (5-HT, 4.14)
HO
NH2
OH
HO
Norepinephrine (NE, 4.13)
HO
HO NH2
Dopamine (DA, 4.12)  
Figure 4.9. The neurotransmitters, which concentrations are mostly affected        
by ATDD. 
 
The mode of action ATDD act is descripted as follows: The neurotransmitters 
are released by the presynapse, transmiting neuronal signals by binding and, therefore 
activating or deactivating the postsynaptic receptors. To end this signalling cascade, 
monoamine re-uptake transporters remove the neurotransmitters from the synaptic 
cleft back to the presynapse. If these transporters are inhibited by ATDD, a higher 
neurotransmitter concentrations results, subsequently causing profound changes in 
signal transmission (Fig. 4.10).145 
 
 
 
 
 
 
                                                
145 a) A. S. Kristensen, J. Andersen, T. N. Jorgensen, L. Sorensen, J. Eriksen, C. J. 
Loland, K. Stromgaard, U. Gether, Pharmacol. Rev. 2011, 63, 585–640. b) G. E. 
Torres, R. R. Gainetdinov, M. G. Caron, Nat. Rev. Neurosci. 2003, 4, 13–25. 
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MICRODIALYSIS
Analytical technique that is used
to monitor extracellular levels of
neurotransmitters or other
molecules in vivo. A cannula is
inserted into the brain and test
solution is perfused through it.
Dialysis takes place between the
test and the extracellular
solutions,making it possible to
measure the transmitter levels at
the tissue surrounding the tip of
the cannula.
14 | JANUARY 2003 | VOLUME 4  www.nature.com/reviews/neuro
R E V I EW S
ofmonoamine transporters, for substrates and inhibitors,
has been examined in brain preparations and in het-
erologous systems with recombinant transporters.
In general, there is good agreement between these 
two approaches. Although all three monoamines are
substrates of their cognate transporter, it has been
shown that either DAT or NET can transport both
dopamine and noradrenaline6. The heterologous
uptake of dopamine by NET has been shown in vivo by
MICRODIALYSIS7 and in synaptosomal preparations from
mouse cerebral cortex8.
made in the research on neurotransmitter trans-
porters for dopamine, noradrenaline, and 5-HT in the
central nervous system, emphasizing the most recent
developments.
Pharmacology of monoamine transporters
Transporters for dopamine, noradrenaline, and 5-HT
— DAT, NET and SERT, respectively — represent
established targets for many pharmacological agents
that affect brain function, including psychostimulants,
antidepressants and neurotoxins3–5 (FIG. 1). The sensitivity
DA receptors
DA 
autoreceptors
DA
DA
L-DOPA
Tyrosine Amph.
MPP+
DAT
Dopamine neuron
Cocaine
GBR 12935
WIN 35,428
RTI-121
Adrenergic receptors
Adrenergic 
autoreceptors
DA
NA
DA
L-DOPA
Tyrosine
Amph.
NET
Noradrenaline neuron
Cocaine
Nisoxetine
Reboxetine
5-HT receptors
5-HT 
autoreceptors
5-HT 
5-HT
5-hydroxytryptophan
Tryptophan Amph.
MDMA
SERT
5-Hydroxytryptamine neuron
Cocaine
Fluoxetine
Paroxetine
Sertraline
Figure 1 | Schematic representation of dopamine, noradrenaline and 5-HT synaptic terminals. Monoamine transporters are
localized to perisynaptic sites, where they are crucial for the termination of monoamine transmission and the maintenance of
presynaptic monoamine storage. Several selective pharmacological agents acting at each monoamine transporter are shown.
Amph., amphetamine; DA, dopamine; DAT, Dopamine transporter; L-DOPA, L-3,4-dihydroxyphenylalanine; 5-HT, 5-hydroxytryptamine;
MPP+, 1-methyl-4-phenylpyridinium; MDMA, (+)-3,4-methylenedioxymethamphetamine; NA, noradrenaline; NET, noradrenaline
transporter; SERT, 5-HT transporter.
Box 1 | Localization and distribution of monoamine transporters
In the brain,monoamine transporters are expressed almost exclusively in the neurons that contain their cognate
transmitter. In situ hybridization studies showed prominent dopamine transporter (DAT) expression in the cell bodies of
the substantia nigra and ventral tegmental area (VTA),noradrenaline transporter (NET) expression in the locus
coeruleus and other brainstem nuclei,and 5-HT transporter (SERT) expression in the median and dorsal raphe nuclei161.
In the mouse brain,DAT-like immunoreactivity was detected in the striatum,nucleus accumbens,olfactory tubercle,
nigrostriatal bundle and lateral habenula. In addition, cell bodies from neurons of the substantia nigra and VTA,as well as
neuronal processes in the substantia nigra, in layers I, II and III of the cingulate cortex and in the medial prefrontal cortex,
were DAT positive54,162,163.NET immunoreactivity in the brain was confined to noradrenergic somata,dendrites and
axons within the hippocampus and cortex164. SERT immunoreactive fibers were found widely distributed throughout the
brain, with the highest densities in regions that receive a dense serotonergic innervation, such as the cerebral cortex and
the CA1 and CA3 regions of the hippocampus. Immunopositive staining for SERT revealed that it was also present in the
cell bodies of the raphe nucleus165,166. In general, there is good agreement between the distribution ofmonoamine
transporters by immunocytochemical approaches and the use of radioactive uptake inhibitors to label transporter sites.
The specific localization ofmonoamine transporters within synaptic terminals has also been examined164,167–169.
Immunoelectron microscopy revealed that DAT,NET and SERT were localized at the plasma membrane,away from the
synaptic area (peri-synaptic area) indicating that transmitter release at the synapse diffuses out of the cleft to be transported
back into the terminal.These studies also found DAT,NET and SERT immunoreactivity that was associated with
intracellular organelles of tubulo-vesicular structure.
Monoamine transporters have also been found in peripheral locations170. In situ hybridization and immunohistochemical
studies indicate that DAT is expressed in the stomach,pancreas, and kidney170.NET is expressed in sympathetic
peripheral neurons, the adrenal medulla, the lung and the placenta170. The SERT protein has been detected in platelets171,
the intestinal tract172 and the adrenal gland173. In addition, SERT activity has been reported in astrocytes in culture174.
 
 
The diverse psychological and physical responses of ATDD are based on the 
different potencies by which they inhibit the respective monoamine transporters. The 
effects of MDMA 4.11a on abusers are “entactogenic”, meaning that the drug induces 
delightful psychotropic ffects such as increas d mpathy nd c nfidence or 
intensified sensory perception. These effects derive from an expanded serotonin 
(4.14) concentration upon MDMA’ preferential action on th  serotonin transporter. 
Methamphetamine on the other hand acts more potently on the dopamine and 
norepinephrine transport rs. This pr ference results in reduced app tite, improved 
attention o  decreased need of sleep.146 Since these are qualities useful to soldiers, 
me ha phetamine was wid ly used by military ersonnel during th  2nd World War 
on both sides.147 Dopamine (4.12) is the crucial neurotransmitter involved in the 
development of an addiction, which explains that “crystal-meth” 4.12 causes stronger 
addictions than “ecstasy” 4.14. Since a wide range of medical complications caused 
                                                
146 C. C. Cruickshank, K. R. Dyer, Addiction 2009, 104, 1085–1099. 
147 M. D. Anglin, C. Burke, B. Perrochet, E. Stamper, S. Dawud-Noursi, J. Psy. 
Drugs. 2000, 32, 137–141. 
Figure 4.10. Sche atic draw g of monoamin rgic synapse, indicating the
target transporters of ATDD, like 4.10a and 4.11b. These ATDD inhibit the 
DA (4.12), NE (4.13), and 5-HT (4.14) re-uptake inhibitors and prevent 
the transporters from neurotransmitter recycling, leading to increased 
neurotransmitter levels in the synaptic cleft and an increase in signal 
transmission. (Reprinted from Ref.: 147b with permission from NPG) 
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by ATDD are known, illegalization of these substances is reasonable to improve 
public health.148 
When new psychoactive drugs appear to become popular among drug users, 
pharmacological studies are conducted to gain information about their possible effects 
and dangers for abusers. One way to address this is by in vitro monoamine re-uptake 
inhibition studies. Therefore, human embryonic kidney (HEK) 293 cells that stably 
express human DA, NE or 5-HT transporters, respectively, are grown in well 
plates.149 Then, the compounds of interest are added before the respected tritium (3H) 
labelled neurotransmitter. After a short incubation time, the cells are washed. After 
cell lysis it is then possible to determine the amount of neurotransmitter present in the 
cells by β−count measurements. A small radioactive signal then corresponds to a 
strong re-uptake inhibition.150 
 
4.1.7 The MTT Assay 
 
Our brain accounts for only a few percent of the human body weight, but 
demands around 20% of the oxygen consumed. This results in high levels of reactive 
oxygen species (ROS) and, therefore, leads to oxidative stress. Our brain evolved 
mechanisms to manage a certain amount of oxidative stress well. The βΑ peptide 
however is known to facilitate the formation of ROS. One of the significant 
characteristics of Alzheimer’s disease is the βΑ peptide overproduction and its miss-
folding, leading to the formation and deposition of βΑ plaques, as well as increased 
oxidative stress by free radicals for the brain. To address the oxidative stress problem, 
the consumption of external antioxidants such as phenolic phytochemicals or vitamins 
                                                
148 a) J. C. Cole, H. R. Sumnall, Pharmacol. Therapeutics 2003, 98, 35–58 b) L. D. 
Simmler, T. A. Buser, M. Donzelli, Y. Schramm, L.-H. Dieu, J. Huwyler, S. Chaboz, 
M. C. Hoener, M. E. Liechti, Br. J. Pharmacol. 2012, 168, 458–470. 
149 M. Tatsumi, K. Groshan, R. D. Blakely, E. Richelson, Euro. J. Pharmaco. 1997, 
340, 249–258. 
150 a) L. D. Simmler, T. A. Buser, M. Donzelli, Y. Schramm, L.-H. Dieu, J. Huwyler, 
S. Chaboz, M. C. Hoener, M. E. Liechti, Br. J. Pharmacol. 2012, 168, 458–470. b) C. 
M. Hysek, L. D. Simmler, V. G. Nicola, N. Vischer, M. Donzelli, S. Krähenbühl, E. 
Grouzmann, J. Huwyler, M. C. Hoener, M. E. Liechti, PLOS ONE, 2012, 7, e36476. 
 CHAPTER 4 - INVESTIGATIONS ON THE MODE OF ACTION AND MOLECULAR                 71                                                                           
TARGETS OF NEURONAL DIFFERENTIATION  
seems a valid general defence strategy.151 Since farinosone C (3.4) and most of its 
analogs contain a phenolic moiety, we aimed to examine their antioxidant properties 
by investigating their neuroprotective properties.152 Kim developed a procedure to 
address this question using a modification of the widely used MTT assay.153 MTT 
stands for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (4.15). This 
yellow, water soluble MTT (4.15) is reduced by NADH to the purple and insoluble 
formazan (4.16) inside living cells. After a given time, the growth medium is replaced 
by DMSO, which solubilizes the dye (4.16). Since only living cells can reduce MTT, 
absorption measurements allow for quantitative determination of viability. The more 
purple a solution is, the more cells survived a given conditions.154   
 
Me
MeN
SHN N
NH+N
NADH
NAD+
N
N
NH
N
S
N
Me
Me
MTT (4.15) Formazan (4.16)  
   Figure 4.11. Schematic view of the MTT assay. 
      
                                                
151 a) S. G. Lee, H. Lee, T. G. Nam, S. H. Eom, H. J. Heo, C. Y. Lee, D.-O. Kim, J. 
Food Sci. 2011, 76, C250–C256. b) J. Gaugler, B. James, T. Johnson, K. Scholz, W. 
J, Alzheimer's & Dementia 2013, 9, 208–245. 
152 H. J. Jessen, D. Barbaras, M. Hamburger, K. Gademann, Org. Lett. 2009, 11, 
3446–3449. 
153 a) M. B. Hadimani, M. K. Purohit, C. Vanampally, R. Van der Ploeg, V. Arballo, 
D. Morrow, K. E. Frizzi, N. A. Calcutt, P. Fernyhough, L. P. Kotra, J. Med. Chem. 
2013, 56, 5071–5078. b) S. G. Lee, H. Lee, T. G. Nam, S. H. Eom, H. J. Heo, C. Y. 
Lee, D.-O. Kim, J. Food Sci. 2011, 76, C250–C256. 
154 a) R. D. Brinton, R. S. Yamazaki, Pharmaceu. Res. 1998, 15, 386–398 b) T. 
Mosmann, J. Immuno. Met. 1983, 65, 55-63. c) J. Qi, Y. Luo, L. Gao, Mini-Rev. Med. 
Chem. 2011, 658–677. 
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We set out to combine application of our compounds with βΑ peptide in PC12 
cells to allow us to find small molecules that are able to protect neurons from 
oxidative stress using MTT as visual readout.155   
 
4.2. Result and Discussion  
4.2.1 Computational Results using the SEA Search Tool  
 
As mentioned in chapter 3, our SAR study revealed triol 3.20t as the most 
potent farinosone C analog. Its structure was therefore submitted to the online SEA 
search tool (SEArch), developed by the Shoichet group.156 The molecular descriptor 
used to encode the submitted compounds, was Scitegic ECFP4 and the database to 
search against was the ChEMBL Medical Chemistry Database Version 10. For triol 
3.20e, the SEArch tool suggested 45 different protein targets. The targets are ranked 
according to their maximum Tanimoto coefficient (mTC). The value describes the 
amount of similarity to the nearest neighbour of the submitted structure to the 
annotated ligands in the respective receptor subset and the e-value allows judgement 
of the quality of this result (Table 4.2).157  
 
# Code Lds Receptor Subset e-Value mTC 
1 GRIA1_HUMAN_10000 125 
Glutamate receptor 
ionotropic, AMPA 1 
8.66e-42 0.44 
2 OPRM_RAT_10000 2143 Mu opioid receptor 8.26e-25 0.43 
3 ACHD_HUMAN_10000 12 
Acetylcholine receptor protein 
delta chain 
2.26e-27 0.43 
4 SOAT1_RAT_10000 480 
Acyl coenzyme A: cholesterol 
acyltransferase 1 
3.29e-5 0.42 
5 NEP_HUMAN_10000 490 Neprilysin 1.52e-21 0.41 
6 HYES_HUMAN_10000 763 Epoxide hydratase 1.62 0.41 
7 HDAC9_HUMAN_10000 354 Histone deacetylase 9 1.51e-21 0.4 
                                                
155 a) S. G. Lee, H. Lee, T. G. Nam, S. H. Eom, H. J. Heo, C. Y. Lee, D.-O. Kim, J. 
Food Sci. 2011, 76, C250–C256. b) J. Gaugler, B. James, T. Johnson, K. Scholz, W. 
J, Alzheimer's & Dementia 2013, 9, 208–245. 
156 www.sea.bkslab.org/search 
157 M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, B. K. 
Shoichet, Nat. Biotechnol. 2007, 25, 197–206. 
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8 HDAC5_HUMAN_10000 364 Histone deacetylase 5 4.38e-21 0.4 
9 HDAC1_HUMAN_10000 1521 Histone deacetylase 1 4.22e-29 0.4 
10 HDAC2_HUMAN_10000 614 Histone deacetylase 2 3.62e-29 0.4 
11 HDAC3_HUMAN_10000 489 Histone deacetylase 3 8.64e-27 0.4 
12 CNR2_HUMAN_10000 1759 Cannabinoid CB2 receptor 1.88e-01 0.39 
13 CNR1_HUMAN_10000 2267 Cannabinoid CB1 receptor 1.56 0.39 
14 CEGT_HUMAN_10000 6 Ceramide glucosyltransferase 1.43e-8 0.39 
15 OPRD_RAT_10000 1622 Delta opioid receptor 2.87e-10 0.38 
16 ACE_HUMAN_10000 654 
Angiotensin-converting 
enzyme 
3.51e-1 0.38 
17 GRIA1_RAT_10000 113 
Glutamate receptor 
ionotropic, AMPA 1 
2.33e 0.37 
18 CNR1_RAT_10000 1279 Cannabinoid CB1 receptor 2.13e-6 0.37 
19 ACE_RABIT_10000 95 
Angiotensin-converting 
enzyme 
1.68e-11 0.37 
20 CNR2_MOUSE_10000 237 Cannabinoid CB2 receptor 7.92e-9 0.37 
21 OPRM_HUMAN_10000 2816 Mu opioid receptor 3.32e-6 0.37 
22 MMP8_HUMAN_10000 628 Matrix metalloproteinase 8 1.18e 0.36 
23 OPRD_MOUSE_10000 413 Delta opioid receptor 1.11e-8 0.36 
24 ACE_RAT_10000 253 
Angiotensin-converting 
enzyme 
1.43e-9 0.35 
25 PIN1_HUMAN_10000 26 
Peptidyl-prolyl cis-trans 
isomerase NIMA-interacting 
1 
2.30e-4 0.35 
26 OPRD_HUMAN_10000 2216 Delta opioid receptor 1.02e-3 0.35 
27 GLCM_MOUSE_10000 12 Beta-glucocerebrosidase 5.99e-31 0.34 
28 ATS5_HUMAN_10000 88 ADAMTS5 2.02 0.33 
29 OPRM_MOUSE_10000 256 Mu opioid receptor 5.87e-4 0.33 
30 PAPA1_CARPA_10000 52 Papain 9.5 0.33 
31 AMPN_HUMAN_10000 92 Aminopeptidase N 1.23e-1 0.33 
32 PA21B_PIG_10000 11 Phospholipase A2 group 1B 2.96e-15 0.32 
33 MIF_HUMAN_10000 40 
Macrophage migration 
inhibitory factor 
3.91e 0.32 
34 OPRK_MOUSE_10000 137 Kappa opioid receptor 1.81e-2 0.31 
35 A2AMS1_MOUSE_10000 172 Sigma opioid receptor 7.92e-1 0.31 
36 OPRK_RAT_10000 552 Kappa opioid receptor 5.88e-1 0.31 
37 NMT2_HUMAN_10000 82 Peptide N- 2.38e-3 0.31 
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myristoyltransferase 2 
38 NMT1_HUMAN_10000 89 
Peptide N-
myristoyltransferase 1 
5.01e-3 0.31 
39 CNR2_RAT_10000 81 Cannabinoid CB2 receptor 2.41e-6 0.31 
40 CASP1_HUMAN_10000 460 Caspase-1 1.20e-3 0.3 
41 LYAM3_HUMAN_10000 9 P-selectin 3.82e-4 0.3 
42 NK3R_HUMAN_10000 342 Neurokinin 3 receptor 4.09e-3 0.3 
43 KPCB_HUMAN_10000 537 Protein kinase C beta 3.07 0.29 
44 CATB_RAT_10000 15 Cathepsin B 4.27e-2 0.29 
45 HIS7_CRYNE_10000 22 
Imidazoleglycerol-phosphate 
dehydratase 
2.29e-4 0.29 
 
Table 4.2. Results of the similarly search against triol 3.20e using the SEArch 
  tool developed by Shoichet (Lds = amount of ligands in this subset).158 
 
The ligand set of the ionotropic glutamate receptor AMPA 1 showed the 
highest proximity.159 These receptors are present in many parts of the brain and are 
the most frequently found receptors in the nervous system.160 It is, therefore, no 
surprise that these ion channels are modulated by glutamate (4.17) as this compound 
is the most abundant excitatory neurotransmitter in the mammalian cortex. The 
biogenic amine of glutamate, γ-aminobutyric acid (GABA, 4.18) is the chief 
inhibitory neurotransmitter that primarily acts on the GABA receptor ion channel 
complexes. These two neurotransmitters can be enzymatically transformed into each 
other and their interplay mediates the fast excitatory synaptic transmission and 
underlying several forms of synaptic plasticity, among other things (Fig. 4.12).161  
 
 
                                                
158 a) M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, B. K. 
Shoichet, Nat. Biotechnol. 2007, 25, 197–206.  b) www.sea.bkslab.org/search 
159 O. A. Petroff, The Neuroscientist 2002, 8, 562–573. 
160 S. R. Platt, Vet. J. 2007, 173, 278–286. 
161 a) A. Nilsen, P. M. England, J. Am. Chem. Soc. 2007, 129, 4902–4903. b) O. A. 
Petroff, The Neuroscientist 2002, 8, 562–573. 
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NH2
O
HO
O
OH
O
HO NH2
Glutamate (4.17) GABA (4.18)  
Figure 4.12. The two most abundant neurotransmitters glutamate (4.17) and  
 GABA (4.18).  
 
A closer look on the top three ranked ionotropic glutamate receptor AMPA 1 
subset ligands, the philanthotoxin derivatives 4.19a-f reveals the structural similarities 
with the triol 3.20t. These compounds 4.19a-f are able to block AMPA receptors in 
the low µM range (Fig. 4.13).162 However, due to the enormous breadth of this 
receptor family, other active receptor subsets might provide more insight. 
O
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N NH2
O
N
H
OH
O
H
N N
H
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N
H
OH
O
H
N
H
N NH2
4.19a Rank 1, TC: 0.4386
4.19b Rank 2, TC: 0.4310
4.19c Rank 3, TC: 0.4035
HO HO
H
N
O
OH
Triol 3.20t  
Figure  4.13.  Top  three  ionotropic  glutamate  receptor  AMPA  1  inhibitors  
 4.19a-c according to their Tanimoto coefficient, and triol 3.20t.    
                                                
162 a) H. Kromann, S. Krikstolaityte, A. J. Andersen, J. Med. Chem. 2002, 45, 5745-
5754. b) A. Nilsen, P. M. England, J. Am. Chem. Soc. 2007, 129, 4902–4903. 
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 Other receptor subsets of interest involve the histone deacetylase, opioid and 
cannabinoid receptors. We then visually screened hundreds of ligands associated to 
these receptors. The ideal ligand would be a close structural mimics of 3.20t that 
bears a tyrosinol moiety, due to this being the common structural motive every 
member of our farinosone C derivative collections has in common.  
 Our initial attempts where unsuccessful identifying the L-tyrosinol-derived 
ligands. However, in the CB1 receptor subset (CNR1_RAT_10000) the 44 ligands, 
which scored the highest out of 1279, are all AEA 4.8 and 2-AG 4.10 analogs, which 
comes as no surprise (Fig 4.14). Of special interest is compound 4.20 (Fig 4.14) that 
ranked 13th. It does not contain a tyrosinol-derived ligand, but the para-phenolic 
moiety was encouraging enough for us to perform a literature search where we 
replaced the 4-hydroxybenzyl part of this amphiphile 4.20 by L-tyrosinol.  
 
HO
H
N
O
O
O
H
NHO
HO
HO
H
N
O
O
N
H
HO 4.20 Rank 13 TC: 0.3333
Rank 3 TC: 0.3673
Rank 2 TC: 0.3684
Rank 1 TC: 0.3729
 
Figure 4.14. Top three CB1 inhibitors according to their Tanimoto coefficient 
 and the dopamine derived analog 4.20.  
 
To our delight, we found this exact compound and close analogs, which where 
descripted as potent CB1 receptor agonists.163 These tyrosinol-derived fatty acid 
analogs are not registered in the ChEMBL Medical Chemistry Database and could, 
therefore, not attract our attention on the first glance.  
                                                
163 F. Schmidt, G. Le Douaron, P. Champy, M. Amar, B. Seon-Meniel, R. Raisman-
Vozari, B. Figadere, Bioorg. Med. Chem. 2010, 18, 5103–5113. 
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O
H
N∗
HO HO
O
H
N∗
HO HO (S) :  MDMO-3 4.21c
(R) :  MDMO-4 4.21d
(S) :  MDMO-1 4.21a
(R) :  MDMO-2 4.21b
 
Fig. 4.15. Selective tyrosinol derived CB1 inhibitors developed by Di Marzo.164 
 
This literature search revealed inconclusive results regarding the relationship 
between tyrosinol-derived CB1 inhibitors and neuronal differentiation. As discussed 
in section 4.1.2 Figadère reported on tryptamine derived fatty acid derivatives with 
neuritogenic properties.165 We speculated that if we replace the tryptamine with a 
tyrosinol unit, eventually compounds would be furnished which 1) interact with the 
CB1 receptor system, and 2) are able to induce neuronal differentiation which may 
allow a connection to be made between these to phenomenas. 
 As highlighted in table 4.1, a 16-atom alkyl chain yielded the best results. 
Consequently, we also intended to use the same length for the fully saturated alkyl 
chains. Table 4.3 shows the molecular probes we synthesized. We were especially 
interested in the bioactivity of compound 4.22b/f since both also bear a hydroxyl 
group terminus as the neuritogenic triol 3.20t does.   
 
 
 
 
 
 
 
 
                                                
164 G. Ortar, A. Ligresti, L. De Petrocellis, E. Morera, V. Di Marzo, Biochem. 
Pharmacol. 2003, 65, 1473–1481. 
165 F. Schmidt, G. Le Douaron, P. Champy, M. Amar, B. Seon-Meniel, R. Raisman-
Vozari, B. Figadere, Bioorg. Med. Chem. 2010, 18, 5103–5113. 
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HO
H
N X
HO
6
R
 
  Cpd                X  R 
4.22a –CH2 –(CH2)7–CH3 
4.22b –CH2 –(CH2)7–OH 
4.22c –CH2 –CH=CH–CH2–CH=CH–(CH2)4–CH3 
4.22d –CH2 –(CH=CH–CH2)3–CH3 
4.22e –C=O –(CH2)7–CH3 
4.22f –C=O –(CH2)7–OH 
4.22g166 –C=O –CH=CH–CH2–CH=CH–(CH2)4–CH3 
4.22h –C=O –(CH=CH–CH2)3–CH3 
 
Table 4.3. Tyrosinol fatty acid analogs 4.22a-h. 
 
4.2.2 Synthesis of Tyrosinol Fatty Acid Analogs 4.22a-h 
 
We first synthesized the tryptamine-derived compounds 4.6c and its amine 
analog 4.6l following the reported procedure, obtaining similar yields.167 These two 
compounds will then later serve as reference compounds. As previously mentioned 
(section 4.1.2), Figadère and co-workers evaluated the neuritogenic properties using 
primary dopaminergic neurons,169 therefore we also had to examine if these results 
could be repeated in our PC12 cell model.  
 
N
H
X R
n
N
H
NH2
HO
O 13
X = NH–C=O : 4.6c, 76% Lit:. 88%
X = NH–CH2 : 4.6l, 53% Lit.: 70%
LiALH4, THF, 
reflux, 4.5 h
C2O2Cl2, DMF (cat),
TEA, MeCN, 16-18 h,
 r.t.
 
Scheme 4.1. Synthesis of reference compounds 4.6c/l as described by Figadère.169  
                                                
166 also referred as BSL34 
167 F. Schmidt, G. Le Douaron, P. Champy, M. Amar, B. Seon-Meniel, R. Raisman-
Vozari, B. Figadere, Bioorg. Med. Chem. 2010, 18, 5103–5113. 
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We initially planed to adopt the peptide coupling/reduction sequence using 
LiAlH4 for our L-tyrosinol derived analogs. However, we were not able to synthesize 
compound 4.22e, 4.22f, or the double unsaturated amide 4.22g using oxalyl chloride 
and catalytic amounts of DMF. The same was true for these three compounds when 
PyBOB 4.23 was used as coupling agent. We instead found that HOBt in combination 
with EDC afforded compound 4.22e and 4.22f in reasonable yields (scheme 4.2). 
Nevertheless, using LiAlH4 to reduce the amide bond was insufficient and no 
conversion of the starting material was observed. Also, neither acetic acid with 
NaBH4 salt nor BH3-THF complex solution under reflux transformed amide 4.22e 
into the amine 4.22a.168 Since these direct reduction approaches were not successful, 
we employed HDMS in combination with a catalytic amount of TMSCl, first mixed 
with amides 4.22e or 4.22f and refluxed for up to 2 h in MeCN to give rise to the 
respective TMS-formimidate analogs. The MeCN was then replaced by dioxane and 
BH3-DMS complex solution was added in excess. Reflux overnight yielded the 
desired secondary amines 4.22a and 4.22b.169  
HO
NH2
HO HO
O
R
13
EDC, HOBt, TEA
MeCN, 16-18 h, r.t.
HO HO
H
N
O
R
13
R = CH3 :  4.22e, 68%
R = OH :  4.22f, 62%
i) TMSCl, HDMS, MeCN,
reflux, 1-2 h
ii) BH3-DMS, dioxane, 
reflux, 13-20 h
HO HO
H
N R
13
R = CH3 : 4.22a, 68%
R = OH : 4.22b, 62%
O
N
N
N
P
PF6
PyBOB 4.23
 
Scheme 4.2. Peptide coupling/reduction sequence for fully saturated  
 tyrosinol analogs. 
  
                                                
168 a) T. M. Fong, S. B. Heymsfield, Int. J. Obes. 2009, 33, 947–955. b) R. Lan, Q. 
Liu, P. Fan, S. Lin, S. R. Fernando, D. McCallion, R. Pertwee, A. Makriyannis, J. 
Med. Chem. 1999, 42, 769–776. 
169 a) B. Ravinder, S. R. Reddy, A. P. Reddy, Tetrahedron 2013, 54, 4908-4913. b) A. 
Giannis, K. Sandhoff, Angew. Chem. Int. Ed. 1989, 28, 218–220. 
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This established sequence could not be applied to the unsaturated fatty acid 
derivatives. Activation of the fatty omega-3 or omega-6 fatty acid using DCC and 
PFP yielded the desired amides 4.22g and 4.22h (Scheme 4.3). Reduction of amide 
4.22g using LiAlH4 under reflux overnight led to a complex mixture, including 
starting material. The previously applied approach using HMDS/TMS and BH3-DMS 
resulted in complete saturation of all non-aromatic double-bonds. We then decided to 
try to bypass the amide reduction via a reductive animation. Ethyl linoleate 4.24 or 
ethyl linolenate 4.25 were dissolved in toluene and cooled to –78 °C before 1 equiv. 
of a pre-cooled DIBAL-H solution was added. A standard work-up after 50 minutes 
afforded the crude aldehyde, which was then dissolved in MeOH and glacial acetic 
acid, L-tyrosinol and sodium cyanoborohydride were added at room temperature to 
provide the remaining members of the desired collection, as shown in table 4.3.   
 
i) DIBAL-H, PhMe, –78 °C
ii) AcOH, L-tryrosinol HCl,
NaCNBH3, MeOH, r.t. 2 h
O
HO
HO
O
or
i) PFP, DCC, DMF, 
r.t. 18 h, 60 °C, 20 h
ii)L-tryrosinol HCl, TEA, r.t.
20-30 h
H
N
H
N
HO HO
HO HO
O
O
O
O
or
H
N
H
N
HO HO
HO HO
O
O
4.22c 27%
4.22d 22%
4.22g 63%
4.22h 56%
4.25
4.24
 
Scheme 4.3. Synthesis of OMDM-2 4.21b analogs 4.22c-g.  
4.2.3 Biological Evaluation  
Compounds 4.6c and 4.6l and the commercially available CB1 selective 
antagonist OMDM-2 (4.21b) were first screened for neurite outgrowth at 10 µM 
concentration using the same assay conditions as in chapter 3, but with a higher NGF 
concentration (40 ng/mL instead of 20 ng/mL) for the overnight priming. All 
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compounds (4.22a-d and 4.6l) bearing a secondary amine function were not tolerated 
by the PC12 cells, resulting in partial or complete cell death. After reduction of the 
concentration by one order of magnitude, neither toxicity nor neuritogenic activity 
could be observed for these amines. Among the amide bearing amphiphiles 4.22f-h, 
only 4.22g (hereafter referred to as BSL34) showed a significant activity at 10 µM 
concentration (Fig. 4.16), suggesting that the degree of unsaturation of the alkyl chain 
plays a crucial role. Also, the length of the alkyl chain is of importance as expected; 
triol 3.20t was been identified as the most potent compound, whereas triol 4.22f was 
inactive, but they only differ in the length of the alkyl chain (C7 versus C14). 
Trypatmine-derived compounds were either toxic (4.6l) or completly inactive (4.6c), 
even at a 100-fold higher concentration. This results is contraty to Figadère’s 
findings,170 demonstrating the difficulty in transforming obeservations from one cell 
type to another.  
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170 F. Schmidt, G. Le Douaron, P. Champy, M. Amar, B. Seon-Meniel, R. Raisman-
Vozari, B. Figadere, Bioorg. Med. Chem. 2010, 18, 5103–5113. 
Fig. 4.16. Neuritogenic activity of OMDM-2 (4.21b) and fatty acid analogs. 
Values were determined at 10 µM (4.21b, 4.22e-h, BSL24, 4.6c) or 1 µM 
(4.22a-d, 4.6l), NGF control: 20 ng mL-1. DMSO control: 0.1%. Incubation 
period: 2 days. Values are reported as means ± SEM (unpaired tow-tailed t-test 
significance: *** = P < 0.0001). 
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4.2.4 Examination of the Cannabinoid System  
 
Next the CB1/2 binding affinities for this set of compounds (Fig. 6.1A and 
6.1B) were evaluated in collaboration with Prof. Dr. Jurg Gertsch and Dr. Andrea 
Chicca (University of Bern). We were very pleased to discover that 4.22b and, more 
importantly, the neuritogenic omega-6 fatty acid amide derivative BSL34 selectively 
bind to the CB1 receptor with moderate Ki potencies values of 530 and 810 nM, 
respectively (Fig. 4.17).171  
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To further clarify the role of the CB1 receptor, we performed a co-incubation 
study in the PC12 system using the CB1 selective antagonists rimonabant or 
AM251. 172  Despite multiple attempts under a variety of conditions, neuronal 
differentiation could not be suppressed using the above-mentioned selective CB1 
antagonists in combination with BSL34, nor were phenotypic changes detected when 
AM251 or rimonabant was administered alone. The same results were observed when 
the CB1 selective agonist O-689173 at a 100 nM concentration was investigated. Extra- 
                                                
171 A. Chicca, J. Marazzi, S. Nicolussi, J. Gertsch, J. Biological Chem. 2012, 287, 
34660–34682. 
172 a) T. M. Fong, S. B. Heymsfield, Int. J. Obes. 2009, 33, 947–955 b) R. Lan, Q. 
Liu, P. Fan, S. Lin, S. R. Fernando, D. McCallion, R. Pertwee, A. Makriyannis, J. 
Med. Chem. 1999, 42, 769–776. 
173 S. Lin, A. D. Khanolkar, P. Fan, A. Goutopoulos, C. Qin, D. Papahadjis, A. 
Makriyannis, J. Med. Chem. 1998, 41, 5353–5361. 
Fig. 4.17. EMT inhibition parameters. EC50 values and maximal effect 
were determined from full concentration-dependent curves performed in 
U937 cells as previously described.173  
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and intercellular endocannabinoid levels can also be controlled by the putative 
endocannabinoid membrane transporter (EMT) or the enzymes FAAH, ABHDs, and 
MAGL as introduced earlier (section 4.1.4). Modulation of these targets’ functions is 
known to affect the endocannabinoid concentrations, indicating indirect CB1/2-
dependent effects.174 Consequently, we tested our compounds (both collections) in 
this regard. All compounds showed no or only a weak inhibition (up to 20-25%) at 1 
µM of fatty acid amide hydrolase (FAAH, Fig. 6.2). Similarly, 2-AG hydrolysis by 
MAGL and ABHDs is not significantly inhibited at the screening concentration of 1 
µM (6.3A and 6.3B). Next, we examined the EMT inhibition capacities (Fig. 6.4). We 
discovered fatty acid analogs displaying excellent EMT inhibitory patterns (Table 
4.4). Four of the tested compounds inhibited AEA (4.8) cellular re-uptake with sub-
micromolar EC50 values. The most potent compound was again BSL34 with a 10-fold 
higher activity than UCM707, a potent benchmark inhibitor.175 
 
Cpd EC50 ± SEM (nM) Max Inhibition 
4.22c 975 ± 201 51 % 
4.22d 966 ± 252 60 % 
4.22f 757 ± 326 73 % 
BSL34 228 ± 139 52 % 
UCM707  1800 ± 801 80 % 
 
 
 
 
 
 
 
 
                                                
174 A. Chicca, J. Marazzi, S. Nicolussi, J. Gertsch, J. Biological Chem. 2012, 287, 
34660–34682. 
175 a) A. Chicca, J. Marazzi, S. Nicolussi, J. Gertsch, J. Biological Chem. 2012, 287, 
34660–34682 b) P. Hasanein, K. Javanmardi, Fund. Clin. Pharmacol. 2008, 22, 517–
522 b) E. de Lago, J. Fernández-Ruiz, S. Ortega-Gutiérrez, A. Viso, M. L. López-
Rodrı́guez, J. A. Ramos, Euro. J. Pharmaco. 2002, 449, 99–103. 
Table 4.4. EMT inhibition parameters. EC50 values and maximal effect 
were determined from full concentration-dependent curves performed in 
U937 cells as previously described.176 
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4.2.5 HIP HOP Profiling 
  
The tyrosinol fatty acid analogs 4.22a-h and all members of the farinosone C 
collection (3.5, 3.20a-t) were investigated in the HIP HOP assay at Novartis by Dr. 
Dominic Höpfner and co-workers. Most of the compounds already failed the initial 
uptake screening with the yeast cells. Of the few compounds that passed this first 
hurdle, 4.22b expressed an interesting profile (Fig. 4.18). It is unclear why only one 
members of the tyrosinol fatty acid collection 4.22a-h was taken up by the yeast cells, 
although their structural similarity is very high. However, at a concentration of 150 
µM, 4.22b induced lipid stress. This observation is supported by the fact that yeast 
strains in which one gene copy of APL6 and NEO1 has been deleted (HIP) showed 
reduced viability. Both genes are linked to membrane stress.176 Moreover, TDA10 is a 
“frequent hitter” associated with compounds known to induce membrane 
destabilisation.177 Due to the lipophilicity of compound 4.22b, this was expected. 
Moreover, besides also being associated to lipid stress, ERG24 inhibition indicates 
that the sterol biosynthesis is affected.178 This result is supported by the synthetic 
lethality of the UPC2 strain. This gene decodes the main relator unit of the sterol 
biosynthesis. 179  As explained in section 4.1.5, when a compound inhibits a 
compensating pathway (ERG24) and the main pathway (UPC2) is abundant, HOP 
allows for confirmation of HIP results.  
GEF1 is known for membrane destabilisation as well180 and ILM1 is expected 
to be an experiment-specific false positive, because it was observed with unrelated 
compounds during this run but never before. These results however do not allow the 
conclusion that 4.22f directly inhibits ERG24 or that the compound’s ability to induce 
membrane stress is the main reason for sterol biosynthesis inhibition. In summary, the 
                                                
176 a) C. R. Cowles, G. Odorizzi, G. S. Payne, S. D. Emr, Cell 1997, 91, 109–108. b) 
S. Wicky, H. Schwarz, B. Singer-Kruger, Molec. Cell. Biol. 2004, 24, 7402–7418. c) 
H. R. Panek, The EMBO J. 1997, 16, 4194–4204. 
177 Personal communication from Dr. Dominic Höpfner, 2013. 
178 N. Jia, B. Arthington-Skaggs, W. Lee, C. A. Pierson, N. D. Lees, J. Eckstein, R. 
Barbuch, M. Bard, Antimicrob. Agents Chemother. 2002, 46, 947–957. 
179 L. W. Parks, W. M. Casey, Annu. Rev. Microbiol. 1995, 49, 95–116. 
180 A. Lopez-Rodriguez, A. Carabez-Trejo, L. Coyne, R. F. Halliwell, R. Miledi, A. 
Martinez-Torres, FEMS Yeast Res. 2007, 7, 1218–1229. 
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HIP HOP assay represents an impressive target identification platform, but did not 
support us in our attempt to find the lock to our neuritogenic keys.181  
 
 
 
 
4.2.6 Amphetamine-Type Bioactivity of Farinosone C Analogs 
  
As described in section 4.1.6, multiple ATDD are well established. 
Examination of the structures shown in figure 4.7 and 4.8 reveals that re-uptake 
transporters tolerate a wide range of different structural moieties. This fact, in 
combination with a certain structural analogy from ATDD drugs and members of our 
farinosone C library, made their potential to act on monoamine re-uptake transporters 
of interest. Therefore, a dozen compounds where selected (Fig. 4.19) and screened for 
re-uptake transport inhibition (Fig. 4.20) in collaboration with Dr. Linda Simmler and 
PD Dr. Matthias Liechti (University Hospital, Basel). At 20 µM concentration, the 
compounds 3.20l and 3.20o showed weak dopamine (DA, 4.12) and norepinephrine 
(Ne, 4.13) re-uptake inhibition. The amine 3.20l inhibited DA re-uptake to 53 ± 9% 
and NE re-uptake to 64 ± 4%, and the molecular probe 3.20o inhibited DA re-uptake 
to 52 ± 14% and NE re-uptake to 81 ± 5%. It was expected that amine 3.20l showed 
                                                
181 www.yeastgenome.org 
Fig. 4.18. Results obtained form the HIP HOP assay conducted at Novartis in 
Basel by Dr. Dominic Höpfner and co-workers. The z-score (= sensitivity 
score / standard deviation) allows judging the relevance of the obtained 
results: > ± 5 is considered interesting.  
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superior properties than analogs bearing an amide group. Consequently, no amide 
bond is present in the introduced amphetamine-derivatives. However, a drug that 
exhibits about 50% re-uptake inhibition efficacy at 20 µM would not be considered as 
pharmacologically relevant DA or NE re-uptake inhibitor, as known transporter 
inhibitors like MDMA and methamphetamine inhibit DA transport and NE transport 
have a 50% inhibitory concentration below 1 µM in this assay. MDMA 4.11a inhibits 
50% of NE re-uptake at 0.5 µM and methamphetamine inhibits 50% NE re-uptake at 
6 nM and DA re-uptake at 1 µM concentration.182 The abnormal negative binding 
observed by the dopamine-derived amide 3.20k in case of the dopamine transporter is 
hard to rationalize. In vitro hydrolysis of the amide bond revealing dopamine would 
lead to re-uptake inhibition.183 Another reason for this type of observation are pH-
changes, hence acid 3.20g did not induce such an effect, the catechol 3.20k should not 
either. However, if 3.20k acts as a substrate for the DA transporter, a general re- 
uptake acceleration could eventually occur. In Summary, these findings did not justify 
further investigation such as determination of Ki values for transporter affinity or 
transporter-mediated release properties. Possible ethical considerations prior to 
publication are therefore not necessary, as we did not discover a potent monoamine 
re-uptake transporter inhibitor that can be obtained in one-step form non-controlled 
substances.  
                                                
182 L. D. Simmler, T. A. Buser, M. Donzelli, Y. Schramm, L.-H. Dieu, J. Huwyler, S. 
Chaboz, M. C. Hoener, M. E. Liechti, Br. J. Pharmacol. 2012, 168, 458–470. 
183 R. B. Rothman, M. H. Baumann, C. M. Dersch, D. V. Romero, K. C. Rice, F. I. 
Carroll, J. S. Partilla, Synapse 2001, 39, 32–41. 
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Fig. 4.19. Compounds selected for monoamine re-uptake inhibition studies.  
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Fig. 4.20. Re-uptake inhibition study results. Reference: fluoxetine (hSERT),  
mazindole (hDAT) and nisoxetine (hNET) all at 10 µM.   
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4.2.7 Fluorescent Labelling   
 
A common method to localize a general cell region, such as the membrane, 
nucleolus or mitochondrion core in which active compounds interacted with their 
respective receptors is fluorescent labelling.184 We envisioned that a tyrosinol-type 
pharmacophore linked to a fluorescent label may retain its neuritogenic activity and, if 
so, the interaction of our fluorescent ligand with its respected molecular target might 
be strong enough to allow for a local accumulation. This eventually would narrow 
down the possible molecular targets. Therefore, dansyl chloride (4.26) was coupled 
with 6-aminocaproic acid (4.27) following a literature procedure.185 The resulting 
dansyl tag 4.28 was attached to L-tyrosinol using HATU 4.29, which proceeded well 
and yielded the fluorescently labelled compound 4.30 (Scheme 4.4).  
N
CH3H3C
SO O
Cl
H2N OH
O
N
H3C CH3
S OO
HN
O
OH
N
H3C CH3
S OO
HN
O
H
N
OH OH
N
N
N
O
N
N
H3C CH3
CH3
CH3
BF4
L-tyrosinol, TEA,
DMF, o.n., r.t.
TEA, NaHCO3,
H2O/acetone, 
o.n., r.t.
4.28 83%, Lit.: 85%
4.30 63%
4.29
4.26 4.27
 
Scheme 4.4. Synthesis of fluorescent L-tyrosinol derived label 4.30.  
 
With the labelled tyrosinol derivative 4.30 in hand, we investigated its 
neuritogenic properties. Unfortunately, no bioactivity could be observed under 
standard PC12 assay conditions. Nevertheless, fluorescent staining investigations 
                                                
184 a) G. Zimmermann, B. Papke, S. Ismail, N. Vartak, A. Chandra, M. Hoffmann, S. 
A. Hahn, G. Triola, A. Wittinghofer, P. I. H. Bastiaens, et al., Nature 2013, 497, 638–
642. b) H. Sahoo, RSC Advances 2012, 2, 7017–7029. 
185 T. H. Walls, S. C. Grindrod, D. Beraud, L. Zhang, A. R. Baheti, S. 
Dakshanamurthy, M. K. Patel, M. L. Brown, L. H. MacArthur, Bioorg. Med. Chem. 
2012, 20, 5269–5276. 
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were performed. Compound 4.30 did stain the cells fluorescently, but no specific 
localisation could be recognized (Fig. 4.20A), even at higher magnification (picture 
not shown). 4.28 was used as control, to see if the L-tyrosinol terminus does make any 
difference (Fig. 4.20B). Comparison of these two different picture series however 
revealed no difference. 
 
 
Fig. 4.20. Fluorescently stained PC12 cells. A: 4.30 50 µM, B: 4.28 50 µM.  
 
A 
B 
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4.2.8 Neuroprotective Properties  
 
The attempts to establish the MTT assay were unsuccessful. The procedure of 
Kim186 was followed as described using the same (40 µM) or higher (100 µM) 
concentrations of βΑ peptide fragment 25-35. The incubation times were also 
extended from the proposed 2 h to 1-2 days but no βΑ−induced cytotoxicity could be 
detected and, therefore, prevented any neuroprotective examination in combination 
with our compounds. Experiments using higher concentrations of βΑ were not 
conducted due to high material costs.         
 
4.3 Conclusion 
 
Our investigations discussed in this chapter did not result in the definition of a 
precise molecular target responsible for neurite outgrowth. Nevertheless, a broad 
insight into various tools of chemical biology was acquired and evidence was found 
that the ECS might be involved in neuronal differentiation mediated by some of our 
compounds. We consider the discovery of four simple and potent EMT inhibitors an 
important one. Especially since BSL34 clearly outruns the potent benchmark inhibitor 
UCM707. This advancement is expected to by appreciated by numerous researchers 
working on the endocannabinoid system.     
 
 
 
 
 
 
 
 
 
 
 
                                                
186 S. G. Lee, H. Lee, T. G. Nam, S. H. Eom, H. J. Heo, C. Y. Lee, D.-O. Kim, J. Food 
Sci. 2011, 76, C250–C256. 
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5.1 Introduction 
5.1.1 General Outline 
 
The previous three chapters have presented results that could potentially 
contribute to establishing small molecule-based therapies for patients suffering from 
neurodegenerative dementia (ND). This chapter however addresses a different unmet 
medical condition: Spinal cord injuries (SCI). Although, ND and SCI disable patients 
in different ways, both conditions could be addressed if neuronal cells are forced to 
re-connect in a controlled fashion. To help paralyzed people to regain their locomotor 
control, researchers from distinguish fields such as medicine, natural sciences and 
engineering have to join efforts. An increasing number of new therapeutic approaches 
emerged from research laboratories and seek transformation into clinical trials.187 This 
chapter reports on a facile, robust and carefully explored method to turn glass slides 
into neuritogenic surfaces. 
5.1.2 Spinal Cord Injuries 
In the US, every year 10’000 new people are being diagnosed with traumatic 
SCI. More than one third is caused by motor vehicle accidents followed by falls and 
violence (primarily gunshot wounds).188 Depending on which section of the spinal 
column and the ferocity the traumatic interruption has occurred, the symptoms differ 
from light chronic pain to total paralysis. It is also crucial to receive adequate medical 
treatment within the first couple of hours after the incident to prevent secondary 
lesions. In order to prevent further damage of the spinal cord, the removal of bone 
fragments or internal stabilization of the injured area showed to be critical for the 
success of later rehabilitation.189 Another major problem is caused by inflammation 
resulting from the uncontrolled release of chemicals from damaged blood vessels, 
axons and cells. Healthy axons e.g. normally deliver small and controlled amounts of 
                                                
187 a) B. K. Kwon, E. B. Okon, W. Plunet, D. Baptiste, K. Fouad, J. Hillyer, L. C. 
Weaver, M. G. Fehlings, W. Tetzlaff, J. Neurotrauma 2011, 28, 1589–1610. b) W. 
Tetzlaff, E. B. Okon, S. Karimi-Abdolrezaee, C. E. Hill, J. S. Sparling, J. R. Plemel, 
W. T. Plunet, E. C. Tsai, D. Baptiste, L. J. Smithson, et al., J. Neurotrauma 2011, 28, 
1611–1682. 
188 Spinal Cord Injury: Facts and Figures at a Glance, The National SCI Statistical 
Center, 2012, University of Alabama, Brimingham.  
189 J. W. McDonald, C. Sadowsky, The Lancet 2002, 359, 417-425. 
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the neurotransmitter glutamate (4.17) to stimulate other cells to fire electrical 
impulses (also see section 4.2.1). Nevertheless, injuries can result in an uncontrolled 
release of glutamate (4.18), which then leads to over-excitation. This can results in the 
formation of free radicals resulting in the death of healthy cells. This process is called 
excitotoxicity and one way to prevent this is the local admission of glutamate-receptor 
blockers shortly after the injury.190  
Approved long-term treatments include additional surgeries, medication, 
electrical stimulations and large amount of physical therapies. A good combination of 
these methods can enable heavily paralysed people to regain back some of their 
locomotor control, eventually after years of intensive therapy. However, full recovery 
remains very rare.191 Experimental therapies include stem cell transplantations,192 
electrochemical neuroprosthesis in combination with a robotic interface193 or antibody 
treatments.194 Another approach is to engineer materials that can promote and guide 
neuronal growth and at the same time also act as stabilizing and bridging device.195  
 
5.1.3 Surface-Mediated Neuronal Growth and Guidance 
 
Multiple approaches, mainly originating form the field of neural interfaces, are 
reported where surface-based neuronal differentiation and guidance was induced. 
These results were achieved e.g. via topographical changes of surfaces using 
lithographic modifications and pattering,196 the alignment of nanofibers, -particles or 
                                                
190 a) D. D. Yang, C. Y. Kuan, A. J. Whitmarsh, M. Rincón, T. S. Zheng, R. J. Davis, 
P. Rakic, R. A. Flavell, Nature 1997, 389, 865–870. b) C. Matute, M. V. Sánchez-
Gómez, L. Martínez-Millán, R. Miledi, Proc. Natl. Acad. Sci. 1997, 8830–8835. 
191 J. W. McDonald, C. Sadowsky, The Lancet 2002, 359, 417-425. 
192 a) J. W. McDonald, Sci. Am. 1999, 64–73. b) O. Tsuji, K. Miura, Y. Okada, K. 
Fujiyoshi, M. Mukaino, N. Nagoshi, K. Kitamura, G. Kumagai, M. Nishino, S. 
Tomisato, et al., Proc. Natl. Acad. Sci. 2010, 107, 12704–12709. b) J. W. McDonald, 
X. Z. Liu, Y. Qu, S. Liu, S. K. Mickey, D. Turetsky, D. I. Gottlieb, D. W. Choi, Nat. 
Med. 1999, 5, 1410–1412. 
193 R. van den Brand, J. Heutschi, Q. Barraud, J. DiGiovanna, K. Bartholdi, M. 
Huerlimann, L. Friedli, I. Vollenweider, E. M. Moraud, S. Duis, et al., Science 2012, 
336, 1182–1185. 
194 I. C. Maier, R. M. Ichiyama, G. Courtine, L. Schnell, I. Lavrov, V. R. Edgerton, 
M. E. Schwab, Brain 2009, 132, 1426–1440. 
195 J. W. McDonald, C. Sadowsky, The Lancet 2002 , 359, 417-425. 
196 a) N. A. Kotov, J. O. Winter, I. P. Clements, E. Jan, B. P. Timko, S. Campidelli, S. 
Pathak, A. Mazzatenta, C. M. Lieber, M. Prato, Adv. Mater. 2009, 21, 3970–4004.     
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–tube arrays,197 or with biomimetic polymers.198 The fabrication of these materials 
however, often requires multiple layers and a combination of several specific 
components. Other approaches include the decoration of surfaces with neurotrophic 
proteins such as NGF to promote neuronal differentiation.199  Nevertheless, this 
method is linked to several drawbacks such as 1) the rapid metabolic degradation, 2) 
slow tissue penetration, 3) the relatively large size of NGF and 4) potential toxicity at 
high concentrations of growth factors.200 
 
5.1.4 Gentiside B Analog as ideal Candidate for Coating Applications  
 
Recently Qi et al. reported the isolation and neuritogenic evaluation of the 
gentiside family (also see section 4.1.2). These amphiphlic natural products originate 
from the plant Gentiana rigescens used in traditional Chinese medicine. A subsequent 
SAR study showed that simplified analogs also possess similarly strong neurite 
outgrowth inducing capabilities in the PC12 cell line. The most potent among them is 
compound (5.1, Fig. 5.1).201 Since amphiphiles202 and catechols203 are known to 
absorb to surfaces, we hypothesized that this natural product analog (5.1) might allow 
                                                                                                                                       
b) F. Patolsky, B. P. Timko, G. Yu, Y. Fang, A. B. Greytak, G. Zheng, C. M. Lieber, 
Science 2006, 313, 1100–1104. 
197 a) A. Solanki, S.-T. D. Chueng, P. T. Yin, R. Kappera, M. Chhowalla, K.-B. Lee, 
Adv. Mater. 2013, 38, 5477-485. b) T. D. B. Nguyen-Vu, H. Chen, A. M. Cassell, R. 
Andrews, M. Meyyappan, J. Li, Small 2006, 2, 89–94. c) A. F. Quigley, J. M. Razal, 
B. C. Thompson, S. E. Moulton, M. Kita, E. L. Kennedy, G. M. Clark, G. G. Wallace, 
R. M. I. Kapsa, Adv. Mater. 2009, 21, 4393–4397. d) M. K. Gheith, V. A. Sinani, J. P. 
Wicksted, R. L. Matts, N. A. Kotov, Adv. Mater. 2005, 17, 2663–2670. 
198 C. B. Gumera, Y. Wang, Adv. Mater. 2007, 19, 4404–4409. 
199 S. Tang, J. Zhu, Y. Xu, A. P. Xiang, M. H. Jiang, D. Quan, Biomaterials 2013, 34, 
7086–7096. 
200 P. Tayalia, D. J. Mooney, Adv. Mater. 2009, 21, 3269–3285. 
201 a) L. Gao, J. Li, J. Qi, Bioorg. Med. Chem. 2010, 18, 2131–2134. b) L. Gao, L. 
Xiang, Y. Luo, G. Wang, J. Li, J. Qi, Bioorg. Med. Chem. 2010, 18, 6995–7000. c) Y. 
Luo, K. Sun, L. Li, L. Gao, G. Wang, Y. Qu, L. Xiang, L. Chen, Y. Hu, J. Qi, 
ChemMedChem 2011, 6, 1986–1989. 
202 A. B. Jòdar-Reyes, J. L. Ortega-Vinuesa, A. M. Rodrìguez, J. Colloid. Interface. 
Sci. 2005, 282, 9–9. 
203 a) J. Gomes, A. Grunau, A. K. Lawrence, L. Eberl, K. Gademann, Chem. 
Commun. 2013, 49, 155–157. b) S. Zürcher, D. Wäckerlin, Y. Bethuel, B. Malisova, 
M. Textor, S. Tosatti, K. Gademann, J. Am. Chem. Soc. 2006, 128, 1064–1065. c) B. 
Malisova, S. Tosatti, M. Textor, K. Gademann, S. Zürcher, Langmuir 2010, 26, 4018–
4026. d) P. B. Messersmith, Science 2008, 319, 1767–1768. e) R. Wehlauch, J. 
Hoecker, K. Gademann, ChemPlusChem 2012, 77, 1071–1074. 
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the assembly of neuritogenic surfaces (NS) by simple absorption on a given solid 
support. 
OH
OHO
O
NP Analog 5.1  
Fig. 5.1. The potent neuritogenic genteside B analog 5.1. 
 
5.2 Results and Discussion 
5.2.1 Optimization Studies 
 
In the context of this surface functionalization study, initial experiments 
showed promising results and therefore justified a broad and systematic exploration of 
these first findings. To start with, the best concentration of 5.1 had to be determined. 
Given that the ideal solution concentration of 5.1 is 1 µM204 we chose to screen a 
range from 10 mM to 10 nM. Therefore amphiphile 5.1 was dissolved in DMSO and 
mixed in a 1:10 ratio with a 0.01% collagen aqueous solution. Collagen is widely 
used to support cell attachment to surfaces.205 Microscope cover slides were then 
incubated with this coating solution (CS) for 4 h at 36 °C and afterwards intensively 
washed with H2O. These slides were then placed in a new collagen coated 24-well 
plate, dried and sterilized under UV-light for 2 h. NGF primed PC12 cells were then 
grown on these slides and incubated for two days, fixed, stained and examined 
following known procedures (also see Fig. 5.12).206 As in the earlier discussed 
projects, NGF (20 ng mL-1) can be used as positive control, similar as in chapters 2-4. 
In this case, glass slide coated only with collagen, for the cells to grow on, were used 
as blanks. Another positive control was the normal addition of the NP analog used for 
coating, to ensure compound specific quality control where needed. These runs are 
marked with “*”. Values are reported as means (unpaired tow-tailed t-test 
                                                
204 L. Gao, J. Li, J. Qi, Bioorg. Med. Chem. 2010, 18, 2131–2134. 
205 a) T. D. B. Nguyen-Vu, H. Chen, A. M. Cassell, R. Andrews, M. Meyyappan, J. 
Li, Small 2006, 2, 89–94. b) J. Heino, Bioessays 2007, 29, 1001–1010. 
206 a) P. Burch, M. Binaghi, M. Scherer, C. Wentzel, D. Bossert, L. Eberhardt, M. 
Neuburger, P. Scheiffele, K. Gademann, Chem. Eur. J. 2013, 19, 2589–2591. b) K. 
Schmidt, W. Gunther, S. Stoyanova, B. Schubert, Z. Li, M. Hamburger, Org. Lett. 
2002, 4, 197–199. c) L. A. Greene, A. S. Tischler, Proc. Natl. Acad. Sci. 1980, 77, 
1701–1705. d) Y. Obara, T. Aoki, M. Kusano, Y. Ohizumi, J. Pharm. Exp. Ther. 
2002, 301, 803–811. d) I. Dikic, J. Schlessinger, I. Lax, Curr. Biol. 1994, 4, 702–708. 
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significance: *** = P < 0.0001, **P = < 0.001, *P = < 0.01) and the error bars denote 
SEM.  
 Figure 5.2 illustrated that concentrations from 1 mM to 100 nM significantly 
induce neurite outgrowth. At 10 mM, and to a much lesser extent at 1 mM 
concentration, the PC12 cells did not attach to the surface anymore, but are still 
viable. This phenomenon was examined in more detail by placing droplets of 1 mM 
solution of 5.1 on the bottom of a collagen coated 6-well plate. After evaporation, 
PC12 cells were incubated for two days, fixed and fluorescently stained using 4,6-
diamidin-2-phenylindol (DAPI). As figure 5.3 clearly visualizes, the neurons only 
attached to the non-modified surface areas, but they are doing this in close proximity 
to the “restricted area”, indicating that a high concentration of the neurotrophin-like 
compound 5.1 prohibits surface adherence only, but shows no visual toxicity. 
However, from the results summarized in figure 5.2 a 10 µM to 100 µM concentration 
was considered best for further evaluations.  
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Fig 5.2 Activity of NS using 5.1 at different concentrations in the PC12 assay. 
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Next, we performed a solvent screen with water-miscible solvents. DMSO, 
1,4-Dioxane, THF, MeOH, EtOH, MeCN, DMF solutions of 5.1 were therefore 
mixed again with 0.01% collagen aqueous solution (1:10, v:v) to a final concentration 
of 100 µM. After two days of incubation and examination, all glass slides showed 
neuritogenic properties and all solvents were acceptable (Fig. 5.4). Since DMSO is 
non-toxic in low concentrations207 and widely used in medical applications208 all 
additional experiments were performed using this solvent. To further optimize our 
method we turned our focus towards the incubations conditions.   
                                                
207 G. Da Violante, N. Zerrouk, I. Richard, G. Provot, J. C. Chaumeil, P. Arnaud, Biol. 
Pharm. Bull. 2002, 25, 1600–1603. 
208 N. C. Santos, J. Figueira-Coelho, J. Martins-Silva, Biochem. Pharmacol. 2003, 65, 
1035–1041. 
5.3A 
 
5.3B 
5.3A’ 
 
5.3B’ 
Fig. 5.3 Assambly of “restricted areas”. 100 µL droplets of a 5.1 solution 
(EtOH, 0.01% collagen aqueous solution, 1:10, v:v) were added directly on 
the plastic 6-well bottom. 5.3A and A’ are contrast micrograph and 5.3B and 
B’ their respected fluorescent images. 
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Fig. 5.4. Activity of NS using different water-miscible solvents for coating.  
 For 5.1 1 µM* and blank DMSO was used as solvent. 
Figure 5.5 shows that time and temperature play the expected critical role in 
the coating procedure. One hour of coating time is not sufficient to detect any 
bioactivity. Coating of 4 h is only effective at 36 °C. Coating for 16 h at 4 °C resulted 
in no biological activity. The best result was obtained at the longest incubation time in 
combination with the highest temperature. Higher temperatures than 36 °C where not 
examined, but incubation times up to two days showed no increase in neurite 
outgrowth. Summarizing these experiments, we could define our standard coating 
conditions: 10 µM final concentration of 5.1, DMSO as organic solvent and 
incubation for 16 h at 36 °C.  
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Fig. 5.5. Activity of NS using different coating conditions.  
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5.2.2 Scope Exploration 
 
Concentration measurements after two days of incubation with PC12 cells 
showed that the actual concentration of 5.1 in the media was below our detection limit 
of 1 µM when standard coating conditions were applied. This indicates that we are not 
only dealing with slow diffusion phenomena. This hypothesis was put on an even 
stronger fundament by performing mixed incubation experiments (MIE). Slides 
coated with and without 5.1 were incubated in the same well of a 6-well plate. For this 
experiment the different round slides were placed at opposite ends in the same well. A 
small piece of the blank slide was removed to ensure differentiation (Fig. 5.6A). We 
repeated this experiment by fixing coated squared glass slides next to each other by 
melting some of the plastic well bottom (Fig. 5.6B). Again, similar results were 
obtained; showing diffusion of 5.1 from the surface does not play a limiting role for 
this method. Significant more neurite outgrowth was detected on the expected slides 
as shown in figure 5.7. 
        
 
 
 
  
 
Fig. 5.6. Setting for mixed incubation experiments (MIE).  
5.6A 5.6B 
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 Fig. 5.7. Activity of NS for MIE experiments A: Fig. 5.6A and B: Fig. 5.6B. 
All experiments performed with our method so far gave robust and 
reproducible results. To broaden the scope further we asked ourselves if it would be 
possible to recycle used glass slides. Therefore, blank and slides coated with 5.1 were 
placed in a 24-well plate and incubated for 2 days. Then the PC12 cells were gently 
removed using trypsine solution. The slides were washed twice with H2O, transferred 
to a new 24-well plate, dried and sterilized by UV irradiation. Microscopic 
examination of the slides showed no remaining cells. The slides were then re-used for 
another incubation run. This experiment showed that the coated slides maintain their 
bioactivity for at least three cycles (Fig. 5.8).    
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Fig. 5.8. Recycling of coated slides over three cycles. 
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Another widely used substance that increases the cell adherence to surfaces is 
poly-L-lysine.209 Therefore MIE using 50 µg/mL of poly-L-lysine instead of collagen 
were performed. The obtained results clearly show that collagen could be replaced by 
poly-L-lysine if needed. This results also indicates, that collagen is not directly or 
exclusively involved in the adherence of 5.1 to the glass surface (Fig. 5.9). 
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Fig. 5.9. Replacing collagen by poly-L-lysine to support cell adherence. 
 
Since a method, which only allowed the use of a single molecule would not be 
of great use, we performed MIE with another two neuritogenic natural product 
analogs 3.5,210 and 3.16211 (Fig. 5.10). Slides coated with these structurally diverse 
molecules also show similar activities as compound 5.1, albeit at higher 
concentrations: 100 µM (3.5) or 50 µM (3.16), respectively (Fig. 5.11). This 
experiment highlights the modularity of this method once more and shows that it is 
not limited to amphiphilic catechol type molecules.  
 
 
 
                                                
209 A. Khademhosseini, K. Y. Suh, J. M. Yang, G. Eng, J. Yeh, S. Levenberg, R. 
Langer, Biomaterials 2004, 25, 3583–3592. 
210 a) H. J. Jessen, D. Barbaras, M. Hamburger, K. Gademann, Org. Lett. 2009, 11, 
3446–3449. b) B. Sellergren, L. Anderson, J. Org. Chem. 1990, 55, 3381–3383. 
211 F. Schmid, H. J. Jessen, P. Burch, K. Gademann, 2013, 4, 135–139. 
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Fig. 5.10. Structurally diverse NP analogs 3.5 and 3.16.   
Xxxx xxxxx  
Fig. 5.11. NS assembled using different, less amphiphilic and more polar 
 NP analogs (3.5, 3.16).  
 
5.3 Conclusions and Outlook 
 
In conclusion, we developed a robust and modular method for the assembly of 
neurite outgrowth inducing glass surfaces. Figure 5.12 summarizes the coating 
process applying our standard conditions and visualized how straightforward the 
methodology is. The fact that the recycling of the slides is possible while retaining 
bioactivity, further demonstrates its potential utility. This work represents to the best 
of our knowledge the first example where NP analogs have been adapted to coat 
surfaces in such an uncomplicated fashion to induce neuronal differentiation. This 
study also follows the requirements of function-orientated synthesis (see section 1.2) 
in several ways. In the early stages of this project, it was essential that supply of 
bioactive molecules was unlimited, as a lot of material was necessary to perform the 
experiments. Fortunately, we were working with optimized and simplified natural 
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product analogs, therefore this was not a concerned issue. The project also aimed to 
be as function orientated as possible. In this regard, we used the intrinsic surface 
adherence properties of the respective molecules and herewith avoiding the 
attachment of linker and anchor moieties. Moreover, some limitations of previously 
developed neuritogenic materials such as 1) low general stability of growth factor 
based approaches, 2) laborious multilayer coatings or 3) the use of expensive 
materials could be avoided. Further work will involve the adoption of this method to 
different types of cells and other cell responses than neurite outgrowth such as anti-
inflammatory. It is also important to use biocompatible materials instead of glass, 
which at the same time could also act as stabilizing bridges and ideally would be 
biodegradable in a slow rate. We expect that this approach will inspire the 
development of new and efficient methods to biologically activate surfaces in a 
surprisingly simple and modular way.  
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Fig. 5.11. Schematic view of the developed coating procedure using our  
 standard conditions (graphic designed by Ruth Pfalzberger) 
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Parts of this chapter are published similarly or identically as mentioned 
previously.2121 
 
6.1 List of Abbreviations, Acronyms and Symbols 
 
°C Degrees centigrade 
 3D Three dimensional  
 Ac Acetyl 
 Ac2O Acetic anhydride 
 AcOH Acetic acid 
 ACS American chemical society  
 AD Alzheimer’s disease 
 AIBN azo-bis-(isobutyronitrile) 
 ATDD Amphetamine-type designer drug(s) 
 Aβ β-Amyloid 
 BuBox tert-Butylbis(oxazoline) 
 BuOH Butanol 
 Cat. Catalytic  
 CDCl3  Deuterochloroform-d1 
 CNS Central nervous system 
 Cpd Compound 
 d Days 
 DAPI 4,6-diamidin-2-phenylindol 
 DBU Diazabicycloundecene 
 DCC N,N'-Dicyclohexylcarbodiimide 
 DCM  Dichloromethane 
 DEAD Diethyl diazenedicarboxylate 
 DIBAL-H Diisobutylaluminum hydride 
 DMF Dimethylformamide 
 DMP Dimethylpyridine 
 """"""""""""""""""""""""""""""""""""""""""""""""""""""""
212"a) P. Burch, M. Binaghi, M. Scherer, C. Wentzel, D. Bossert, L. Eberhardt, M. 
Neuburger, P. Scheiffele, K. Gademann, Chem. Eur. J. 2013, 19, 2589–2591. b) M. 
Scherer, Master Thesis, 2012. c) D. Bossert, Master Thesis, 2012."
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DMS Dimethyl sulfide 
 DMSO Dimethyl sulfoxide 
 ECS Endocannabinoid system 
 EDC 3-(Ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine 
 equiv. Equivalent(s) 
 Et2O Diethyl ether 
 EtOAc Ethyl acetate 
 EtOH Ethanol 
 FC Flash column chromatography 
 FDA Federal drug administration 
 FTIR Fourier transform infrared spectroscopy 
 g Gram 
 Glc Glucose 
 h Hour(s)  
 HOBt 1-Hydroxybenzotriazol 
 Hz Hertz [s-1] 
 IEDDA Inverse-electron demand Diels-Alder  
 IR Infrared 
 J Coupling constant [Hz] 
 L Liter 
 L-DOPA L-3,4-Dihydroxyphenylalanine 
 Lit. Literature 
 
M Molarity [mol/Liter] 
 M.P. Melting point 
 MDMA 3,4-Methylenedioxymethamphetamine, "ecstasy” 
 MeOH Methanol 
 MIE Mixed incubation experiments 
 MS Mass spectroscopy 
 MW Molecular weight 
 NAD+ Nicotinamide adenine dinucleotide 
 NGF Nerve growth factor 
 NMR Nuclear magnetic resonance 
 NPG Nature publishing group  
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NS Neuritogenic surfaces 
 o.n. Over night 
 PCC Pyridinium chlorochromate 
 PEP Pseudoephedrinepropionamide 
 PFP Pentafluorophenol 
 PhMe Toluene  
 ppm Part per million 
 PTSA p-Toluenesulfonic acid 
 Py Pyridine 
 
PyBOP 
Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
 r.t. Room temperature 
 R&D Research and developement  
 Ref. Reference 
 Rf Retention factor 
 sat. Saturated 
 SEM Single electron microscopy 
 TBTA Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
 tert Tertiary 
 TFA Trifluoroacetic acid 
 THF Tetrahydrofuran 
 TIPSCl Triisopropylsilyl chloride 
    6.2 General Materials and Methods 
6.2.1 Synthesis 
 
Nuclear magnetic resonance (NMR) spectra were performed using a Bruker Avance 
400 MHz spectrometer. Coupling constants J are quoted in Hertz (Hz). Splitting 
patterns are abbreviated as follows: singlet (s), doublet (d), doublet of doublet (dd), 
doublet of doublet of doublet (ddd), doublet of triplet (dt), triplet (t), quartet (q), 
quartet of triplet (qt), multiplet (m). Chemical shifts are reported in parts per million 
(ppm). NMR-solvents were obtained from Cambridge Isotope Laboratories, Inc. 
(Andover, MA, USA). Dry solvents were used from the Solvent System PS-MD5 
(Innovative Technology, Inc., USA) or obtained from Sigma-Aldrich. Technical 
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solvents used for extractions and purifications (pentane, Et2O, EtOAc, MeOH and 
CH2Cl2) were distilled prior to use. Chemicals obtained from commercial suppliers 
were used without further purification, except Et3N that was distilled prior to use. 
Thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 glass 
precoated plates. TLCs were analyzed by UV and KMnO4-dip stain (1.50 g KMnO4, 
10 g K2CO3, 1.25 ml 10% NaOH in 200 ml dist. H2O). Flash column chromatography 
(FC) was performed with the declared solvents using Silicycle SiliaFlash® P60 (230–
400 mesh) silica. Reactions were performed in flame-dried glassware under an argon 
atmosphere. Product purification was performed on an ultimate 3000 semi-preperative 
HPLC from Thermo Scientific applying a Gemini-NX5 10u C18 column. High-
resolution mass spectra (HRMS) were recorded on a Bruker maXis 4G mass 
spectrometer using electrospray ionisation. Infrared spectroscopy and melting point 
measurements were performed on a Varian 800 FT-IR machine or on a Büchi melting 
point B-545 apparatus, respectably. The melting points are uncorrected. The optical 
rotation was measured on a JASCO P-2000 digital polarimeter (sodium D lamp) 
adding 1.0 mL of solution in a 3.5 x 100 mm glass cuvette. The concentration is 
referred as g/100 ml. 
 
6.2.2 PC12 Assay 
 
Collagen coated 6- or 24-well plates (Becton Dickinson Labware, UK), Giemsa stain 
(modified solution), NGF-7S from murine submaxillary gland, penicillin-
streptomycin solution, phosphate-buffered saline (PBS) (10X, 7.4 pH), culture flasks 
(Corning® cell culture flasks, 75 cm2) were ordered from Sigma-Aldrich. Horse 
serum, MEM GlutaMAXTM, fetal bovine serum (heat inactivated) and F-12K media 
were purchased from Invitrogen. Adherent PC12 cells were obtained from LTC 
Standards, Paris. The cells were cultured in growth media (GM) (F-12K media, 15% 
horse serum, 2.5% fetal bovine serum, 100 U/mL Penicillin, 100 mg/mL 
streptomycin). Cells were then scratched off the surface using a cell scraper (BD 
Falcon) and disaggregated by passage several times through a 21-gauge needle. The 
cell suspensions (35K cells/mL) was then subjected to the 24-well plates and 
incubated (36 °C, 5% CO2) for 4 h. The GM was replaced by differentiation media 
(DM) (MEM GlutaMAXTM, 1% horse serum, 0.5% fetal bovine serum) containing 
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NGF 7S (20 ng mL-1) and incubated for 16 h. After the media was replaced by DM 
without NGF the cells were incubated for 2 d with the compounds of interest. 
Thereafter, cells were fixed with 4% buffered formaldehyde solution for 2 h at 4 °C, 
then stained with Giemsa stain (modified solution), washed twice with PBS and 
pictured under a phase contrast microscope (Leica DMI 4000B). The ratio of 
differentiated cells (at least one neurite with a length equal to at least one cell 
diameter) to the total cell number per picture was evaluated by manual counting. At 
least six photographs were taken form three different wells with the same compound. 
On average 200-300 cells per picture were examined. Samples with DMSO (0.1%) 
and NGF 7S (10 ng mL-1) were used as controls. All experiments were performed in 
triplicate and carried out under sterile conditions. Plots were drawn using the Prism 
software (National Security Agency, Inc., USA). 
 
6.3 Experimental Procedure 
6.3.1 Total Synthesis of Gelsemiol 
 
Bis(cyclopentadienyl)zirconium(IV) chloride hydride (Schwartz’s Reagent)2213  
 
Bis(cyclopentadienyl)zirconium(IV) dichloride (10.2 g, 34.5 mmmol, 
1.00 equiv.) was dissolved in dry THF (120 mL) under argon and 
excluded from light. To this solution was added dropwise LiAlH4 (1 M 
solution in THF, 8.64 mL, 8.64 mmol, 0.25 equiv.). The mixture was 
stirred for 4 h at r.t. and was then filtered under argon. The filter cake was washed 
with dry THF (3x30 mL), CH2Cl2 (30 mL) and Et2O (20 mL). The obtained white 
solid was dried over night under vacuum, yielding the desired product as colorless 
solid (7.63 g, 33.8 mmol, 85%). 1H-NMR (400 MHz, MeOD) δ = 6.34 (s, 10H). 13C-
NMR (101 MHz, MeOD) δ = 115.2. (NMR spectra not added)  
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
213 S. L. Buchwald, S. J. LaMaire, R. B. Nielsen, B. T. Watson, S. M. King, Org. 
Synth. 1998, 9, 162. 
Zr
Cl
H
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 (E)-(3-(benzyloxy)prop-1-en-1-yl)(phenyl)selane (2.41) 
 
In a 250 mL three necked round bottom flask excluded 
from light the benzyl protected propagyl alcohol (3.77 
g, 25.8 mmol, 1.00 equiv.) was added to a solution of 
Cp2Zr(H)Cl (6.65 g, 25.8 mmol, 1.00 equiv.) in dry THF (160 mL) under argon. The 
resulting mixture was stirred for 30 min at r.t. before a solution of phenylselenyl 
bromide (6.01 g, 25.8 mmol, 1.00 equiv.) in dry THF (50 mL) was added. The 
suspension was stirred for 4 h at r.t. and was then treated with pentane (500 mL). The 
obtained white precipitate was filtered off through a short plug of silica gel and the 
filter cake was washed with a mixture of pentane/Et2O (2:1, 2x100 mL). The solvents 
were removed under reduced pressure and the residue dissolved in pentane (100 mL) 
and filtered again. The crude product was purified by FC (pentane/CH2Cl2/Et2O 
100:5:1) to yield selane 2.41 as slightly yellow oil (5.62 g, 18.5 mmol, 72%).  
 
Rf = 0.35 (pentane/Et2O 30:1). 1H-NMR (400 MHz, CDCl3) δ = 7.57 - 7.47 (m, 2H), 
7.38 - 7.27 (m, 8H), 6.74 (dt, J = 15.4, 1.2 Hz, 1H), 6.07 (dt, J = 15.3, 5.9 Hz, 1H), 
4.53 (s, 2H), 4.06 (dd, J = 5.9, 1.4 Hz, 2H). 13C-NMR (101 MHz, CDCl3) δ = 138.1, 
132.8, 132.0, 129.6, 129.3, 128.5, 127.8, 127.7, 127.5, 122.1, 72.2, 71.0. FTIR ν̃ = 
3060m, 3029m, 2909w, 2850s, 1610w, 1578m, 1495w, 1477s, 1453m, 1356m, 1250w, 
1203w, 1101s, 1070s, 1023s, 1001w, 945m, 736s, 694s, 631s cm-1. 
 
Selane 2.44 
 
Tert-BuBox (678 mg, 2.30 mmol,  0.12 equiv.) was added to a 
stirred solution of copper(II) triflate (694 mg, 1.92 mmol, 0.10 
equiv.) in dry CH2Cl2 (140 mL). The resulting green solution was 
stirred for 2 h at r.t. and was then cooled to –18 °C before 3-
carbomethoxy-2-pyrone 2.42 (2.96 g, 19.2 mmol, 1.00 equiv.) in dry CH2Cl2 (15 mL) 
and phenylvinylselenide derivate 2.41 (5.82 g, 19.2 mmol, 1.00 equiv.) in CH2Cl2 (15 
mL) were added. The resulting red mixture was stirred for 5 min at –18 °C and was 
then allowed to warm up to r.t.. The solvent was removed under reduced pressure at 
r.t. and the obtained red viscous residue was stirred under high vacuum for 20 h. The 
OSe
O
O
Se
OBn
OMe
O
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crude mixture was directly purified by FC (pentane/EtOAc 5:1) to yield selane 2.44 as 
colorless solid (7.95 g, 17.4 mmol, 91%, 83% ee).  
 
Rf = 0.58 (pentane/EtOAc 4:1). M.P. = 63 - 64 °C, 1H-NMR (400 MHz, CDCl3) δ = 
7.57-7.48 (m, 2H), 7.44-7.18 (m, 8H), 6.90 (d, 7.4 Hz, 1H), 6.57 (m, 1H), 5.31 (m, 
1H), 4.62-4.43 (m, 2H), 3.65 (dd, J = 5.57, 9.23 Hz, 1H), 3.55 (s, 3H), 3.54 (t, J = 9.5 
Hz, 1H), 3.29 (m, 1H), 2.45 (m, 1H), 13C-NMR (101 MHz, CDCl3) δ = 168.7, 166.9, 
137.6, 135.6, 132.0, 131.6, 129.1, 128.7, 128.5, 128.5, 127.9, 127.8, 74.7, 73.5, 68.2, 
60.1, 52.5, 49.1, 39.1. FTIR ν̃ = 3062w, 3032w, 2952w, 2861w, 1747s, 1616w, 
1578w, 1477m, 1453m, 1364m, 1310m, 1282s, 1197m, 1170w, 1102s, 1066s, 1024m, 
1000w, 984w, 739s, 694s, 612s cm-1. Optical rotation: α !!"= –47.3 (c = 0.50, 
MeOH). For X-Ray see Annexes 
 
The tert-BuBox ligand was either purchased by Sigma-Aldrich (S,S) or prepared 
following the Evans’ protocol (S,S and R,R).314 
 
(3S or 3R, 3aS,4R,6aS)-methyl 4-((benzyloxy)methyl)-2-oxo-3,3a,4,6a-tetrahydro-
2H-cyclopenta[b]furan-3-carboxylate (2.39a/b) 
 
A solution of selenide 2.44 (7.42 g, 16.2 mmol, 1.00 
equiv.), triphenyltinhydride (7.57 g, 21.6 mmol, 1.33 
equiv.) and AIBN (879 mg, 5.35 mmol, 0.33 equiv.) in 
dry benzene (1250 mL) was degassed four times under 
argon. The solution was maintained under argon and stirred under reflux for 4.5 h. 
The mixture was allowed to reach r.t. and dry silica gel (220 g) was added. The 
suspension was vigorously stirred at r.t. for 60 h. The solvent was evaporated and the 
silica gel washed with Et2O (900 mL). The solvent was removed and the obtained 
yellow oil was purified by FC (pentane/EtOAc 3:1) to yield a mixture of lactones 
2.39a and 2.39b (d.r. 3:2) as colorless liquid (4.05 g, 13.4 mmol, 83%).  
 
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
314 D. A. Evans, G. S. Peterson, J. S. Johnson, D. M. Barnes, K. R. Campos, K. A. 
Woerpel, J. Org. Chem. 1998, 63, 4541–4544. 
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Rf = 0.58 (pentane/EtOAc 1:1). HRMS-ESI calcd. for C10H16O4+: [100%, M]+ 
303.1227, found 303.1217. FTIR ν̃ = 3064w, 3032w, 2953w, 2927w, 2862w, 2801w, 
1774s, 1737s, 1619w, 1496w, 1454w 1437w, 1367m, 1279m, 1160m, 1141m, 1085m, 
1015m, 935w, 832w, 741m, 700m, 642w cm-1. 
 
2.39a: 1H-NMR (400 MHz, CDCl3): δ = 7.42 - 7.22 (m, 5H), 5.99 - 5.90 (m, 2H), 
5.57 - 5.53 (m, 1H), 4.51 - 4.39 (m, 2H), 3.75 - 3.71 (m, 1H), 3.69 (s, 3H), 3.68 - 3.67 
(m, 1H), 3.63 (dd, J = 9.8, 4.6 Hz, 1H), 3.41 (dd, J = 9.8, 8.3 Hz, 1H), 3.27 - 3.19 (m, 
1H). 13C-NMR (101 MHz, CDCl3): δ = 172.26, 168.57, 137.55, 137.49, 132.19, 
128.57, 127.94, 127.7, 87.77, 73.2, 69.04, 53.08, 48.07, 46.56, 43.40. 
2.39b: 1H-NMR (400 MHz, CDCl3) δ = 7.42 - 7.22 (m, 5H), 6.77 (ddd, J = 7.7, 1.9, 
0.8 Hz, 1H), 6.57 (dd, J = 7.8, 5.1 Hz, 1H), 5.35 (dt, J = 5.1, 1.6 Hz, 1H), 4.59 - 4.50 
(m, 2H), 3.87 (s, 3H), 3.60 - 3.54 (m, 1H), 3.53 - 3.46 (m, 1H), 2.28 - 2.20 (m, 1H), 
1.89 (dd, J = 13.3, 10.7 Hz, 1H), 1.80 - 1.73 (m, 1H). 13C-NMR (101 MHz, CDCl3) δ 
= 170.35, 168.57, 137.83, 132.23, 132.1, 128.49, 127.86, 127.75, 75.49, 73.54, 69.92, 
54.6, 53.18, 38.37, 26.51.  
 
(3R,3aS,4S,5R,6R,6aR)-4-((benzyloxy)methyl)-6-iodo-5-methyl-2-oxohexahydro-
2H-cyclopenta[b]furan-3-carboxylic acid (2.49) 
 
To a solution of CuBr-DMS complex (4.49 g, 21.8 mmol, 4.00 
equiv.) in THF (200 mL) was added dropwise methyllithium (1.6 M 
solution in Et2O, 27.3 mL, 43.7 mmol, 8.00 equiv.) at –18 °C. The 
mixture was stirred for 15 min at the same temperature, before it was 
cooled to –48 °C and lactones 2.39a/b and (1.65 g, 5.46 mmol, 1.00 equiv.) in THF 
(40 mL) and TMSCl (1.74 mL, 13.6 mmol, 2.50 equiv.) were added. The mixture was 
stirred for 3.5 h at –48 °C and was then quenched with aqueous H2SO4 solution (160 
ml, 1 M) at the same temperature. The suspension was allowed to reach r.t., the 
aqueous and the organic phases were separated after brine (40 mL) has been added. 
The aqueous phase was extracted with Et2O (3x200 mL). The combined organic 
layers were washed with sat. NH4Cl solution (600 mL) dried (Na2SO4) and 
concentrated. The mixture was dissolved in aqueous NaOH (80 mL, 1.0 M) and the 
resulting suspension stirred for 24 h at r.t.. Solid CO2 was added in small portions to 
O
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set pH of the solution to 8 - 9. The mixture was cooled to 0 °C and a solution of I2 
(1.82 g, 7.26 mmol, 1.33 equiv.) in THF (45 mL) was added. The resulting brown 
solution was stirred for 50 min, quenched with aqueous sat. Na2S2O3 solution (8 mL) 
and treated with aqueous H2SO4-solution (180 mL, 1 M). The aqueous phase was 
extracted with Et2O (3x50 mL), the combined organic layers were dried (Na2SO4) and 
evaporated under reduced pressure. The crude residue was purified by FC 
(pentane/EtOAc 4:1 + 0.01 TFA) to yield 4.49 as a slightly yellow solid (1.05 g, 2.44 
mmol, 45%).  
 
Rf = 0.68 (pentane/EtOAc 1:1 + 0.1 AcOH). M.P. = 95 - 97 °C.  1H-NMR (400 MHz, 
CDCl3) δ = 7.51 - 7.03 (m, 5H), 5.39 (d, J = 6.2 Hz, 1H), 4.57 (d, J = 4.6 Hz, 1H), 
4.55 - 4.43 (m, 2H), 3.92 (d, J = 2.7 Hz, 1H), 3.64 - 3.58 (m, 1H), 3.54 (ddd, J = 9.4, 
6.2, 2.7 Hz, 1H), 3.46 (dd, J = 10.3, 6.7 Hz, 1H), 2.31 (tdd, J = 12.1, 6.8, 2.8 Hz, 1H), 
1.38 (tt, J = 11.7, 6.0 Hz, 1H), 0.98 (d, J = 6.2 Hz, 3H). 13C-NMR (101 MHz, CDCl3) 
δ = 171.8, 171.7, 137.2, 128.6, 128.1, 127.9, 90.9, 73.6, 66.3, 48.9, 45.5, 43.7, 41.6, 
36.9, 18.9. HRMS-ESI calcd. for C17H18IO5–: [100%, M]– 429.0204, found 429.0208; 
FTIR ν̃ = 3056w, 2962w, 2899w, 2872w, 1755m, 1721s, 1453w, 1380w, 1362w, 
1308w, 1292w, 1260m, 1209m, 1182s, 1152s, 1105m, 1082m, 1058m, 985m, 963s, 
878m, 853m, 807m, 736s, 716s, 653m cm-1. Optical rotation:! α !!"= +1.5 (c = 1.00, 
MeOH). For X-Ray data see Annexes. 
 
Gelsemiol (2.1) 
 
Acid 2.49 (100 mg, 0.24 mmol, 1.00 equiv.) was dissolved in THF (8 
mL). The solution was cooled to 0 °C and BH3-DMS complex (2.0 M 
solution in THF, 3.02 mL, 6.04 mmol, 26.0 equiv.) was added 
dropwise to the solution and the mixture stirred for 3 h at 0 °C. The 
reaction was carefully quenched with MeOH (10 mL) and the solvents 
were removed under reduced pressure. The crude mixture was dissolved in EtOH (30 
mL) and added to a decanted solution of Raney-Nickel (20 mL, 50% w/w solution in 
water). The resulting suspension was stirred for additional 60 h at r.t. under an 
atmosphere of H2 and was then filtered over a short plug of silica gel and washed with 
EtOAc (3x30 mL). The solvents were removed and the crude product purified by FC 
O
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(EtOAc) to give gelsemiol (2.1) as a white solid and the diasteromeric lactols 2.50a/b 
as side products, which were again stirred for 24 h in a solution of Raney-Nickel (10 
mL, 50% w/w solution in water) in EtOH (15 mL) under an argon atmosphere. The 
suspension was again filtered over a short plug of silica gel and washed with EtOAc 
(3x30 mL). The solvents were removed and the crude product purified by FC (EtOAc) 
to gain additional 2.1 (30 mg, 0.15 mmol, 65% combined yield over two steps).  
 
Rf = 0.25 (EtOAc), M.P. = 89 - 91 °C 1H-NMR (600 MHz, D2O) δ = 5.09 (ddt, J = 
7.0, 6.3, 0.6, 0.6 Hz, 1H), 3.93 (dd, J = 11.3, 4.3 Hz, 1H), 3.83 (dd, J = 11.6, 4.5 Hz, 
1H), 3.81 (dd, J = 11.3, 4.0 Hz, 1H), 3.59 (dd, J = 11.5, 9.5 Hz, 1H), 3.10 (td, J = 7.7, 
5.2 Hz, 1H), 2.95 (dt, J = 5.1, 4.2 Hz, 1H), 2.12 (dd, J = 14.6, 6.2 Hz, 1H), 1.85 
(dddd, J = 11.6, 9.5, 8.1, 4.5 Hz, 1H), 1.74 (dtq, J = 6.0, 12.1, 6.2 Hz, 1H), 1.54 (ddd, 
J = 14.6, 12.1, 6.3 Hz, 1H), 0.99 (d, J = 6.3 Hz, 3H). 13C-NMR (151 MHz, D2O) δ = 
183.2, 86.5, 62.6, 61.3, 51.1, 44.7, 44.7, 41.9, 33.5, 17.4. HRMS-ESI calcd. for 
C10H16O4+: [100%, M]+ 201.1121, found 201.1119. FTIR ν̃ = 3247s, 2964w, 2928m, 
2885m, 2864w, 1756s, 1481w, 1462m, 1379m, 1330w, 1314w, 1218s, 1204s, 1080s, 
1012s, 989s, 956w, 939w, 920w, 879w, 845w, 705m, 679m, 645m cm-1. Optical 
rotation: α !!"= +12.8 (c = 0.50, MeOH). The reported data is in accordance with the 
literature.4215  
 
2.50a: Rf = 0.18 (EtOAc). 1H-NMR (500 MHz, CDCl3) δ = 5.45 (d, J = 4.7 Hz, 1H), 
4.71 (t, J = 6.7 Hz, 1H), 3.84 - 3.72 (m, 2H), 3.71 - 3.63 (m, 2H), 2.57 (dt, J = 8.9, 7.3 
Hz, 1H), 2.27 (tt, J = 9.3, 5.1 Hz, 1H), 1.84 (dd, J = 14.3, 5.5 Hz, 1H), 1.71 - 1.59 (m, 
2H), 1.38 - 1.29 (m, 1H), 0.95 (d, J = 5.9 Hz, 3H). 13C-NMR (126 MHz, D2O) δ = 
98.2, 82.8, 60.9, 60.0, 50.6, 47.0, 44.7, 40.7, 32.0, 16.4. 
2.50b: Rf = 0.18 (EtOAc). 1H-NMR (500 MHz, CDCl3) δ = 5.10 (d, J = 4.9 Hz, 1H), 
4.49 (t, J = 6.5 Hz, 1H), 3.83 - 3.73 (m, 2H), 3.70 - 3.63 (m, 2H), 2.62 (dd, J = 8.5, 
6.6 Hz, 1H), 0.98 - 0.95 (m, 1H), 2.08 (p, J = 6.0 Hz, 1H), 1.92 (d, J = 13.7 Hz, 1H), 
1.69 - 1.60 (m, 1H), 1.34 (dd, J = 11.7, 6.3 Hz, 1H), 0.96 (d, J = 6.2 Hz, 3H); 13C-
NMR (126 MHz, D2O) δ = 100.7, 82.1, 62.1, 60.6, 50.4, 48.8, 46.2, 41.6, 32.5, 16.7. 
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(3R,3S,4S,5R,6R,6R)-4-((benzyloxy)methyl)-3-(hydroxymethyl)-6-iodo-5-
methylhexa-hydro-2H-cyclopenta[b]furan-2-one (2.51) 
 
Oxalyl chloride (148 µL, 1.75 mmol, 6.00 equiv) was added to a 
solution of dry DMF (45 µL, 0.58 mmol, 2.00 equiv) in dry CH2Cl2 
(6 mL) at 0 °C under an atmosphere of Ar. After 5 min the ice-bath 
was removed and the solution was stirred for 1 h at r.t.. The solvent 
was evaporated by first bubbling Ar into the solution and then by 
applying a vacuum. The residual white powder was dissolved in dry CH3CN (8 mL) 
and dry THF (8 mL) before a solution of 2.49 (125 mg, 0.29 mmol, 1.00 equiv) in dry 
THF (8 mL) was added at –48 °C under argon. The reaction mixture was stirred for 
3.5 h at the same temperature. At this point, to the reaction mixture was added a 
solution of NaBH4 (66 mg, 1.75 mmol, 6.00 equiv) in dry DMF (5 mL) and dry THF 
(5 mL) at –48 °C, stirred for additional 3 h at the same temperature and quenched 
with aqueous H2SO4-solution (1.0 M, 25 mL). The aqueous phase was extracted with 
Et2O (3x40 mL) and the combined organic layers were washed with brine (100 mL), 
dried over Na2SO4 and evaporated under reduced pressure. The crude residue was 
purified by FC (pentane/Et2O, 1:2) to give the benzyl protected alcohol as viscous oil 
(80 mg, 0.195 mmol, 67%).  
 
Rf = 0.78 (EtOAc). 1H-NMR (500 MHz, CDCl3) δ = 7.55 - 7.25 (m, 5 H), 5.35 (d, J = 
6.8 Hz, 1H), 4.60 - 4.44 (m, 3H), 3.91 (dd, J = 10.5, 5.2 Hz, 1H), 3.80 (dd, J = 10.5, 
4.9 Hz, 1H), 3.63 (dd, J = 10.0, 3.9 Hz, 1H), 3.51 (dd, J = 10.0, 8.8 Hz, 1H), 3.14 
(ddd, J = 9.0, 6.9, 3.4 Hz, 1H), 2.93 - 2.87 (m, 1H), 2.42 (dtd, J = 12.6, 8.9, 3.9 Hz, 
1H), 1.22 - 1.13 (m, 1H), 1.02 (d, J = 6.2 Hz, 3H). 13C-NMR (126 MHz, CDCl3) δ = 
178.1, 137.3, 128.6, 128.1, 128.0, 90.7, 73.6, 67.6, 63.5, 45.8, 44.1, 42.7, 42.7, 37.4, 
19.1. HRMS-ESI calcd. for C10H16O4+: [100%, M]+ 417.0557, found 417.0560. FTIR 
ν̃ = 3453m, 2858m, 1764s, 1454m, 1366m, 1309m, 1261m, 1176s, 1092s, 999s, 794m, 
741m, 700m, 647m cm-1. Optical rotation:! α !!"= +12.1 (c = 0.38, CHCl3). 
 
Raney Nickel (about 3 mL activated catalyst, 50% slurry in water) was decanted and 
the solid added to a solution of benzyl protected alcohol 2.51 in EtOH (5 mL). The 
reacting mixture was stirred over night under an atmosphere of H2. The catalyst was 
O
HH
OHO
OBnCH3
H
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then removed by filtration and the solution was concentrated under reduced pressure. 
The crude residue was purified by FC on silica gel (pure EtOAc) to give gelsemiol 
(2.1) as white solid (4.0 mg, 0.02 mmol, 52%). The analytical data matched the 
reported above.  
 
Diacylated gelsemiol 2.51 
 
To a solution of gelsemiol (2.1, 1.9 mg, 1.0 mmol) in dry pyridine 
(0.5 mL) at 0 °C were added three drops of acetic anhydride. The 
mixture was stirred overnight and extracted with EtOAc and sat. 
NH4Cl solution. The crude product was then purified by FC 
(pentane/Et2O, 1:2) to give the diacetylated gelsemiol (2.1) (1.8 mg, 
0.76 mmol, 93%).  
 
Rf  = 0.68 (MeOH/CH2Cl2, 1:20). 1H-NMR (600 MHz, CDCl3) δ 4.96 (t, J = 6.7 Hz, 
1H), 4.38 - 4.29 (m, 3H), 3.99 (dd, J = 11.8, 9.2 Hz, 1H), 3.03 - 2.93 (m, 1H), 2.82 (q, 
J = 4.2 Hz, 1H), 2.22 (dd, J = 14.5, 6.2 Hz, 1H), 2.08 (s, 3H), 2.07 (s, 2H), 2.00 - 1.90 
(m, 1H), 1.84 (tp, J = 12.4, 6.2 Hz, 1H), 1.49 (ddd, J = 14.5, 12.1, 6.3 Hz, 1H), 1.05 
(d, J = 6.3 Hz, 3H). 13C-NMR (151 MHz, CDCl3) δ 176.87, 170.88, 94.65, 83.04, 
63.89, 63.06, 47.88, 44.37, 41.78, 41.08, 33.41, 20.98, 20.95, 17.31, 0.15. HRMS-
ESI calcd. for C14H20NaO4: [100%, M+Na]+ 307.1158, found 307.1155. FTIR ν̃ = 
2961w, 2926w, 2873w, 2854w, 1769w, 1743w, 1463w, 1371m, 1242s, 1185m, 1033w 
cm-1. Optical rotation:! α !!"= +13.0 (c = 0.03, MeOH). The reported data is in 
accordance with the literature.5216  
 
 
 
 
 """"""""""""""""""""""""""""""""""""""""""""""""""""""""
216 S. R. Jensen, O. Kirk, B. J. Nielsen, R. Norrestam, Phytochem. 1987, 6, 1725–
1731. 
217 a) H. J. Jessen, D. Barbaras, M. Hamburger, K. Gademann, Org. Lett. 2009, 11, 
3446–3449 b) B. Sellergren, L. Anderson, J. Org. Chem. 1990, 55, 3381–3383. 
O
HH
O
OAc
H
CH3
OAc
	
  CHAPTER 6 – EXPERIMENTAL PART                                                                                             117 
6.3.2 Farinosone C Analogs Collection 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)propionamide (3.5)217 
 
To a solution of L-tyrosinol hydrochloride (400 mg, 1.96 
mmol, 1.00 equiv.) in THF (4.00 mL), K2CO3 (1.22 g, 8.84 
mmol, 4.40 equiv.) dissolved in H2O (3.50 mL) was added at once. The reaction 
mixture was stirred for 45 min at r.t. before propanoyl chloride (308 mg, 3.53 mmol, 
1.80 equiv.) was added. The mixture was stirred for 15 h at r.t.. The organic solvent 
was then evaporated and brine was added before the aqueous layer was extracted with 
EtOAc (3x). The combined organic layers were dried over MgSO4 and concentrated. 
The crude product was purified by FC on SiO2 (CH2Cl2/EtOAc, 20:1) and yielded the 
products 3.5 (313 mg, 1.40 mmol, 71%), 3.20c (8.0 mg, 0.028 mmol, 1%) and 3.20e 
(13.4 mg, 0.048 mmol, 2%) as yellow oils.  
 
Rf = 0.49 (CH2Cl2/MeOH, 8:2). 1H-NMR (400 MHz, MeOD) d 7.03 (d, J = 8.3 Hz, 
2H), 6.69 (d, J = 8.4 Hz, 2H), 4.09 - 3.93 (m, 1H), 3.63 - 3.39 (m, 2H), 2.80 (dd, J = 
13.8, 6.3 Hz, 1H), 2.60 (dd, J = 13.8, 8.2 Hz, 1H), 2.14 (q, J = 7.6 Hz, 2H), 1.04 (t, J 
= 7.6 Hz, 3H). 13C-NMR (101 MHz, MeOD) d 176.87, 156.86, 131.23, 130.53, 
116.05, 64.19, 54.22, 37.13, 30.29, 10.51. HRMS ESI-TOF calcd. for C12H17NO3 
(100%, [M+H]+): 224.1287; found 224.1287. FTIR ν̃ 3276m, 2940w, 2882w, 1616s, 
1545s, 1514s, 1451m, 1373m, 1236s, 1042m, 823m, 634s cm-1. Optical 
rotation: α !!"= –3.7 (c = 1.2, MeOH).  
 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)propionamide (3.20a)2186  
 
To a solution of (S)-(–)-2-Amino-3-phenyl-1-propanol (100 mg, 
1.17 mmol, 1.00 equiv.) in H2O/THF (1:1, 10.0 mL) was K2CO3 
(647 mg, 4.68 mmol, 4.00 equiv.) added at r.t.. The mixture was stirred for 1 h before 
propionyl chlorid (204 µL, 2.34 mmol, 2.0 equiv.) was added. The reaction mixture 
was then stirred for 17 h under argon atmosphere. The organic solvent was evaporated 
and the aqueous layer was extracted with CH2Cl2 (3x), brine (1x), dried over Na2SO4 	
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and concentrated. The crude product was purified by FC on SiO2 (EtOAc/CH2Cl2, 1:5) 
to yield the product 3.20a (200 mg, 0.97 mmol, 82%) as colorless solid. 
 
Rf = 0.34 (MeOH/CH2Cl2, 1:20). M.P. = 77 - 78 °C. 1H-NMR (400 MHz, CDCl3) δ 
7.42 - 7.15 (m, 5H), 5.89 (d, J = 6.7 Hz, 1H), 4.31 - 4.08 (m, 1H), 3.69 (dd, J = 11.0, 
3.3 Hz, 1H), 3.60 (dd, J = 11.0, 5.0 Hz, 1H), 3.04 - 2.79 (m, 2H), 2.18 (q, J = 7.7 Hz, 
2H), 1.11 (t, J = 7.7 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 174.68, 137.81, 129.33, 
128.73, 126.77, 64.25, 52.92, 37.10, 29.88, 9.92. HRMS ESI-TOF calcd. for 
C12H18NO2+ (100%, [M+H]+): 208.1332; found  208.1332. FTIR ν ̃3325m br, 2962m, 
2361m, 2337m, 1634m, 1615m, 1515s, 1453m, 1367m, 1229m, 1043m, 826w cm-1. 
Optical rotation:! α !!"= –10.7 (c = 1.0, MeOH). 
 
(S)-N-(1-hydroxy-3-(4-methoxyphenyl)propan-2-yl)propionamide (3.20b) 
 
To a solution of propionamide 3.5 (120 mg, 0.538 mmol, 1.00 
equiv.) in MeCN (8.0 mL) was added CsCO3 (193 mg, 0.592 
mmol, 1.10 equiv.) and MeI (40 µL, 0.644 mmol, 1.20 equiv.). The reaction mixture 
was stirred at r.t. under an argon atmosphere. After 18 h additional MeI (30 µL, 0.482 
mmol, 0.9 equiv.) and CsCO3  (150 mg, 0.778 mmol, 0.85 equiv) were added and the 
mixture was stirred for another 32 h. The solvent was evaporated and the crude 
products were extracted using EtOAc (3x) and brine (1x). The combined organic 
layers were dried over MgSO4 and concentrated. The crude product was purified by 
FC on SiO2 (CH2Cl2/MeOH 20:1) and yielded the products 3.20b (118 mg, 0.50 
mmol, 52 %) and 3.20f (21 mg, 0.083 mmol, 9 %) as white solids.  
 
Rf = 0.68 (MeOH/CH2Cl2, 1:10). M.P. = 80 - 82 °C. 1H-NMR (400 MHz, MeOD) δ 
8.37 (dt, J = 8.3 Hz, 1H), 8.03 - 7.80 (m, 2H), 7.72 - 7.56 (m, 2H), 5.56 (t, J = 5.5 Hz, 
1H), 4.74 - 4.57 (m, 2H), 4.51 (s, 3H), 4.14 - 4.00 (m, 2H), 3.56 (dd, J = 13.7, 5.6 Hz, 
1H), 3.38 - 3.25 (m, 2H), 2.82 (q, J = 7.6 Hz, 2H), 1.72 (t, J = 7.6 Hz, 3H). 13C-NMR 
(101 MHz, MeOD) δ 182.10, 167.02, 140.63, 139.56, 123.00, 72.12, 64.46, 61.94, 
45.21, 38.11, 19.54. HRMS ESI-TOF calcd. for C13H20NO3 (100%, [M+H]+): 
238.1443; found 238.1451. FTIR ν̃ 3494w, 3300m, 3080w, 2939w, 2922w, 1640s, 
O HO
H
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1540s, 1513s, 1463m, 1442m, 1247s, 1178m, 1075m, 1030s, 810m, 697m cm-1. 
Optical rotation:! α !!!= –4.0 (c = 0.68, MeOH).  
 
(S)-4-(3-hydroxy-2-propionamidopropyl)phenyl propionate (3.20c) 
 
 For experimental please see compound 3.5.  
 
Rf = 0.27 (EtOAc/CH2Cl2, 4:6). 1H-NMR (400 MHz, DMSO) δ 7.36 - 7.11 (m, 1H), 
7.10 - 6.81 (m, 2H), 7.11 - 6.89 (m, 2H), 4.22 - 4.02 (m, 1H), 3.61 - 3.43 (m, 2H), 
2.93 (dd, J = 13.7, 5.3 Hz 1H), 2.72 (dd, J = 13.7, 5.4 Hz, 1H), 2.65 - 2.53 (q, J = 7.6 
Hz, 2H), 2.14 (q, J = 7.6 Hz, 2H), 1.22 (t, J = 7.5 Hz, 3H), 1.04 (t, J = 7.6 Hz, 3H). 
13C-NMR (101 MHz, DMSO) δ 172.57, 172.52, 148.70, 136.70, 129.94, 121.25, 
62.65, 52.11, 35.89, 28.56, 26.88, 9.97, 8.87. HRMS ESI-TOF calcd. for 
C15H21NNaO4+ (100%, [M+Na]+): 302.1363; found 302.1366 FTIR ν̃ 3454w, 3386w, 
3339w, 3284w, 2976w, 2922m, 2877w, 2852w, 1753s, 1647s, 1617s, 1550s, 1510s, 
1361s, 1196s, 1167s, 1074s, 1046m, 1021m, 900s, 825m, 667m cm-1. Optical 
rotation: α !!!= –17.6 (c = 0.17, CHCl3). 
 
(S)-methyl 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-propionamidopropanoate 
(I) 
 To a solution of the methyl ester 3.20h (100 mg, 0.398 mmol, 
1.00 equiv) in dry CH2Cl2 (5.00 mL) TBSCl (120 mg, 0.796 
mmol, 2.00 equiv.), DMAP (9.72 mg, 80 µmol, 0.2 equiv.) 
and NEt3 (168 mL, 1.19 mmol, 3.00 equiv.) were added. The 
reaction mixture was stirred for 5 h at r.t. under argon before sat. NH4Cl-solution was 
added. The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2 (2x). The combined organic layers were dried (Na2SO4) and concentrated 
under reduced pressure. The crude product was purified by gradiental FC on SiO2 
(first EtOAc/CH2Cl2, 1:4, then MeOH/CH2Cl2, 1:5) to yield the TBS-protected methyl 
ester I (140 mg, 0.383 mmol, 96%) as yellow oil. 
 
Rf  = 0.61 (CH2Cl2).  1H-NMR (400 MHz, CDCl3) δ 7.12 - 7.04 (m, 2H), 6.80 - 6.73 
(m, 2H), 4.63 (dd, J = 9.0, 5.8 Hz, 1H), 3.68 (s, 3H), 3.09 (dd, J = 13.9, 5.8 Hz, 1H), 
O HO
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2.89 (dd, J = 13.9, 9.0 Hz, 1H), 2.19 (q, J = 7.6 Hz, 2H), 1.05 (t, J = 7.6 Hz, 3H), 0.99 
(s, 9H), 0.19 (s, 6H), 13C-NMR (101 MHz, MeOD) δ 176.74, 173.65, 155.79, 131.23, 
131.01, 121.00, 55.19, 52.58, 37.71, 29.77, 26.17, 19.04, 10.34, –4.29. HRMS ESI-
TOF calcd. for C19H31NNaO4Si+ (100%, [M+Na]+): 388.1920; found 388.1912. FTIR 
ν̃ 3290w, 2955w, 2933w, 2858w, 2361w, 2340w, 1745m, 1651m, 1510s, 1464w, 
1439w, 1254s, 1212m, 1173m, 914s, 840s, 625m cm-1. Optical rotation:! α !!!= 20.4 
(c = 2.13, MeOH). 
 
 (S)-N-(1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-hydroxypropan-2-
yl)propionamide (II)  
 
The TBDMS-protected methyl ester I (170 mg, 0.465 mmol, 
1.00 equiv.) was dissolved in dry DMF (5.00 mL). The 
solution was cooled to 0 °C before LiAlH4 (176 mg, 4.65 
mmol, 10.0 equiv.) was added in one portion. The reaction 
mixture was stirred for 1 h under an argon atmosphere. The reaction mixture was 
quenched using H2O (5.00 mL) followed by NaOH-solution (5.00 mL, 1 M). The 
mixture was then stirred for an additional hour, filtered over celite and washed with 
H2O and hot EtOAc. The mixture was then extracted using statured NH4Cl-solution, 
dried (Na2SO4) and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on SiO2 (MeOH/CH2Cl2, 1:40) to yield the product 
II (132 mg, 0.391 mmol, 84%) as colorless oil.  
 
Rf  = 0.36 (MeOH/CH2Cl2, 1:20). 1H-NMR (400 MHz, CDCl3) 7.13 - 6.98 (m, 2H), 
6.86 - 6.69 (m, 2H), 5.62 (d, J = 6.8 Hz, 1H), 4.19 - 4.03 (m, 1H), 3.76 - 3.65 (m, 1H), 
3.63 - 3.49 (m, 1H), 2.95 - 2.70 (m, 2H), 2.17 (q, J = 7.4 Hz, 2H), 1.09 (t, J = 7.6 Hz, 
3H), 0.97 (s, 9H), 0.18 (s, 6H). 13C-NMR (101 MHz, CDCl3) δ 174.78, 154.60, 
130.23 (2C), 120.42, 77.48, 77.16, 76.84, 64.90, 53.24, 36.30, 29.90, 25.81, 18.34, 
9.93, –4.29. HRMS ESI-TOF calcd. for C18H31NNaO3Si+ (100%, [M+H]+): 360.1971; 
found: 360.1963. FTIR ν̃ 3326m, 2946w, 2834w, 1651w, 1511w, 1451w, 1415w, 
1259w, 1115w, 1025s, 638s cm-1. Optical rotation:! α !!!= 1.9 (c = 1.0 MeOH).  
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(S)-N-(1-(4-hydroxyphenyl)-3-methoxypropan-2-yl)propionamide (3.20d)  
 
To a solution the TBS-protected alcohol II (500 mg, 1.48 
mmol, 1.00 equiv.) in dry DMF (15.0 mL) at 0 °C was added 
NaH (60% in mineral oil, 89.0 mg, 2.22 mmol, 1.5 equiv.) in 
one portion. The mixture was allowed to reach r.t. before iodomethane (466 µL, 7.41 
mmol, 5.00 equiv.) was added drop wise. The reaction mixture was stirred for 24 h 
under argon and then quenched using citric acid solution (5 %, 50 ml). The mixture 
was extracted using EtOAc (3x10 mL), brine (10mL), dried (Na2SO4) and 
concentrated under reduced pressure. The crude was filtered over a short plug of silica 
(EtOAc/CH2Cl2, 1:10) and concentrated again. The yellow residue was dissolved in 
dry THF (8.0 mL) and tetrabutylammonium fluoride (1 M  solution in THF, 1.01 mL, 
3.41 mmol, 3.00 equiv.) was added. The mixture was stirred overnight under argon 
before MeOH (3.0 mL) was added. The solvents were removed and the crude was 
extracted with CH2Cl2 (3x10 ml), dried (Na2SO4) and concentrated. The crude product 
was purified first by flash chromatography on SiO2 (MeOH/CH2Cl2, 1:40) followed 
by preparative HPLC separation to yield the ether 3.20d (80 mg, 0.337 mmol, 23%) 
as white solid. 
 
Rf  = 0.54 (MeOH/CH2Cl2, 1:10). 1H-NMR (400 MHz, CDCl3) δ 7.16 - 6.94 (m, 2H), 
6.84 - 6.70 (m, 2H), 5.79 (d, J = 8.6 Hz, 1H), 4.10 - 4.19 (m, 1H), 3.47 - 3.24 (m, 4H), 
2.77 (d, J = 7.4 Hz, 2H), 2.27 - 2.11 (m, 2H), 1.10 (t, J = 7.6 Hz, 3H). 13C-NMR (101 
MHz, CDCl3) δ 173.91, 155.01, 130.47, 129.61, 115.54, 77.48, 77.16, 76.84, 72.65, 
59.19, 50.50, 36.84, 30.01, 9.98. HRMS ESI-TOF calcd. for C13H20NO3+ (100%, 
[M+H]+): 238.1438; found: 238.1438. FTIR ν̃ 3286br, 2938w, 2830w, 2362m, 
2339w, 1644m, 1546m, 1515s, 1457m, 1239m, 1124w, 1025w, 770m, 634s cm-1. 
Optical rotation: α !!"= –10.4 (c = 0.35 MeOH).  
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(S)-3-(4-hydroxyphenyl)-2-propionamidopropyl propionate (3.20e)  
 
For experimental procedure please see compound 3.5 
 
 
Rf = 0.43 (EtOAc/CH2Cl2, 4:6). 1H-NMR (400 MHz, DMSO) δ 9.17 (s, 1H), 7.72 (d, 
J = 8.3 Hz, 1H), 6.98 (d, J = 8.4 Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 4.13 - 4.02 (m, 
1H), 3.99 (dd, J = 10.9, 4.8 Hz, 1H), 3.86 (dd, J = 10.9, 6.6 Hz, 1H), 2.61 (m, 2H), 
2.02 (q, J = 7.5 Hz, 3H), 2.02 (q, J = 7.4 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H), 0.93 (t, J = 
7.6 Hz, 3H). 13C-NMR (101 MHz, DMSO) δ 173.49, 172.63, 155.64, 129.88, 128.21, 
114.95, 64.77, 49.13, 35.82, 28.54, 26.76, 9.95, 8.96. HRMS ESI-TOF calcd. for 
C14H20NO4– (100%, [M]–): 279.1471; found 279.1392. FTIR ν̃ 3365m, 3312m, 2986w, 
2929w, 2853w, 1706s, 1650s, 1536s, 1515s, 1444m, 1363m, 1268m, 1209s, 1030m, 
980m, 823m, 657m cm-1. Optical rotation: α !!!= –12.1 (c = 0.14, CHCl3). 
 
(S)-N-(1-methoxy-3-(4-methoxyphenyl)propan-2-yl)propionamide (3.20f) 
 
For experimental procedure please see compound 3.20b  
 
 
Rf = 0.40 (EtOAc/CH2Cl2, 4:6). 1H-NMR (400 MHz, CDCl3) δ 7.17 - 7.01 (m, 2H), 
6.83 (d, J = 8.4 Hz, 2H), 5.71 (d, J = 6.0 Hz, 1H), 4.19 - 4.24 (m, 1H), 3.82 (s, 3H) 
3.34 (s, 3H), 3.29 (d, J = 3.8 Hz, 2H), 2.79-2.85 (m, 2H), 2.18 (q, J = 7.6 Hz, 2H), 
1.12 (t, J = 7.7 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 173.27, 158.21, 130.37, 
130.07, 113.88, 72.16, 59.00, 55.26, 50.13, 36.46, 29.86, 9.85. HRMS ESI-TOF 
calcd. for C14H22NO3+ (100%, [M+H]+): 252.1600; found 252.1564. FTIR ν̃ 3290w, 
3072w, 2923w, 1743w, 1644s, 1512s, 1462m, 1444m, 1245s, 1179m, 1123m, 1083m, 
1035m, 966w, 912w, 816w, 659m cm-1. Optical rotation:! α !!!= –7.2 (c = 0.06, 
MeOH).  
 
 
HO O
H
N
O
O
O O
H
N
O
"CHAPTER 6 – EXPERIMENTAL PART                                                                                             123 
(S)-3-(4-hydroxyphenyl)-2-propionamidopropanoic acid (3.20g)2197  
 
To a solution of L-tyrosine hydrochloride (3.00 g, 16.6 mmol, 
1.00 equiv.) in H2O/THF (1:1, 40.0 mL) was K2CO3 (9.15 g, 
66.2 mmol, 4.00 equiv.) added at r.t. The mixture was stirred for 1 h before propionyl 
chlorid (1.59 mL, 18.2 mmol, 1.1 equiv.) was added. The reaction mixture was then 
stirred for 16 h under an argon atmosphere. The organic solvent was evaporated and 
HCl-soluiton (10 %, 50.0 mL) was added. The aqueous layer was extracted with 
EtOAc (3x), dried over Na2SO4 and concentrated. The crude product was purified by 
flash chromatography on SiO2 (CH2Cl2/MeOH, 15:1 + 2‰ TFA) to yield the acid 
3.20g (3.42 g, 14.3 mmol, 87%) as viscous colorless oil. 
 
Rf = 0.15 (MeOH/CH2Cl2, 1:15). 1H-NMR (400 MHz, D2O) δ 7.18 - 7.11 (m, 2H), 
6.88 - 6.81 (m, 2H), 4.57 (dd, J = 8.9, 5.4 Hz, 1H), 3.15 (dd, J = 14.0, 5.4 Hz, 1H), 
2.92 (dd, J = 14.0, 9.0 Hz, 1H), 2.19 (q, J = 7.7 Hz, 2H), 0.99 (t, J = 7.7 Hz, 3H). 13C-
NMR (101 MHz, D2O) δ 177.72, 175.10, 173.85, 154.34, 130.50, 130.46, 128.38, 
128.22, 115.34, 54.17, 54.00, 52.79, 35.77, 28.73, 9.27 (rotamer present) HRMS ESI-
TOF calcd. for C12H16NO4+ (100%, [M+H]+): 238.2625; found 238.1074. (100%, 
[M]+). FTIR ν̃ 3320w br, 2979w, 2941w, 1721m, 1638m, 1613m, 1514s, 1444m, 
1377w, 1221s, 1125m, 1016w, 911w, 828m, 660m cm-1. Optical rotation:! α !!!= 
34.9 (c = 0.35, H2O). The reported data is in accordance with the literature.219 
 
(S)-methyl 3-(4-hydroxyphenyl)-2-propionamidopropanoate (3.20h) 
 
To a solution of L-tyrosinol methyl ester (1.01 g, 5.07 mmol, 
1.00 equiv.) in H2O/THF (1:1, 9.00 mL) was K2CO3 (2.10 g, 
15.2 mmol, 3.00 equiv.) added at r.t.. The mixture was stirred 
for 1 h before propionyl chloride  (0.531 µL, 6.08 mmol, 1.20 equiv.) was added. The 
reaction mixture was then stirred for 2 d under an argon atmosphere. The organic 
solvent was evaporated and the aqueous layer was extracted with CH2Cl2 (3x). The 
combined organic layers were washed with brine, dried over Na2SO4 and """"""""""""""""""""""""""""""""""""""""""""""""""""""""
219"K. Ueda, M. Yoshihara, M. Nakao, T. Tanaka, J. Agric. Food Chem. 2010, 58, 
6053–6063."
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concentrated. The crude product was purified by flash chromatography on SiO2 
(CH2Cl2/MeOH 30:1) to yield the methyl ester 3.20h (1.24 g, 4.93 mmol, 97%) as 
white solid.  
 
Rf  = 0.43 (MeOH/CH2Cl2, 1:20). M.P. = 103 - 104 °C. 1H-NMR (400 MHz, CDCl3) 
δ 6.93 (m, 2H), 6.84 - 6.64 (m, 2H), 6.08 (m, 1H), 4.87 (dt, J = 8.0, 6.0 Hz, 1H), 3.74 
(s, 3H), 3.09 (dd, J = 14.0, 5.7 Hz, 1H), 2.97 (dd, J = 14.0, 6.2 Hz, 1H), 2.21 (q, J = 
7.8 Hz, 2H), 1.11 (t, J = 7.6 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 174.25, 172.57, 
155.76, 130.35, 126.97, 115.71, 77.48, 77.16, 76.84, 53.32, 52.57, 37.32, 29.68, 9.80. 
HRMS ESI-TOF calcd. for C13H18NO4+ (100%, [M+H]+): 252.1230; found: 
252.1230. FTIR ν̃ 3300m, 3024w, 2981w, 2953w, 2361m, 2340m, 1736m, 1650m, 
1516s, 1444m, 1373m, 1225m cm-1. Optical rotation:! α !!!= 19.1 (c = 1.6, MeOH). 
 
(R)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)propionamide (3.20i)   
 
Amide 3.20i was prepared similar than 3.5 but D-tyrosinol 
hydrochloride was used as starting material instead. The 
analytical data is in accordance with the one of its enantiomer 3.5. Yield: 92%, 
Optical rotation: α !!"= 1.8 (c = 0.25, MeOH).  
 
N-(4-hydroxyphenethyl)propionamide (3.20j) 
 
Tryamine (300 mg, 2.19 mmol, 1.00 equiv.) was dissolved in 
H2O/THF (1:1, 10.0 mL). To this solution K2CO3 (907 mg, 6.56 
mmol, 3.00 equiv.) was added at r.t.. The mixture was stirred for 1 h before propionyl 
chloride (263 µL, 2.19 mmol, 1.3 equiv.) was added. The reaction mixture was then 
stirred for 2 h under an argon atmosphere. The organic solvent was evaporated and 
the aqueous layer was extracted with EtOAc (3x), brine (1x), dried over Na2SO4 and 
concentrated. The crude product was purified by flash chromatography on SiO2 
(MeOH/CH2Cl2, 1:30) to yield the product 3.20j (432 mg, quant.) as colorless solid.  
 
Rf = 0.31 (MeOH/CH2Cl2, 1:20). M.P. = 109 - 110 °C. 1H-NMR (400 MHz, CDCl3) δ 
7.05 - 6.98 (m, 2H), 6.74 - 6.67 (m, 2H), 3.33 (t, J = 7.3 Hz, 2H), 2.68 (t, J = 7.3 Hz, 
HO
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2H), 2.15 (q, J = 7.6 Hz, 2H), 1.09 (t, J = 7.6 Hz, 3H). 13C-NMR (101 MHz, MeOD) 
δ 176.98, 156.88, 131.25, 130.71, 116.19, 42.26, 35.69, 30.22, 10.56. HRMS ESI-
TOF calcd for C11H16NO2+ (100%, [M+H]+): 194.1176; found 194.1176. (100%, 
[M+H]+). EA: calc. (%) for C11H15NO2: C 68.37, H 7.82, N 7.25; found C 68.16, H 
7.65, N 7.25. FTIR ν̃ 3393m br, 2978m, 2938m, 2360m, 2343m, 1638s, 1615s, 
1546m, 1515s, 1454m, 1364m, 2337m, 829w, 632s cm-1.   
 
N-(3,4-dihydroxyphenethyl)propionamide (3.20k) 
 
 To a solution of dopamine hydrochloride (1.00 g, 5.27 mmol, 
1.00 equiv.) in a mixture of H2O/THF (1:1, 4.00 mL) was 
K2CO3 (2.19 g, 15.8 mmol, 3.00 equiv.) added. The mixture was stirred for 1 h under 
argon before propionyl chloride (24.7 µL, 0.223 mmol, 1.05 equiv.) was added. The 
mixture was then stirred overnight at r.t.. The solvent was removed and the dark 
residue was purified directly by flash chromatography on SiO2 (CH2Cl2/MeOH 20:1) 
to yield the amide 3.20k as brown oil (420 mg, 2.01 mmol, 38%).  
 
Rf  = 0.55 (MeOH/CH2Cl2, 1:20). M.P. = 112 - 113 °C. 1H-NMR (400 MHz, D2O) δ 
6.85 - 6.58 (m, 2H), 6.60 - 6.30 (m, 2H), 3.34 - 3.27 (m, 2H), 2.61 (t, J = 7.4 Hz, 2H), 
2.14 (q, J = 7.6 Hz, 2H), 1.08 (t, J = 7.6 Hz, 3H). 13C-NMR (101 MHz, D2O) δ 
176.98, 146.16, 144.67, 132.02, 121.01, 116.84, 116.32, 42.22, 35.87, 30.20, 10.55. 
HRMS ESI-TOF calcd. for (100%, [M+H]+): 210.1130; found: 210.1130. FTIR ν̃ 
3373m, 3100m br, 2974w, 2941w, 1631m, 1608s, 1545s, 1529m, 1440s, 1376m, 
1276m, 1252s, 1192s, 1114m, 949m, 873m, 821m, 660m cm-1.  
 
(S)-4-(3-hydroxy-2-(propylamino)propyl)phenol (3.20l) 
 
To a solution of L-tyrosinol hydrochloride (60 mg, 0.295 
mmol, 2.00 equiv.) in a mixture of H2O/THF (1:1, 2.00 mL) 
was K2CO3 (100 mg, 0.442 mmol, 3.00 equiv.) added. The mixture was stirred for 10 
min at r.t. before prior to use distilled 1-bromopropane (9 µL, 0.73 mmol, 1.00 equiv.) 
was added. The mixture was then stirred overnight at 70 °C under an argon 
atmosphere. The organic solvent was removed and the residue was first directly 
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purified by flash chromatography on SiO2 (CH2Cl2/MeOH, 20:1) followed by reverse 
phase preparative HPLC separation to yield the amine 3.20l (12 mg, 57.3 µmol, 39%) 
as colorless fluffy solid.  
 
Rf  = 0.17 (MeOH/CH2Cl2, 1:5).  1H-NMR (400 MHz, D2O) δ 7.24 - 7.17 (m, 2H), 
6.93 - 6.86 (m, 2H), 3.81 (dd, J = 12.7, 3.5 Hz, 1H), 3.63 (dd, J = 12.7, 5.2 Hz, 1H), 
3.56 - 3.45 (m, 1H), 3.11 - 2.88 (m, 4H), 1.68 (hept, J = 7.5 Hz, 2H), 0.95 (t, J = 7.5 
Hz, 3H). 13C-NMR (101 MHz, D2O) δ 154.79, 130.65, 127.23, 115.79, 60.01, 57.96, 
46.44, 32.51, 19.23, 10.15. HRMS ESI-TOF calcd. for C12H20NO2+ (100%, [M+H]+): 
210.1489; found 210.1489. FTIR ν̃ 3365w, 3241m, 3098w, 2975w, 2822w, 1614w, 
1573m, 1514s, 1458s, 1260s, 1224s, 1172w, 1094m, 1073m, 1031m, 968s, 844m, 
828m cm-1. Optical rotation: α !!!= –10.4 (c = 0.14, H2O). 
 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)benzamide (3.20m)2208  
 
To a solution of L-tyrosinol hydrochloride (100 mg, 0.49 
mmol, 1.00 equiv.) and benzyl chloride (60 mL, 0.51 mmol, 
1.05 equiv.) in MeCN (4.00 mL) was added K2CO3 (311 mg, 
2.25 mmol, 4.50 equiv.) dissolved in H2O (3.00 mL) drop wise during 0.3 h at r.t.. 
The reaction mixture was then stirred for 3.5 h at r.t.. The organic solvent was 
evaporated and the aqueous layer was extracted with EtOAc (4x). The combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated. The 
crude product was purified by flash chromatography on SiO2 (CH2Cl2/MeOH, 20:1) to 
yield the products 3.20m (98 mg, 0.361 mmol, 73%) as colorless solid.  
 
Rf  = 0.43 (EtOAc/ CH2Cl2, 4:6). M.P. = 37 - 41°C. 1H-NMR (400 MHz, MeOD) δ 
8.09 (d, J = 8.4 Hz, 1H), 7.82 - 7.64 (m, 2H), 7.56 - 7.35 (m, 2H), 7.19 - 6.95 (m, 2H), 
6.80 - 6.59 (m, 2H), 4.37 - 4.17 (m, 1H), 3.63 (d, J = 5.4 Hz, 2H), 2.91 (dd, J = 13.8, 
6.4 Hz, 1H), 2.77 (dd, J = 13.8, 8.2 Hz, 1H). 13C-NMR (101 MHz, DMSO) δ 165.98, 
155.43, 134.84, 130.93, 129.93, 129.41, 128.11, 127.22, 114.90, 62.78, 53.54, 35.67. 
FTIR ν̃ 3448w, 3308m, 2956w, 2928w, 1630s, 1602m, 1519s, 1488m, 1332m, 1239s, 
1030s, 820m, 805m, 689s, 658s cm-1. HRMS ESI-TOF calcd. for C16H18NO3 (100%, """"""""""""""""""""""""""""""""""""""""""""""""""""""""
220"H. Gershon, R. Rodin, J. Med. Chem. 1965, 8, 864–866."
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[M+H]+): 272.1287; found 272.1482. Optical rotation:! α !!"= –67.7 (c = 0.26, 
MeOH). 
 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)isobutyramide (3.20n) 
 
To a solution of L-tyrosinol (3.00 g, 16.6 mmol, 1.00 equiv.) in 
H2O/THF (1:1, 4.0 mL) was K2CO3 (61 mg, 0.442 mmol, 3.00 
equiv.) added at r.t.. The mixture was stirred for 1 h before isobutyryl chloride (19 
µL, 0.177 mmol, 1.20 equiv.) was added. The reaction mixture was then stirred for 15 
h under argon atmosphere. The organic solvent was evaporated and sat. NH4Cl-
solution (5.0 mL) was added. The aqueous layer was extracted with CH2Cl2 (3x). The 
combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated. The crude product was purified by flash chromatography on SiO2 
(CH2Cl2/MeOH, 30:1) to yield the product 3.20n (33 mg, 0.139 mmol, 94%) as 
colorless oil.  
 
Rf = 0.21 (MeOH/CH2Cl2, 1:20). 1H-NMR (400 MHz, MeOD) δ 7.08 - 7.01 (m, 2 H), 
6.79 - 6.56 (m, 2H), 4.13 - 3.94 (m, 1H), 3.51 (d, 5.4 Hz, 2H), 2.82 (dd, J = 13.9, 6.0 
Hz, 1H), 2.60 (dd, J = 13.9, 8.5 Hz, 1H), 2.38 (hept, J = 6.9 Hz, 1H), 1.01 (dd, J = 
27.9, 6.9 Hz, 6H). 13C-NMR (101 MHz, MeOD) δ 179.94, 156.82, 131.26, 130.56, 
116.03, 64.33, 53.96, 37.12, 36.32, 20.04, 19.68. HRMS ESI-TOF calcd. for 
C13H20NO3+ (100%, [M+H]+): 238.1438; found 238.1438. (100%, [M]+). FTIR ν̃ 
3299m br, 2970m, 2932m, 2876w, 2357w, 2339w, 1639s, 1615s, 1542s, 1515s, 
1456m, 1373m, 1241s, 1097w, 1041m, 771m, 630s cm-1. Optical rotation: α !!"= –
10.7 (c = 0.1, MeOH). 
 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)pivalamide (3.20o) 
 
To a solution of L-tyrosinol (100 mg, 0.491 mmol, 1.00 equiv.) 
in H2O/THF (1:1, 5.0 mL) was K2CO3 (204 mg, 1.470 mmol, 
3.00 equiv.) added at r.t.. The mixture was stirred for 0.5 h before trimethylacetyl 
chloride (73 µL, 0.589 mmol, 1.20 equiv.) was added. The reaction mixture was then 
stirred overnight under argon atmosphere. The organic solvent was evaporated and 
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sat. NH4Cl-solution (10.0 mL) was added. The aqueous layer was extracted with 
CH2Cl2 (3x). The combined organic layers were washed with brine, dried over Na2SO4 
and concentrated. The crude product was purified by flash chromatography on SiO2 
(CH2Cl2/MeOH, 30:1) to yield the product 3.20o (114 mg, 0.454 mmol, 92%) as 
colorless oil.  
 
Rf = 0.26 (MeOH/CH2Cl2, 1:20). M.P.  = 116 - 117 °C. 1H-NMR (400 MHz, MeOD) 
δ 7.11 - 7.00 (m, 2H), 6.75 - 6.57 (m, 2H), 4.13 - 4.02 (m, 1H), 3.61 - 3.45 (m, 2H), 
2.83 (dd, J = 13.8, 6.1 Hz, 1H), 2.65 (dd, J = 13.8, 8.6 Hz, 1H), 1.09 (s, 9H). 13C-
NMR (101 MHz, MeOD) δ 180.99, 156.80, 131.27, 130.54, 116.03, 64.18, 54.14, 
39.63, 36.94, 27.76. HRMS ESI-TOF calcd. for C14H22NO3+ (100%, [M+H]+): 
252.1594; found 252.1594. FTIR ν̃ 3478w, 3441w, 3360w, 3335w, 3183w broad, 
2962w, 2935w, 2868w, 2360w, 1706w, 1615w, 1530s, 1366w, 1227s, 1038m, 822m 
cm-1. Optical rotation: α !!! = –8.8 (c = 1.0, MeOH). 
 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)hex-5-ynamide (III) 
 
To a solution of L-tyrosinol hydrochloride (1.00 g, 4.91 
mmol, 1.00 equiv.) in THF/H2O (1:1, 16.0 mL) K2CO3 
(1.69 g, 12.27 mmol, 4.40 equiv.) was added. The reaction mixture was stirred for 1 h 
at r.t. before hex-5-ynoyl chloride (770 mg, 5.89 mmol, 1.20 equiv.) was added. After 
stirring for 4 h additional hex-5-ynoyl chloride (150 mg, 1.15 mmol, 0.23 equiv.) was 
added. The mixture was then stirred for another 1.2 h. The organic solvent was 
evaporated and the aqueous layer was extracted with EtOAc (4x). The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated. The 
crude product was purified by gradiental flash chromatography on SiO2 (MeOH in 
CH2Cl2, 1-10%) to yield alkin III (1.03 g, 3.93 mmol, 85%) as white solid.  
 
Rf = 0.51 (MeOH/CH2Cl2, 1:10). M.P. = 91 - 93 °C 1H-NMR (400 MHz, MeOD) δ 
7.61 (d, J = 8.5 Hz, 1H), 7.13 - 6.89 (m, 2H), 6.78 - 6.57 (m, 2H), 4.14 - 3.91 (m, 1H), 
3.57 -3.38 (m, 2H), 2.80 (dd, J = 13.9, 6.0 Hz, 1H), 2.58 (dd, J = 13.8, 8.5 Hz, 1H), 
2.31 - 2.15 (m, 3H), 2.13 - 1.97 (m, 2H), 1.76 - 1.56 (m, 2H). 13C-NMR (101 MHz, 
MeOD) δ 175.22, 156.86, 131.22, 130.51, 116.07, 84.25, 70.08, 64.38, 54.37, 54.27, 
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37.04, 36.01, 25.99, 18.54. HRMS ESI-TOF calcd. for C15H20NO3 (100%, [M+H]+): 
262.1443; found 262.1443. FTIR ν̃ 3483w, 3314m, 3300m, 3208m, 2690w, 2927w, 
2881w, 1633s, 1615m, 1530s, 1517s, 1453m, 1247m, 1214m, 1031s, 821m, 744m, 
681m, 650s, 627s cm-1. Optical rotation:! α !!!= –19.5 (c = 0.82, MeOH).  
 
(S)-4-(1-(adamantan-1-yl)-1H-1,2,3-triazol-4-yl)-N-(1-hydroxy-3-(4-
hydroxyphenyl)propan-2-yl)butanamide (3.20p) 
 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl) propan-2-   
yl)hex-5-ynamide III (50 mg, 0.191 mmol, 1.00 
equiv.), 1-azidoadamantane (37.3 mg, 0.210 mmol, 1.10 equiv.), L-ascorbic acid 
sodium salt (37.9 mg, 0.191 mmol, 1.00 equiv.), copper(II) sulfate pentahydrate (1.9 
mg, 0.008 mmol, 0.04 equiv.) and tris-(benzyltriazolylmethyl)amine (4.2 mg, 0.008 
mmol, 0.04 equiv.) were dissolved in DMSO (2.00 mL). The reaction mixture was 
stirred for 2 d at r.t. under an argon atmosphere. The organic solvent was removed and 
the crude was extracted with EtOAc (3x). The combined organic layers were washed 
with brine, dried over Na2SO4 and concentrated. Purification of the crude product by 
gradiental FC on SiO2 (MeOH in EtOAc 2-5%) yielded the product 3.20p (64 mg, 
0.146 mmol, 76%) as white solid. 
 
Rf = 0.15 (EtOAc/CH2Cl2, 4:6), M.P. = 76 - 77 °C, 1H-NMR (500 MHz, DMSO) δ 
7.74 (s, 1H), 7.13 - 6.97 (m, 2H), 6.74 - 6.61 (m, 2H), 4.10 (dd, J = 8.8, 5.6 Hz, 1H), 
3.51 (h, J = 5.7 Hz, 2H), 2.83 (dd, J = 13.9, 5.8 Hz, 1H), 2.67 - 2.44 (m, 3H), 2.25 (s, 
10H), 2.18 (t, J = 7.3 Hz, 2H), 1.85 (d, J = 7.0 Hz, 8H). 13C-NMR (101 MHz, CDCl3) 
δ 175.51, 156.87, 131.25, 130.55, 119.94 (2C), 116.10, 64.48, 60.90, 54.16, 37.16, 
36.94, 36.46, 31.00, 26.78, 25.58. HRMS ESI-TOF calcd. for C25H36N4O3+ (100%, 
[M+H]+): 439.2709; found 439.2709. (100%, [M+H]+). FTIR ν̃ 3263m, 2915s, 
2854m, 1732m, 1640s, 1548m, 1515s, 1452s, 1233s, 1144m, 1103m, 1064s, 818m, 
685m, 662m, 649m cm-1. Optical rotation:! α !!!= –7.8 (c = 0.12, MeOH). 
 
 
 
HO
H
N
OHO N N
N
"130                                                                        "CHAPTER 6 – EXPERIMENTAL PART"
N-((R)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)-N-((S)-1-hydroxy-3-(4-
hydroxyphenyl)propan-2-yl)succinamide (3.20q) 
 
To a solution of L-tyrosinol hydrochloride 
(100 mg, 0.491 mmol, 2.00 equiv.) in a 
mixture of H2O/THF (1:1, 4.00 mL) was 
K2CO3 (154 mg, 1.120 mmol, 5.00 equiv.) added. The mixture was stirred for 1 h 
under argon before succinyl chloride (24.7 µL, 0.223 mmol, 1 equiv.), which was 
distilled prior to use, was added. The mixture was stirred for 2 d under an argon 
atmosphere at r.t.. The organic solvent was removed and the pale yellow residue was 
purified directly by FC on SiO2 (CH2Cl2/MeOH, 40:1) to yield the dimer 3.20q as 
colorless solid (51 mg, 0.122 mmol, 55%).  
 
Rf  = 0.37 (MeOH/CH2Cl2, 1:20). M.P. = 167 - 169 °C. 1H-NMR (400 MHz, MeOD) 
7.18 - 6.80 (m, 5H), 6.86 - 6.45 (m, 4H), 4.39 (td, J = 10.3, 9.8, 5.5 Hz, 2H), 4.06 (dd, 
J = 11.4, 9.4 Hz, 2H), 3.72 (dd, J = 11.4, 5.0 Hz, 2H), 3.00 (dd, J = 13.8, 10.3 Hz, 
2H), 2.89 (dd, J = 13.8, 6.1 Hz, 2H), 2.63 - 2.41 (m, 4H). 13C-NMR (101 MHz, 
MeOD) δ 180.25, 157.14, 130.92, 129.64, 116.21, 61.85, 57.50, 33.81, 28.76. FTIR ν̃ 
3204w, 2995w, 2963w, 2946w, 2506w, 2383m, 1758w, 1676s, 1613m, 1517m, 1401m, 
1372m, 1257m, 1172s, 1021m, 889w, 810s, 668s, 620m cm-1.  
 
(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)nonanamide (3.20r) 
 
To a solution of L-tyrosinol (200 mg, 0.982 
mmol, 1.00 equiv.) in H2O/THF (1:1, 8.0 mL) 
was K2CO3 (543 mg, 3.93 mmol, 4.00 equiv.) 
added at r.t. under an argon atmosphere. The mixture was stirred for 0.33 h before 
nonanoyl chloride (248 µL, 1.37 mmol, 1.40 equiv.) was added. The reaction mixture 
was then stirred overnight. The organic solvent was evaporated and sat. NH4Cl-
solution (10.0 mL) was added. The aqueous layer was extracted with CH2Cl2 (3x). 
The combined organic layers were dried over Na2SO4 and concentrated. The crude 
product was purified by FC on SiO2 (CH2Cl2/MeOH 30:1) to yield the product 3.20r 
(213 mg, 0.693 mmol, 71%) as slight yellow solid. 
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Rf = 0.25 (MeOH/CH2Cl2, 1:20). M.P. = 101 - 102 °C. 1H-NMR (400 MHz, MeOD) 
δ 7.14 - 6.98 (m, 2H), 6.77 - 6.62 (m, 2H), 4.17 - 3.98 (m, 1H), 3.52 (d, J = 5.4 Hz, 
2H), 2.84 (dd, J = 13.9, 6.0 Hz, 1H), 2.61 (dd, J = 13.9, 8.6 Hz, 1H), 2.14 (t, J = 7.5 
Hz, 2H), 1.52 (p, J = 7.5 Hz, 2H), 1.44 - 1.15 (m, 10H), 0.92 (t, J = 6.9 Hz, 3H). 13C-
NMR (101 MHz, MeOD) δ 176.13, 156.88, 131.20, 130.51, 116.05, 64.38, 54.19, 
37.27, 37.14, 33.02, 30.44, 30.27, 30.20, 27.06, 23.70, 14.44. HRMS ESI-TOF calcd. 
for C18H29NNaO3+ (100%, [M+Na]+): 330.4232; found; 330.2042. FTIR ν̃ 3300m 
broad, 2933m, 2859w, 2361w, 2338w, 1629w, 1550w, 1516m, 1452w, 1373w, 1243s, 
1044w, 631s cm-1. Optical rotation: α !!! = –13.7 (c = 1.00, MeOH). 
 
8-oxo-8-(perfluorophenoxy)octanoic acid (IV)2219 
 
Pentaflourobenzoic acid (1.32 g, 7.176 mmol, 1.00 
equiv.), octanedioic acid (2.50 g, 14.352 mmol, 2.00 
equiv.) and EDC (1.65 g, 8.61 mmol, 1.20 equiv.) 
were dissolved in DMF/THF (1:3, 135 mL). This reaction mixture was then stirred 
overnight under nitrogen. The solvents were removed, first under slightly reduced 
pressure then under high vacuum while heating. The residue was extracted with 
EtOAc (4x) and aqueous HCl-solution (10 %, v:v). The combined organic layers were 
dried (MgSO4) and concentrated. The crude product was first purified by FC on SiO2 
(CH2Cl2/EtOAc/TFA, 200:20:1) followed by recrystallization from pentane to yield 
the activated acid IV (680 mg, 0.361 mmol, 35%) as white crystals.  
 
Rf = 0.59 (EtOAc). M.P. = 50 - 52 °C.  13C-NMR (101 MHz, MeOD) δ 34.78, 33.80, 
29.73, 29.56, 25.83, 25.66, 14.46. HRMS ESI-TOF calcd. for C14H12O4F5– (100%, 
[M]–): 339.0661; found 339.0656. The analytical data was in accordance with the 
literature.221 
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(S)-8-((1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)amino)-8-oxooctanoic acid 
(3.20s) 
 
To a solution of the mono-activated acid IV (350 
mg, 1.03 mmol, 1.20 equiv.) in DMF/THF (1:3, 
6.0 mL) was L-tyrosinol hydrochloride (175 mg, 
0.857 mmol, 1.00 equiv.) and NEt3 (631 µL, 2.57 mmol, 3.00 equiv.) added. The 
mixture was stirred for 16 h under an argon atmosphere at r.t.. Solvent removal was 
accomplished under high vacuum while heating. The brown residue was extracted 
with EtOAc (4x) and aqueous HCl-solution (10 %, v:v). The crude product was first 
purified by FC on SiO2 (CH2Cl2/MeOH/TFA, 100:10:1) followed by preparative 
HPLC separation to yield the acid 3.20s (70 mg, 0.216 mmol, 25%) as colourless 
solid.  
 
(S)-8-hydroxy-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)octanamide (3.20t) 
 
To a solution of L-tyrosinol (150 mg, 0.736 
mmol, 1.00 equiv.) in MeCN (14.0 mL) was 8-
hydroxyoctanoic acid (118 mg, 0.736 mmol, 
1.00 equiv.), NEt3 (311 µL, 2.21 mmol, 3.00 equiv.), EDC (282 mg, 1.47 mmol, 2.00 
equiv.) and 1-hydroxybenzotriazole hydrate (149 mg, 1.1 mmol, 1.5 equiv.) added. 
The mixture was stirred at r.t. under argon for 12 h. The organic solvent was 
evaporated and sat. NH4Cl-solution was added. The aqueous layer was extracted with 
CH2Cl2 (4x). The combined organic layers were washed with brine, dried over Na2SO4 
and concentrated. The crude product was purified by FC on SiO2 (CH2Cl2/EtOAc 5:1) 
to yield the triol 3.20t (42 mg, 0.136 mmol, 19%) as slight yellow solid. 
 
Rf  = 0.17 (MeOH/CH2Cl2 1:20). M.P. = 124 - 125 °C. 1H-NMR (400 MHz, MeOD) 
δ 7.12 - 6.96 (m, 2H), 6.76 - 6.62 (m, 2H), 4.11 - 4.00 (m, 1H), 3.60 - 3.44 (m, 4H), 
2.82 (dd, J = 13.9, 5.9 Hz, 1H), 2.59 (dd, J = 13.9, 8.7 Hz, 1H), 2.12 (t, J = 7.4 Hz, 
2H), 1.60 - 1.41 (m, 4H), 1.40 - 1.12 (m, 6H). 13C-NMR (101 MHz, MeOD) δ 176.11, 
156.85, 131.20, 130.54, 116.08, 64.44, 62.98, 54.17, 37.22, 37.14, 33.60, 30.27, 
30.11, 26.98, 26.75. HRMS ESI-TOF calcd. for C17H27NNaO4+ (100%, [M+Na]+): 
HO HO
H
N OH
O
HO
H
N
OHO
OH
O
"CHAPTER 6 – EXPERIMENTAL PART                                                                                             133 
332.1832; found; 332.1832. FTIR ν̃ 3293m, 2932m, 2858w, 2362s, 2338s, 1638m, 
1560w, 1515m, 1459w, 1369w, 1243w, 1036w, 758s, 632s cm-1. Optical rotation: α !!!= –12.0 (c = 0.50, MeOH). 
 
6.3.3 Tyrosinol Fatty Acid Analogs Collection 
N-(2-(1H-indol-3-yl)ethyl)hexadecanamide (4.6c)10222 
 
To a cooled solution (0 oC) of palamic 
acid (512 mg, 2.00 mmol, 2.00 equiv.) in 
CH2Cl2 (10 mL) oxalyl chloride (1.03 
mL, 12.00 mmol, 12.00 equiv.) was added. The mixture was stirred for 1 h under 
argon in an ice-bath. The solvent was removed under reduced pressure. The curde 
acid chloride was dissolved in CH2Cl2 (5 mL) and added drop wise to a cooled (0 oC) 
solution of tryptamine (150 mg, 1.00 mmol, 1.00 equiv.) and TEA (281 mL, 2.00 
mmol, 2.00 equiv) in CH2Cl2 (10 mL). The reaction mixture was stirred at r.t. under 
argon for 2.5 h. The solvent was evaporated and the obtained colorless residue was 
directly purified by FC on SiO2 (pentane/acetone 10:1) to yield the product 4.6c (302 
mg, 0.758 mmol, 76%) as colorless solid. (NMR spectra not added) 
 
Rf = 0.76 (CH2Cl2/MeOH 10:1). M.P. = 114 - 116 °C. 1H-NMR (400 MHz, CDCl3) δ 
8.17 (s, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.21 (t, J = 7.5 Hz, 
1H), 7.13 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 2.0 Hz, 1H), 5.51 (s, 1H), 3.61 (q, J = 6.5 
Hz, 2H), 2.98 (t, J = 6.7 Hz, 2H), 2.12 - 2.07 (t, J = 5.2 Hz, 2H), 1.66 - 1.55 (m, 2H), 
1.28 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 173.29, 
136.57, 127.52, 122.35, 122.13, 119.63, 118.89, 113.26, 111.39, 39.79, 37.07, 32.07, 
29.84 (2C), 29.83, 29.80, 29.77 (2C), 29.63, 29.50 (2C), 29.45, 25.90, 25.53, 22.83, 
14.26. FTIR ν̃ = 3394m, 3250w, 3080w, 2951w, 2917s, 2847s, 1629m, 1564m, 
1460m, 1287w, 1225w, 1094w, 1068w, 1011w, 739s, 725m. (NMR spectra not added) 
The reported data is in accordance with the literature.222 
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N-(2-(1H-indol-3-yl)ethyl)hexadecan-1-amine 4.6l22211 
 
To a solution of N-(2-(1H-indol-3-
yl)ethyl)hexadecanamide 4.6c (100 mg, 
0.251 mmol, 1.00 equiv.) in THF (5 mL) 
LiAlH4 (76.2 mg, 2.01 mmol, 8.00 equiv.) was added. The mixture was then refluxed 
under an argon atmosphere for 4.5 h. The reaction mixture was quenched using H2O 
(2 mL) followed by NaOH-solution (1 M, 1 mL). The suspension was filtered over 
celite and washed with EtOAc. The organic layer was separated, dried (NaSO4) and 
concentrated. The crude was purified by FC on SiO2 (MeOH/CH2Cl2 3:97 + 0.2% 
TEA) to yield the product 4.6l (51 mg, 0.133 mmol, 53%) as glittery colorless solid. 
(NMR spectra not added) The reported data is in accordance with the literature.222 
 
Rf = 0.40 (CH2Cl2/MeOH 10:1 + TEA). M.P. = 194 - 195 °C. 1H NMR (400 MHz, 
MeOD) δ 7.58 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.19 (s, 1H), 7.16 - 7.09 
(m, 1H), 7.09 - 7.01 (m, 1H), 3.34 - 3.25 (m, 2H), 3.16 (t, J = 7.6 Hz, 2H), 3.07 - 2.97 
(m, 2H), 1.66 (m, 2H), 1.46 - 1.16 (m, 24H), 0.90 (t, J = 6.9 Hz, 3H). 13C-NMR (101 
MHz, MeOD) δ 138.35, 128.13, 124.21, 122.81, 120.09, 118.88, 112.58, 110.14, 
49.31, 33.07, 30.38, 30.77 (2C), 30.75 (2C), 30.72, 30.62, 30.48, 30.46, 30.19, 27.57, 
27.24, 23.73, 23.44, 14.43. (1 peak overlaid by MeOD) FTIR ν̃ = 3418s, 3334s 
broad, 2957w, 2923w, 2850w, 2361m, 2340m, 1643m, 1460w, 1015m, 815m, 737m, 
647w. (NMR spectra not added) The reported data is in accordance with the 
literature.222 
 
(S)-4-(2-(hexadecylamino)-3-hydroxypropyl)phenol (4.22a) 
 
Amide 4.22e (23.0 mg, 0.055 mmol, 
1.00 equiv.), chlorotrimetyhlsilane (1.0 
mg, 0.009 mmol, 0.17 equiv.) and 1,1,1,3,3,3-hexamethyldisilazane (28.3 mg, 0.175 
mmol 3.20 equiv.) were dissolved in MeCN (1.5 mL) and refluxed (90 oC) under 
argon for 2.5 h. The solvent was removed under reduced pressure and the residue was """"""""""""""""""""""""""""""""""""""""""""""""""""""""
222 F. Schmidt, P. Champy, B. Seon-Meniel, X. Franck, R. Raisman-Vozari, B. 
Figadère, PLOS ONE 2009, 4, e6215. 
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dissolved in dioxane (1.50 mL). Borane dimethyl sulfide complex solution in THF (2 
M) (138 mL, 0.277 mmol, 5.00 equiv.) was added and the mixture was refluxed (100 
oC) under argon for 20 h. Then HCl-solution (10%, v:v, 1.0 mL) was added and the 
mixture was refluxed (100 oC) for another hour. The mixture was then extracted using 
saturated NaHCO3-solution (5.00 mL) and CH2Cl2 (3x). The combined organic layers 
were concentrated and the residue was purified by FC on SiO2 (CH2Cl2/MeOH 4:1 + 
0.1% TFA) to yield the product 4.22a (12.5 mg, 0.031 mmol, 56%) as white solid. 
 
Rf = 0.28 (CH2Cl2/MeOH 10:1). M.P. = 75 - 78 °C. 1H-NMR (400 MHz, MeOH) δ 
7.09 (m, 2H), 6.76 (m, 2H), 3.67 (dd, J = 11.8, 3.5 Hz, 1H), 3.50 (dd, J = 11.9, 4.9 
Hz, 1H), 3.27 - 3.17 (m, 1H), 3.02 - 2.75 (m, 4H), 1.76 - 1.53 (m, 2H), 1.44 - 1.10 (m, 
26H), 0.90 (t, J = 6.7 Hz, 3H). 13C-NMR (101 MHz, MeOH) δ 157.70, 131.35 (2C), 
128.28, 116.62 (2C), 62.15, 59.67, 46.82, 34.93, 33.07, 30.78 (2C), 30.77, 30.76, 
30.71, 30.65, 30.54, 30.47, 30.28, 28.04, 27.77, 23.73, 14.43. HRMS ESI-TOF calcd. 
for C25H46NO2+ (100%, [M+H]+): 392.3523; found; 392.3525. FTIR ν̃ 3298w, 2956w, 
2917s, 2850s, 1615w, 1600w, 1564w, 1516m, 1469m, 1368w, 1249m, 1175w, 1104w, 
1069w, 1041w, 1018w, 991w, 965w, 839w, 818m, 777w, 719w, 649w. Optical 
rotation: = –8.7 (c = 0.28, MeOH).  
 
(S)-4-(3-hydroxy-2-((15-hydroxypentadecyl)amino)propyl)phenol (4.22b) 
 
Amide 4.22f (28.0 mg, 0.069 mmol, 
1.00 equiv.), chlorotrimetyhlsilane (3.6 
mg, 0.033 mmol, 0.50 equiv.) and 1,1,1,3,3,3-hexamethyldisilazane (35.5 mg, 0.220 
mmol 3.20 equiv.) were dissolved in MeCN (2.00 mL) and refluxed (90 oC) under 
argon for 1h. The solvent was removed under reduced pressure and the residue was 
dissolved in dioxane (1.80 mL). Borane dimethyl sulfide complex solution in THF (2 
M, 172 mL, 0.343 mmol, 5.00 equiv.) was added and the mixture was refluxed (100 
oC) under argon for 13 h. Then HCl-solution (10%, v:v, 1.00 mL) was added and the 
mixture was refluxed (100 oC) for another hour. The mixture was extracted using sat. 
NaHCO3-solution and CH2Cl2 (3x). The combined organic layers were concentrated 
and the residue was purified by FC on SiO2 (CH2Cl2/MeOH 6:1 + 0.1% TEA) to yield 
the product 4.22b (11 mg, 0.028 mmol, 41%) as white solid. 
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Rf = 0.14 (CH2Cl2/MeOH 10:1 + TEA). M.P. = 133 - 135 °C. 1H-NMR (500 MHz, 
MeOD) δ 7.13 - 7.05 (m, 2H), 6.80 - 6.73 (m, 2H), 3.69 (dd, J = 11.9, 3.5 Hz, 1H), 
3.57 - 3.48 (m, 3H), 3.24 (td, J = 9.2, 4.8 Hz, 1H), 3.05 - 2.78 (m, 4H), 1.74 - 1.61 (m, 
2H), 1.57 - 1.48 (m, 2H), 1.43 - 1.24 (m, 22H). 13C-NMR (125 MHz, MeOD) δ 
157.73, 131.36 (2C), 128.18, 116.63 (2C), 63.00, 62.13, 59.46, 46.75, 34.79, 33.66, 
30.75 (2C), 30.73 (2C), 30.64, 30.61 (2C), 30.53, 30.26, 27.91, 27.74, 26.95. HRMS 
ESI-TOF calcd. for C24H44NO3+ (100%, [M+H]+): 394.3316; found; 394.3316. FTIR 
ν ̃3310w, 2919s, 2849s, 2523w, 2458m, 1612w, 1515s, 1468s, 1372w, 1258m, 1171w, 
1106w, 1096w, 1064m, 1011w, 940w, 820w. Optical rotation: = –11.3 (c = 0.26, 
MeOH).  
 
4-((S)-3-hydroxy-2-((9Z,12Z)-octadeca-9,12-dien-1-ylamino)propyl)phenol (4.22c) 
 
To a cooled (–78 oC) solution of 
ethyl linoleate (60 mg, 0.194 mmol, 
1.00 equiv.) in toluene (3.00 mL) was added a precooled (–78 oC) DIBAL-H solution 
(1 M in n-hexane) (202 µL, 0.202 mmol, 1.05 equiv.) which was dissolved in toluene 
(1.00 mL). The mixture was stirred for 50 min at this temperature under argon before 
it was quenched using sat. Rochelle salt-solution (3.00 mL) and extracted with Et2O 
(3x). The combined organic layers were dried over NaSO4 and concentrated.  
 The crude linolic aldehyde was dissolved in MeOH (2.00 mL). To this 
solution glacial acetic acid (0.10 mL), L-tyrosinol hydrochloride (53.1 mg, 0.261 
mmol, 1.35 equiv.) and sodium cyanoborohydride (18.2 mg, 0.290 mmol, 1.50 equiv.) 
were added. The mixture was stirred for 2.5 h at r.t. under argon before it was 
quenched with HCl-solution (10%, v:v, 30 mL). The mixture was extracted with Et2O 
(3x10 mL). The combined organic layers were washed with brine, dried using NaSO4 
and concentrated. The residue was purified by FC on SiO2 (MeOH/CH2Cl21:15 + 
0.1% TEA) to yield the product 4.22c  (22 mg, 0.052 mmol, 27%) as colourless oil.  
 
Rf = 0.50 (CH2Cl2/MeOH 10:1 + TEA). 1H-NMR (400 MHz, MeOH) δ 7.11 (m, 2H), 
6.77 (m, 2H), 5.43 - 5.26 (m, 4H), 3.72 (dd, J = 12.1, 3.3 Hz, 1H), 3.53 (dd, J = 12.1, 
4.5 Hz, 1H), 3.40 - 3.32 (m, 1H), 3.13 - 2.82 (m, 4H), 2.78 (t, J = 6.3 Hz, 2H), 2.15 - 
2.00 (m, 4H), 1.76 - 1.59 (m, 2H), 1.60 - 1.23 (m, 18H), 0.91 (t, J = 6.9 Hz, 3H). 13C-
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NMR (101 MHz, MeOD) δ 157.86, 131.39, 130.96, 130.84, 129.14, 129.03, 127.67, 
116.68, 62.06, 58.61, 46.45, 34.25, 32.66, 30.75, 30.47, 30.42, 30.26, 30.20, 28.17, 
27.67, 27.40, 26.53, 23.62, 14.43. HRMS ESI-TOF calcd. for C27H46NO2+ (100%, 
[M+H]+): 416.3523; found; 416.3525. FTIR ν̃ 3263w, 3010w, 2925s, 2854s, 1614s, 
1603w, 1516s, 1453m, 1376w, 1260m, 1231m, 1174w, 1106w, 1044m, 966w, 840w, 
778w, 660s, 618s. Optical rotation: = –5.5 (c = 0.19, MeOH).  
 
4-((S)-3-hydroxy-2-((9Z,12Z,15Z)-octadeca-9,12,15-trien-1-
ylamino)propyl)phenol (4.22d) 
 
To a cooled (–78 oC) solution of 
ethyl linolenate (150 mg, 0.489 
mmol, 1.00 equiv.) in toluene (3.00 mL) was added a precooled (–78 oC) DIBAL-H 
solution (1 M in n-hexane, 514 mL, 0.514 mmol, 1.05 equiv.) which was prior 
dissolved in toluene (1.00 mL). The mixture was stirred for 50 min at this temperature 
under argon before it was quenched using sat. Rochelle-salt-solution (5.00 mL) and 
extracted with Et2O (3x). The combined organic layers were dried over NaSO4 and 
concentrated.   
 The crude linolenic aldehyde was dissolved in MeOH (4.00 mL). To this 
solution glacial acetic acid (0.15 mL), L-tyrosinol hydrochloride (130 mg, 0.636 
mmol, 1.30 equiv.) and sodium cyanoborohydride (46.1 mg, 0.734 mmol, 1.50 equiv.) 
were added. The mixture was stirred for 2 h at r.t. under argon before it was quenched 
with HCl-solution (10%, v:v, 30 mL). The mixture was extracted with Et2O (3x10 
mL). The combined organic layers were washed with brine, dried using NaSO4 and 
concentrated. The residue was purified by FC on SiO2 (MeOH/CH2Cl2, 1:20 + 0.1% 
TEA) to yield the product 4.22d (90 mg, 0.218 mmol, 22%) as colorless oil.  
 
Rf = 0.49 (CH2Cl2/MeOH 10:1). 1H-NMR (400 MHz, MeOD) δ 7.08 (m, 2H), 6.75 
(m, 2H), 5.50 - 5.16 (m, 6H), 3.65 (dd, J = 11.7, 3.6 Hz, 1H), 3.49 (dd, J = 11.7, 5.0 
Hz, 1H), 3.15 (td, J = 9.2, 4.9 Hz, 1H), 3.05 - 2.63 (m, 8H), 2.22 - 2.01 (m, 4H), 1.71 
- 1.55 (m, 2H), 1.34 (s, 10H), 0.97 (td, J = 7.5, 0.7 Hz, 3H). 13C-NMR (101 MHz, 
MeOD) δ 157.54, 132.71, 131.31 (2C), 131.05, 129.18 (2C), 128.84, 128.66, 128.21, 
116.55 (2C), 62.20, 60.29, 47.04, 35.32, 30.72, 30.45, 30.30, 30.26, 28.42, 28.17, 
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27.84, 26.52, 26.40, 21.48, 14.67. HRMS ESI-TOF calcd. for C27H44NO2+ (100%, 
[M+H]+): 414.3367; found; 414.3367. FTIR ν ̃3283w, 3011w, 2962w 2926m, 2854m, 
2361w, 2338w, 1614w, 1595w, 1516m, 1451m, 1393w, 1368w, 1233m, 1172w, 
1106w, 1043w, 839w, 770m, 716m, 655s. Optical rotation: = –8.7 (c = 0.14, 
MeOH).  
 
 (S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)palmitamide (4.22e) 
 
L-Tyrosinol hydrochloride (150 mg, 
0.736 mmol, 1.00 equiv.), palmitic acid 
(189 mg, 0.736 mmol, 1.00 equiv.), EDC (283 mg, 1.472 mmol, 2.00 equiv.), 1H-
benzotriazole (149 mg, 1.100 mmol, 1.50 equiv.) and TEA (311mL, 2.208 mmol, 3.00 
equiv.) were suspended in MeCN (8.00 mL). The mixture was then stirred under 
argon at r.t. for 18 h. The solvent was evaporated and the white residue was directly 
purified by gradiental FC on SiO2 (CH2Cl2/MeOH 10:1 to 4:1) to yield the product 
4.22d (203 mg, 0.500 mmol, 68%) as white fluffy solid.  
 
Rf = 0.44 (CH2Cl2/MeOH 10:1). M.P. = 52 - 55 °C. 1H-NMR (400 MHz, MeOH) δ 
7.04 (m, 2H), 6.68 (m, 2H), 4.05 (dq, J = 11.4, 5.6 Hz, 1H), 4.05 (dq, J = 11.4, 5.6 
Hz, 1H), 3.50 (d, J = 5.3 Hz, 2H), 3.40 - 3.27 (m, 3H), 2.82 (dd, J = 13.9, 6.0 Hz, 1H), 
2.59 (dd, J = 13.9, 8.5 Hz, 1H), 2.12 (t, J = 7.4 Hz, 2H), 1.68- 1.40 (m, 2H), 1.26 (d, J 
= 24.7 Hz, 25H), 0.90 (t, J = 6.8 Hz, 3H). 13C-NMR (101 MHz, MeOH) δ 176.15, 
156.90, 131.21, 130.50, 116.06, 64.36, 54.19, 37.27, 37.15, 33.08, 30.81, 30.77, 
30.59, 30.48, 30.20, 27.06, 23.74, 14.44. HRMS ESI-TOF calcd. for C25H44NO3+ 
(100%, [M+H]+): 406.3316; found; 406.3320. FTIR ν ̃ 3485w, 3314w, 3202w, 2918s, 
2850s, 2390w, 1636s, 1614w, 1537s, 1515m, 1462m, 1451m, 1380w, 1366w, 1246m, 
1224w, 1038s, 830m, 730w, 720w, 686m. Optical rotation: = –12.8 (c = 0.51, 
MeOH).  
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(S)-15-hydroxy-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)pentadecanamide 
(4.22e) 
 
L-Tyrosinol hydrochloride (150 mg, 
0.736 mmol, 1.00 equiv.), 15-
hydroxypentadecanoic acid (196 mg, 0.736 mmol, 1.00 equiv.), EDC (283 mg, 1.472 
mmol, 2.00 equiv.), 1H-benzotriazole (149 mg, 1.100 mmol, 1.50 equiv.) and TEA 
(311 µL, 2.208 mmol, 3.00 equiv.) were suspended in MeCN (8.00 mL). The mixture 
was then stirred under argon at to r. t. for 16 h. The solvent was evaporated and the 
white residue was directly purified by FC on SiO2 (CH2Cl2/MeOH 2:1) followed by a 
recrystallization (pentane/acetone 4:1) to yield the product 33 (188 mg, 0.461 mmol, 
63%) as white solid.  
 
Rf = 0.43 (CH2Cl2/MeOH 10:1). M.P. = 40 - 43 °C.  1H-NMR (400 MHz, MeOD) δ 
7.07 - 7.00 (m, 2H), 6.74 - 6.65 (m, 2H), 4.04 (dt, J = 11.3, 5.6 Hz, 1H), 3.58 - 3.46 
(m, 4H), 2.82 (dd, J = 13.9, 6.0 Hz, 1H), 2.59 (dd, J = 13.9, 8.5 Hz, 1H), 2.12 (t, J = 
7.5 Hz, 2H), 1.58 - 1.41 (m, 4H), 1.39 - 1.00 (m, 20H). 13C-NMR (101 MHz, MeOD) 
δ 176.14, 156.89, 131.20 (2C), 130.50, 116.06 (2C), 64.37, 63.02, 54.20, 37.27, 
37.15, 33.68, 30.79, 30.77 (2C), 30.75 (2C), 30.62, 30.59, 30.48, 30.19, 27.07, 26.96. 
HRMS ESI-TOF calcd. for C24H42NO4+ (100%, [M+H]+): 408.3108; found; 
408.3108. FTIR ν̃ 3451w, 3301m, 3027w, 2920s, 2848s, 1638s, 1556s, 1514s, 1459s, 
1421w, 1377m, 1343w, 1313w, 1271m, 1238s, 1175w, 1083w, 1048s, 1026w, 952w, 
852w, 816w, 778w, 726m. Optical rotation: = –13.3 (c = 0.26, MeOH).  
 
(9Z,12Z)-N-((S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)octadeca-9,12-
dienamide (BSL34) 
 
Linoleic acid (50 mg, 0.178 mmol, 
1.00 equiv.), DCC (73.6 mg, 0.357 
mmol, 2.00 equiv.) and pentafluorophenol (49.2 mg, 0.267 mmol, 1.50 equiv.) were 
suspended in DMF (4.00 mL). The mixture was stirred under argon at 60 oC for 18 h. 
Then L-tyrosinol hydrochloride (38.8 mg, 0.214 mmol, 1.20 equiv.) and TEA (75 mL, 
0.535 mmol, 3.00 equiv.) were added and the mixture was stirred at r.t. for 30 h. The 
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reaction mixture was concentrated and directly purified by FC on SiO2 
(CH2Cl2/MeOH 20:1) without extraction to yield the product BSL34 (22 mg, 0.461 
mmol, 63%) as white solid.  
 
Rf = 0.65 (MeOH/CH2Cl21:20).  M.P. = 52 - 55 °C.  1H-NMR (400 MHz, MeOD) δ 
7.04 (m, 2H), 6.69 (m, 2H), 5.44 - 5.25 (m, 4H), 4.05 (tt, J = 11.3, 5.6 Hz, 1H), 3.50 
(d, J = 5.4 Hz, 2H), 2.88 - 2.72 (m, 3H), 2.59 (dd, J = 13.9, 8.5 Hz, 1H), 2.15 - 2.02 
(m, 6H), 1.56 - 1.45 (m, 2H), 1.42 - 1.15 (m, 14H), 0.90 (t, J = 6.8 Hz, 3H). 13C-NMR 
(101 MHz, MeOD) δ 176.12, 156.90, 131.21, 130.94, 130.50, 129.07, 129.06, 116.07, 
64.36, 54.19, 37.26, 37.15, 32.66, 30.77, 30.48, 30.38, 30.23, 30.18, 28.18, 28.16, 
27.06, 26.54, 23.63, 14.43. HRMS ESI-TOF calcd. for C27H44NO3+ (100%, [M+H]+): 
430.3316; found; 430.3316. FTIR ν̃ 3491w, 3317m, 3186w, 3010w, 2923m, 2853m, 
1642s, 1614w, 1534s, 1515s, 1462m, 1447m, 1384w, 1363w, 1246m, 1220s, 1113w, 
1053m, 1036s, 954w, 823w, 724w, 680m. Optical rotation: = –12.8 (c = 0.21, 
MeOH).  
 
(9Z,12Z,15Z)-N-((S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)octadeca-
9,12,15-trienamide (4.22h) 
 
Linolenic acid (55 mg, 0.198 mmol, 
1.00 equiv.), DCC (81.5 mg, 0.395 
mmol, 2.00 equiv.) and 
pentafluorophenol (54.5 mg, 0.296 mmol, 1.50 equiv.) were suspended in DMF (4.00 
mL). The mixture was stirred under argon at r.t. for 48 h. Then L-tyrosinol 
hydrochloride (50 mg, 0.277 mmol, 1.40 equiv.) and TEA (83 mL, 0.593 mmol, 3.00 
equiv.) were added and the mixture was stirred at r.t. for 20 h. The reaction mixture 
was concentrated, diluted with water and extracted with Et2O (3x). The combined 
organic layers were washed with brine, dried over NaSO4 and concentrated. The crude 
product was purified by flash chromatography on SiO2 (CH2Cl2/MeOH 50:1) yielded 
the product 4.22h (49 mg, 0.111 mmol, 56%) as white solid.  
 
Rf = 0.50 (CH2Cl2/EtOAc 8:2). M.P. = 70 - 72 °C.  1H-NMR (400 MHz, MeOD) δ 
7.03 (m, 2H), 6.69 (m, 2H), 5.45 - 5.23 (m, 6H), 4.05 (tt, J = 11.3, 5.6 Hz, 1H), 3.50 
(d, J = 5.4 Hz, 2H), 2.91 - 2.72 (m, 5H), 2.59 (dd, J = 13.9, 8.5 Hz, 1H), 2.17 - 1.99 
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(m, 6H), 1.55 - 1.45 (m, 2H), 1.41 - 1.12 (m, 8H), 0.97 (t, J = 7.5 Hz, 3H). 13C-NMR 
(101 MHz, MeOD) δ 176.09, 156.88, 132.71, 131.19, 131.12, 130.48, 129.21, 129.18, 
128.79, 128.23, 116.06, 64.35, 54.18, 37.26, 37.15, 30.75, 30.37, 30.22, 30.18, 28.19, 
27.06, 26.52, 26.40, 21.49, 14.66. HRMS ESI-TOF calcd. for C27H41NNaO3+ (100%, 
[M+Na]+): 450.2979; found; 450.2979. FTIR ν̃ 3491w, 3317m, 3182w, 3007w, 
2927m, 2876w, 2852w, 1641s, 1614w, 1600w, 1533s, 1516s, 1448m, 1389m, 1363m, 
1305w, 1248m, 1219m, 1114w, 1079w, 1054m, 1037s, 955w, 935w, 861w, 844w, 
823m, 771m, 714m, 679w. Optical rotation: = –12.9 (c = 0.24, MeOH).  
 
6-((5-(dimethylamino)naphthalene)-1-sulfonamido)hexanoic acid (4.28)12223 
 
6-Aminohexanoic acid 4.27 (750 mg, 5.72 mmol, 5.00 
equiv.) was dissolved in NaHCO3 (1.0 M, 20 mL). To this 
solution 5-(dimethylamino)naphthalene-l-sulfonyl chloride 4.26 (dansyl chloride, 309 
mg, 1.14 mmol, 1 equiv.) in acetone (5 mL) and Et3N (322 mL, 2.29 mmol, 2.0 
equiv.) was added. The solution was stirred for 1 h, acidified to pH 3 with HCl-
solution (2 M) and extracted with ethyl acetate (3 x 15 mL). The organic layer was 
washed with water (1x), brine (1x) and dried (Na2SO4). The solvent was evaporated 
and the crude product was purified by FC on SiO2 (MeOH/CH2Cl2 1:30) to yield 4.28 
as yellow oil (180 mg, 494 mmol, 40%). 
 
Rf = 0.86 (CH2Cl2/CH2Cl2, 1:10). 1H-NMR (400 MHz, CDCl3) δ 8.53 (d, J = 8.5 Hz, 
1H), 8.36 - 8.20 (m, 2H), 7.53 (ddd, J = 12.7, 8.5, 7.5 Hz, 2H), 7.18 (d, J = 7.4 Hz, 
1H), 4.98 (t, J = 6.1 Hz, 1H), 2.88 (m, 8H), 2.17 (t, J = 7.4 Hz, 2H), 1.39 (m, 4H), 
1.19 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ 179.24, 152.06, 134.86, 130.53, 129.98, 
129.74 (2 peak), 128.51, 123.35, 118.88, 115.36, 45.54, 43.07, 33.71, 29.26, 25.88, 
24.00. UPLC MS calcd for C18H25N2O4S (100%, [M+H]+): 362.1; found: 365.2. 
(NMR spectra not added) The reported data is in accordance with the literature.13223   
 
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
223 T. H. Walls, S. C. Grindrod, D. Beraud, L. Zhang, A. R. Baheti, S. 
Dakshanamurthy, M. K. Patel, M. L. Brown, L. H. MacArthur, Bioorg. Med. Chem. 
2012, 20, 5269–5276. 
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(S)-6-((5-(dimethylamino)naphthalene)-1-sulfonamido)-N-(1-hydroxy-3-(4-
hydroxyphenyl)propan-2-yl)hexanamide (4.30) 
 
To a solution of acid 4.28 (125 mg, 0.343 
mmol, 1.00 equiv.) in MeOH (10 mL), was 
added L-tyrosinol hydrochloride, HATU 4.29 (132 mg, 0.412 mmol, 1.20 equiv.) and 
Et3N (68 mL, 0.480 mmol, 1.40 equiv.). The mixture was stirred for 4 h at r.t. under 
argon. The solvent was evaporated under reduced pressure and the residue was 
washed using CH2Cl2 (3x), brine (1x), dried (NaSO4) and concentrated. The crude was 
purified by FC on SiO2 (MeOH/CH2Cl21:15) yielding the product 4.30 as yellow oil 
(111 mg, 216 mmol, 63%).  
 
Rf  = 0.17 (CH2Cl2/CH2Cl2 1:20). 1H-NMR (400 MHz, MeOD) δ 8.53 (d, J = 8.5 Hz, 
1H), 8.35 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 7.3 Hz, 1H), 7.55 (q, J = 7.4 Hz, 2H), 7.23 
(d, J = 7.5 Hz, 1H), 7.00 (m, 2H), 6.67 (m, 2H), 4.02 (m, 1H), 3.60 - 3.43 (m, 2H), 
2.96 - 2.71 (m, 9H), 2.56 (dd, J = 13.9, 8.6 Hz, 1H), 1.94 (t, J = 7.4 Hz, 2H), 1.28 (dq, 
J = 13.9, 7.0 Hz, 4H), 1.04 (q, J = 8.1 Hz, 2H).13C-NMR (101 MHz, MeOD) δ 
175.74, 156.77, 153.11, 137.09, 131.19, 131.14, 131.06, 130.92, 130.49, 130.11, 
129.04, 124.29, 120.53, 116.38, 116.06, 64.32, 54.12, 45.79, 43.66, 37.11, 36.90, 
30.26, 26.91, 26.33. HRMS ESI-TOF calcd. for C27H36N3O5S+ (100%, [M+H]+): 
514.2370; found: 514.2376. FTIR ν̃ = 3280m, 2940w, 2866w, 2836w, 2792w, 1639m, 
1614m, 1259w, 1573m, 1515s, 1454m, 1309s, 1232m, 1160m, 1140s, 1075m, 1024s, 
946w, 824w, 790s, 653s, 621s. Optical rotation:! α !!"= –7.5 (c = 0.83, MeOH). 
 
Compound 5.1 was synthesized following a known procedure and the obtained 
analytical data was in full accordance with the literature.14224 Compound 3.1622515 was 
available in our laboratory originating from previous projects. 
  """"""""""""""""""""""""""""""""""""""""""""""""""""""""
224 Y. Luo, K. Sun, L. Li, L. Gao, G. Wang, Y. Qu, L. Xiang, L. Chen, Y. Hu, J. Qi, 
ChemMedChem 2011, 6, 1986–1989. 
225 F. Schmid, H. J. Jessen, P. Burch, K. Gademann, Med. Chem. Comm. 2013, 4, 
135–139.  
226 A. Chicca, J. Marazzi, S. Nicolussi, J. Gertsch, J. Biological Chem. 2012, 287, 
34660–34682. 
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6.4 Endocannabinoid System Screen 
 
To obtain the biological data regarding the endocannabinoid system, established 
procedures were followed (34 = BSL34).226 
 
Figure 6.1A. CB1 binding at 1 µM, n=2, mean ± SD 
 
Figure 6.1B. CB2 binding at 1 µM, n=2, mean ± SD  
 
Figure 6.2. FAAH activity at 1 µM, n=2, mean ± SD 
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Figure 6.3A. MAGL activity at 1 µM, WWL70 10 µM, Orlistat 20 µM, JZL184 10 
µM, result combined, n=2, mean ± SD 
 
Figure 6.3B. ABHDs activity at 10 µM, WWL70 10 µM, Orlistat 20 µM, result 
combined, n=2, mean ± SD 
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Figure 6.4. EMT activity at 10 µM, WWL70 10 µM, Orlistat 20 µM, result 
combined, n=2, mean ± SD 
 
6.5 Re-Uptake Inhibition Screening22716 
 
For DA re-uptake inhibition assays, we used HEK 293 cells that stably overexpress 
human DA-, NE-, or SER-Transpoter.22817 The cells were cultured to 70% confluence in 
Dulbecco’s Modified Eagle’s Medium (4.5 g/L glucose) supplemented with 10% fetal 
bovine serum, 6 mM L-glutamine, 0.1 mM non-essential amino acids, 1mM sodium 
pyruvate, and 250 g/ml geneticin. For each re-uptake experiment, cells were detached 
with 0.05% trypsin/EDTA and re-suspended in re-uptake assay buffer (10 mM L-
glucose, 0.5 mM MgCl2, 4.6 mM KCl, 120 mM NaCl, 0.7 mM Na2HPO4, 1.3 mM 
NaH2PO4, and 0.015 mM sodium bicarbonate, pH 7.5) to 4 x 106 cells/mL. Distributed 
into 96-well plates, cells were incubated for 10 min at r. t. with the compounds at 20 
µM (final concentration) or controls (vehicle control for 100% re-uptake and 
mazindol, nisoxetine, or fluoxetine at 10 µM for non-specific re-uptake). Then, 5 nM 
(final concentration) 3H-DA, 3H-NE, or 3H-5-HT (specific activity = 30-50 Ci/mmol, 
PerkinElmer, Switzerland or ANAWA, Switzerland) were added and incubated for 
another 10 min at r.t.. Re-uptake was stopped separating cells from re-uptake buffer 
by centrifugation through a silicon oil mixture (1:2, m/m mixture of silicon oil types 
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
227 C. M. Hysek, L. D. Simmler, V. G. Nicola, N. Vischer, M. Donzelli, S. 
Krähenbühl, E. Grouzmann, J. Huwyler, M. C. Hoener, M. E. Liechti, PLOS ONE 
2012, 7, e36476. 
228 M. Tatsumi, K. Groshan, R. D. Blakely, E. Richelson, Euro. J. Pharmaco. 1997, 
340, 249–258. 
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AR20 and AR200) into a 3 M KOH layer in the tube tip. Essentially for 
reproducibility, the centrifuge always ran at high speed (13200 rpm) for 3 min. We 
then froze the tubes in liquid nitrogen and cut the tube tip containing cells underneath 
the silicon oil layer. The cells were disrupted with lysis buffer (0.05 M TRIS-HCl, 50 
mM NaCl, 5 mM EDTA, and 1% NP- 40) and mixed with scintillation fluid 
(UltimaGold, PerkinElmer, Switzerland) and radioactivity was quantified on a β-
counter. For data analysis, we subtracted all non-specific radioactive counts assessed 
with 10 µM mazindol, nisoxetine, or fluoxetine from the total counts derived from 
each drug. The specific vehicle control was set to define 100% re-uptake. 
 
6.6 Surface Coating 
6.6.1 Coating Procedure  
 
Microscope cover glass slides (12 mm Ø, Marienfeld GmBH & Co, Germany) were 
placed in 24-well plates (Falcon) and covered with 1 mL of the respected coating 
solution (CS). The cover glasses were then incubated for 16 h at 36°C. The CS was 
removed and the slides were washed seven times with H2O on both sides, placed in 
new collagen coated 6- or 24-well plates (Becton Dickinson Labware, UK), and 
finally subjected to UV irradiation (Lamp: Philips, TUV, 15W/G15 T8, 15 cm 
distance between lamp and plate) for 2 h for drying and sterilization. In case of the 
mixed incubation experiments where 6-well plates were used and two differently 
coated cover glasses were placed in the same well, a small glass piece was dismantled 
from the blank slide for differentiation as shown (Fig. 5.6).  
 
6.6.2 Coating Solutions (CS) 
 
CS Collagen:  0.01% of collagen (type 1 from rat tail, Sigma-Aldrich) in aqueous 
solution was mix either with: 
- 100 µM DMSO solution of  tetradecyl 2,3-dihydroxybenzoate (5.1), 1:10, v:v. 
- 500 µM DMSO solution of 5-(4-hydroxy-3-methoxyphenyl)-4-methoxy-2-
oxo-1,2-dihydropyridine-3-carboxylate (3.16), 1:10, v:v. 
- 1 mM DMSO solution of (S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-
yl)propionamide (3.5), 1:10, v:v. 
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CS Collagen Blank:  0.01% of collagen in aqueous solution / DMSO, 1:10, 
v:v. 
CS Poly-L-lysine:  50 µg/mL Poly-L-lysine hydrobromide 10’000-20’000 
(Fluka) in aqueous solution / 100 µM DMSO solution of tetradecyl 2,3-
dihydroxybenzoate (5.1), 10:1. 
CS Poly-L-lysine Blank: 50 µg/mL Poly-L-lysine hydrobromide 10’000-20’000 
(Fluka) in aqueous solution / DMSO, 1:10, v:v. 
 
6.6.3 Biological Evaluation - General Procedure 
 
When the PC12 cell concentration was sufficient, the growth medium (GM) in the 
culture flask was replaced by 12 mL of differentiation media (DM) (DMEM 
GlutaMAXTM, 1% horse serum, 0.5% fetal bovine serum) containing NGF-7S (120 
ng/mL) and incubated for 16 h. The media was removed and replaced by fresh DM 
without NGF-7S. The cells were scratched off the surface using a cell scraper (BD 
Falcon) and disaggregated by passage through a 21-gauge needle. The cell 
suspensions (80000 cells/mL) was then subjected to plates containing the coated 
cover glasses and incubated for 2 d at 36 °C. Cells were then fixed with 4% buffered 
formaldehyde solution for 2 h at 4 °C, then stained with Giemsa stain (modified 
solution), washed twice with PBS, mounted on microscope slides using Flouromount 
(Sigma-Aldrich), sealed with nail polisher (Express Finish, Maybelline, New York) 
and pictured under a phase contrast microscope (Leica DMI 4000B). The pictures 
were evaluated as descried in chapter 6.1.2.  
 
6.6.4 Restricted Area Coating  
 
A 200 µL droplet of a 1 mM solution of 5.1 in EtOH was placed on the bottom of a 6-
well plate. After evaporation, the cells were incubation and fixed under identical 
conditions as descried before but the staining procedure was modified. The methanol 
content of the Giemsa stain solution was removed and replaced by an equivalent 
amount of water. After staining and washing with PBS twice, the cells were stained 
with a 300 nM DAPI solution in PBS for 5 min, washed twice with PBS and 
examined under the fluorescent microscope.    
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6.6.5 Recycling Procedure 
 
Instead of fixing the cells after 2 d, the glass slides were incubated for 20 min with 
TrypLE™ Express, washed twice with H2O, transferred in a new collagen coated 24-
well plate and subjected again for 2 h to UV irradiation before being reused for 
another cycle using the same conditions as before.  
 
6.6.6 Close Proximity MIE 
 
Square microscope cover slides (12x12 mm, Marienfeld GmBH & Co, Germany) 
were coated under standard conditions with or without 5.1. To fix them in close 
proximity in a new well, small parts of the well bottom were molten with a glowing 
spatula as shown (Fig. 5.6). 
    
6.6.7  SEM Pictures 
 
Transparent conducting oxide coated glass (TC022-7, 2.2 mm thick, Solaronix, 
Switzerland) was sonicated for 15 min in a cleaning solution (2% of cleaner L2 
solution, Sonoswiss, Switzerland), washed with H2O and EtOH, dried and UV 
irradiated (UVO Cleaner, Jetlight Company Inc., USA) for 20 min. The glass plates 
where then coated under standard conditions using the following CS: Collagen with 
5.1, Collagen blank, Poly-L-lysine, Poly-L-lysine blank. They where then examined 
with a ZEISS/LEO Supra 35 field emission scanning electron microscope. No 
difference on the surface could be detected.  
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Transparent conducting oxide coated glass incubated under standard 
conditions with CS Collagen blank.  
 
Transparent conducting oxide coated glass incubated under standard 
conditions with Coating: DMSO in 0.01% collagen aqueous solution, 1:10, 
v:v, 5.1 10 µM. 
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7.1 X-Ray Parameters 
X-Ray parameters for 2.44: 
 
CCDC ID     CCDC 901009 
Formula    C23H22O5Se 
Formula weight   457.37 
Z, calculated density   1.461 Mg•m-3 
F(000)     936 
Description and size of crystal colourless block, size 0.10•0.15•0.50 mm3 
Absorption coefficient  1.838 mm-1 
Min/max transmission  0.4601 / 0.8376 
Temperature    293(2) K 
Radiation (wavelength)  MoKα (λ = 0.71073 Å) 
Crystal system, space group  orthorhombic, P 21 21 21 
a     6.0133(13) Å 
b     15.952(4) Å 
c     21.670(5) Å 
α     90° 
β     90° 
γ     90° 
V     2078.7(8) Å3 
Max Θ     25.99°    
Number of collected reflections 23949 
Number of independent reflections 4070 (merging r = 0.0822) 
Number of observed reflections 4070 (I>2.0σ(I)) 
Number of refined parameters 263 
R     0.0346 
wR     0.0857 
Goodness of fit   1.070 
""
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X-Ray parameters for 2.49: 
 
CCDC ID    CCDC 901010 
Formula    C17H19IO5 
Formula weight   430.24 
Z, calculated density   1.667 Mg•m-3 
F(000)     856 
Description and size of crystal colourless block, size 0.04•0.17•0.31 mm3 
Absorption coefficient  1.890 mm-1 
Min/max transmission  0.73 / 0.93 
Temperature    123 K 
Radiation (wavelength)  MoKα (λ = 0.71073 Å) 
Crystal system, space group  orthorhombic, P 21 21 21 
a     7.7519(2) Å 
b     9.8721(2) Å 
c     22.3993(5) Å 
α     90° 
β     90° 
γ     90° 
V     1714.16(7) Å3 
Max Θ     34.503°    
Number of collected reflections 53644 
Number of independent reflections 7257 (merging r = 0.032) 
Number of observed reflections 6374 (I>2.0σ(I)) 
Number of refined parameters 209 
R     0.0158 
wR     0.0200 
Goodness of fit   1.090 
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X-Ray parameters for gelsemiol (2.1):  
 
CCDC ID     CCDC 901008 
Formula    C10H16O4 
Formula weight   200.23 
Z, calculated density   1.345 Mg•m-3 
F(000)     432 
Description and size of crystal colorless plate, size 0.030•0.110•0.190 mm3 
Absorption coefficient  0.103 mm-1 
Min/max transmission  0.99 / 1.00 
Temperature    123 K 
Radiation (wavelength)  MoKα (λ = 0.71073 Å) 
Crystal system, space group  orthorhombic, P 21 21 21 
a     5.9236(4) Å 
b     7.8797(6) Å 
c     21.1900(15) Å 
α     90° 
β     90° 
γ     90° 
V     989.07(12) Å3 
Max Θ     32.572°    
Number of collected reflections 14382 
Number of independent reflections 2078 (merging r = 0.041) 
Number of observed reflections 1730 (I>2.0σ(I)) 
Number of refined parameters 127 
R     0.0305 
wR     0.0449 
Goodness of fit   1.1124 
""
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X-Ray parameters for gelsemiol (3.20h):  
              
 
CCDC ID     CCDC 955378 
Formula    C13H17NO4 
Formula weight   251.28 
Z, calculated density   1.260 Mg•m-3 
F(000)     536 
Description and size of crystal colorless plate, size 0.04•0.30•0.45 mm3 
Absorption coefficient  0.094 mm-1 
Min/max transmission  0.95/ 1.00 
Temperature    123 K 
Radiation (wavelength)  MoKα (λ = 0.71073 Å) 
Crystal system, space group  P 2(1), Z = 4 
a     9.4301(4) Å 
b     14.8968(6) Å 
c     10.0047(4) Å 
α     90° 
β     109.569(6)° 
γ     90° 
V     1324.26(9) Å3 
Max Θ     27.49°    
Number of collected reflections 30118 
Number of independent reflections 6060 (merging r = 0.0253) 
Number of observed reflections 6060 (I>2.0σ(I)) 
Number of refined parameters 331 
R     0.028 
wR     0.0726 
Goodness of fit   1.026 
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X-Ray parameters for gelsemiol (3.20s):  
 
 
CCDC ID     CCDC 955377 
Formula    C17H25NO5 
Formula weight   323.38 
Z, calculated density   1.265 Mg•m-3 
F(000)     348 
Description and size of crystal colorless prismatic, size 0.10•0.24•0.30 mm3 
Absorption coefficient  0.093 mm-1 
Min/max transmission  0.95/ 1.00 
Temperature    140 K 
Radiation (wavelength)  MoKα (λ = 0.71073 Å) 
Crystal system, space group  P 21, Z = 2 
a     5.0493(3) Å 
b     16.9091(8) Å 
c     10.1272 Å 
α     90° 
β     100.905(6)° 
γ     90° 
V     849.04(8) Å3 
Max Θ     26.37°    
Number of collected reflections 6522 
Number of independent reflections 3336 (merging r = 0.0142) 
Number of observed reflections 3336 (I>2.0σ(I)) 
Number of refined parameters 308 
R     0.026 
wR     0.0616 
Goodness of fit   1.038 
 
 
""
158 """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""CHAPTER"7"–"ANNEXES""""""""""""""""""""""""
7.2 NMR Spectra 
Gelsemiol (2.1) 
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Gelsemiol (2.1) HMQC 
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(3S or 3R, 3aS,4R,6aS)-methyl 4-((benzyloxy)methyl)-2-oxo-3,3a,4,6a-tetrahydro-
2H-cyclopenta[b]furan-3-carboxylate (2.39a/b) 
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(E)-(3-(benzyloxy)prop-1-en-1-yl)(phenyl)selane (2.41) 
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Selane 2.44 
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(3R,3aS,4S,5R,6R,6aR)-4-((benzyloxy)methyl)-6-iodo-5-methyl-2-oxohexahydro-
2H-cyclopenta[b]furan-3-carboxylic acid (2.49) 
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Gelsemiol lactol 2.50 
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(3R,3S,4S,5R,6R,6R)-4-((benzyloxy)methyl)-3-(hydroxymethyl)-6-iodo-5-
methylhexa-hydro-2H-cyclopenta[b]furan-2-one (2.51) 
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Gelsemiol acetylated (2.52)  
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(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)propionamide (3.5) 
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(S)-N-(1-hydroxy-3-phenylpropan-2-yl)propionamide (3.20a)  
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(S)-N-(1-hydroxy-3-(4-methoxyphenyl)propan-2-yl)propionamide (3.20b) 
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(S)-4-(3-hydroxy-2-propionamidopropyl)phenyl propionate (3.20c) 
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(S)-N-(1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-hydroxypropan-2-
yl)propionamide (I) 
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(S)-methyl 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-propionamidopropanoate 
(II) 
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(S)-N-(1-(4-hydroxyphenyl)-3-methoxypropan-2-yl)propionamide (3.20d) 
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(S)-3-(4-hydroxyphenyl)-2-propionamidopropyl propionate (3.20e)  
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(S)-N-(1-methoxy-3-(4-methoxyphenyl)propan-2-yl)propionamide (3.20g) 
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(S)-3-(4-hydroxyphenyl)-2-propionamidopropanoic acid (3.20h) 
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(S)-methyl 3-(4-hydroxyphenyl)-2-propionamidopropanoate (3.20h)  
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N-(4-hydroxyphenethyl)propionamide (3.20j) 
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N-(3,4-dihydroxyphenethyl)propionamide (3.20k) 
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(S)-4-(3-hydroxy-2-(propylamino)propyl)phenol (3.20l)  
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(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)benzamide (3.20m)  
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(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)isobutyramide (3.20n) 
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 (S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)pivalamide (3.20o) 
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(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)hex-5-ynamide (III) 
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(S)-4-(1-(adamantan-1-yl)-1H-1,2,3-triazol-4-yl)-N-(1-hydroxy-3-(4-
hydroxyphenyl)propan-2-yl)butanamide (3.20p) 
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N-((R)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)-N-((S)-1-hydroxy-3-(4-
hydroxyphenyl)propan-2-yl)succinamide (3.20q) 
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(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)nonanamide (3.20r) 
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(S)-8-((1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)amino)-8-oxooctanoic acid 
(3.20s) 
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(S)-8-hydroxy-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)octanamide (3.20t) 
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(S)-4-(2-(hexadecylamino)-3-hydroxypropyl)phenol (4.22a) 
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(S)-4-(3-hydroxy-2-((15-hydroxypentadecyl)amino)propyl)phenol (4.22b) 
 
		








	




	




	






 !"#$%$%&
'
	
(

)

#

*
		
+,



 
	
	
-



















	

	

		

	

	






























	

















	


	









	


	



	









	
	











	













 !
"#$
%&%&'

 


	
	

	















	


	



	

	


	






"
#
$





"
#
$






"
#
$




"
#
$


	

"
#
$





"
#
$




"
#
$




"
#
$















	




	
	
 
 
""
192 """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""CHAPTER"7"–"ANNEXES""""""""""""""""""""""""
4-((S)-3-hydroxy-2-((9Z,12Z)-octadeca-9,12-dien-1-ylamino)propyl)phenol (4.22c)  
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4-((S)-3-hydroxy-2-((9Z,12Z,15Z)-octadeca-9,12,15-trien-1-
ylamino)propyl)phenol (4.22d)  
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(S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)palmitamide (4.22e)  
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(S)-15-hydroxy-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)pentadecanamide 
(4.22f) 
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(9Z,12Z)-N-((S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)octadeca-9,12-
dienamide (BSL34) 
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(9Z,12Z,15Z)-N-((S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)octadeca-
9,12,15-trienamide (4.22h) 
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